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 Mitochondria are complex organelles that have important roles in energy 
production, intermediary metabolism, signal transduction, and apoptosis. Given these 
critical cellular functions, major efforts have been made to determine the identity of the 
mitochondrial proteome. Remarkably, about one fifth of mitochondrial proteins have 
unknown functions, and many of these are conserved through evolution, suggesting that 
they play a critical role in mitochondrial biology. We have focused on characterizing a 
subset of these evolutionarily conserved genes through a collaborative effort in 
Drosophila and yeast model systems. Through this work, we identified novel 
components of metabolic pathways involved in energy production, represented by the 
mitochondrial pyruvate carrier (MPC) and two succinate dehydrogenase complex 
assembly factors (SDHAFs). 
 The MPC is a multimeric complex comprising the MPC1 and MPC2 proteins. 
Loss of MPC1 in yeast, Drosophila, and humans results in impaired pyruvate 
metabolism stemming from a defect in pyruvate import through the inner mitochondrial 
membrane. A point mutation generated in yeast MPC1 confers resistance to a known 
inhibitor of the MPC, thus linking our discovery to classic biochemical analysis of 
mitochondrial pyruvate transport. Moreover, Drosophila MPC1 mutants display 
hallmarks of diabetes, including hyperglycemia, reduced glucose tolerance, and defects 
in insulin signaling. Taken together, our results demonstrate that the MPC proteins are
 iv  
required for mitochondrial pyruvate transport and, further, that this function is critical 
for maintaining carbohydrate homeostasis in vivo. 
 SDHAF3 and SDHAF4 are mitochondrial matrix proteins that are required for 
maximal SDH activity in yeast, Drosophila, and mammalian cells. Both of these 
proteins interact directly with SDH complex subunits to promote normal assembly of 
the SDH complex. Moreover, Drosophila Sdhaf3 and Sdhaf4 mutants display hallmarks 
of mitochondrial dysfunction, including muscular and neuronal dysfunction. These 
studies provide novel candidate causative loci for human diseases characterized by SDH 
deficiency. 
 Overall, the work described in this thesis yields key insights into mitochondrial 
pyruvate transport and succinate dehydrogenase complex assembly, using Drosophila to 
highlight their importance for energy metabolism and animal physiology.
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Cellular energy production is essential for all forms of life. Mitochondria are 
central to this process in eukaryotes, as they house the enzymes of the tricarboxylic acid 
(TCA) cycle and the electron transport chain (ETC) (Alberts et al., 2002). Most major 
cellular nutrients ultimately feed into the TCA cycle, thus driving the production of high-
energy electron donors used for adenosine triphosphate (ATP) synthesis through 
oxidative phosphorylation (OxPHOS) by the ETC (Berg et al., 2002). ATP generated 
within the mitochondrion is required for a variety of cellular processes, including 
metabolic reactions, active transport across membranes, signaling pathways, cell motility, 
and ribonucleic acid synthesis (Alberts et al., 2002; Berg et al., 2002). Consistent with 
these broad roles, mitochondrial dysfunction is associated with a variety of human 
diseases, including type II diabetes, cancer, neurodegenerative disorders, and myopathies 
(Baysal et al., 2000; Chatterjee et al., 2006; Hanahan and Weinberg, 2011; Lin and Beal, 
2006; Mootha et al., 2003; Patti et al., 2003; Petersen et al., 2004; Wallace, 2005; Yan et 
al., 2009). In addition, mitochondria are critical for other cellular processes, including 
Ca2+ homeostasis, programmed cell death, and iron metabolism (Elmore, 2007; Smaili et 
al., 2013; Xu et al., 2013). 
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Role of the mitochondrion in cellular energy metabolism 
Carbohydrates, lipids, and amino acids are the major nutrients used to fuel cellular 
energy production (Berg et al., 2002). The metabolic pathways of these nutrients 
converge on the mitochondrial TCA cycle, which acts as a central metabolic hub in the 
cell (Figure 1.1). Complex carbohydrates, glucose, and other sugars are catabolized 
through the glycolytic pathway in the cytoplasm (Berg et al., 2002). In addition, the 
metabolic pathways for sugar alcohols, the amino acids serine, alanine, glycine, and 
cysteine, and the pentose phosphate pathway branch from glycolysis (Lunt and Vander 
Heiden, 2011). Gluconeogenesis occurs through the reverse reactions of glycolytic 
enzymes, except for the three rate-limiting steps of glycolysis, hexokinase, 
phosphofructokinase, and pyruvate kinase, where separate unidirectional enzymes are 
used for glucose synthesis (Berg et al., 2002).  Overall, the glycolytic conversion of one 
molecule of glucose to two molecules of pyruvate results in the net production of two 
ATP molecules. Therefore, the full potential energetic yield of glucose (~30 ATP 
molecules) is dependent on pyruvate oxidation through the TCA cycle in mitochondria 
(Alberts et al., 2002). Moreover, mitochondrial pyruvate-derived oxaloacetate is a major 
substrate utilized for gluconeogenesis (Berg et al., 2002). Therefore, mitochondria are 
critical for the metabolism of carbohydrates, some amino acids, and sugar alcohols 
through the critical link between mitochondria and glycolysis represented by pyruvate 
(Figure 1.1).  
Phospholipids and triglycerides are the major sources of lipid utilized for cellular 
energy metabolism (Berg et al., 2002). Fatty acids derived from these molecules are 




















Figure 1.1. Overview of cellular energy metabolism. 
The glycolytic pathway in the cytoplasm and TCA cycle in the mitochondrion are 
diagrammed. The sites at which the metabolism of amino acids and fatty acids link to 
glycolysis and the TCA cycle are shown. Amino acids are shown in blue and fatty acids 
are in red. Several key enzymes discussed in the text are shown in green. DHAP-
dihydroxyacetone phosphate; G3P-glyceraldehyde 3 phosphate; LDH-lactate 
dehydrogenase; ALT-alanine transaminase; MPC-mitochondrial pyruvate carrier; PDH-
pyruvate dehydrogenase; PC-pyruvate carboxylase; SDH-succinate dehydrogenase; FH-
fumarate hydratase; BCAA-branched chain amino acids; AA-amino acids. (Adapted from 







succinyl-CoA. The oxidation of fatty acids occurs within mitochondria, with the 
exception of very long chain fatty acids, whose initial oxidation reactions occur within 
peroxisomes. Moreover, acetyl-CoA derived from the TCA cycle molecule citrate is the 
major substrate used for fatty acid and sterol biosynthesis (Berg et al., 2002). Thus, 
mitochondria are central to lipid catabolic and anabolic pathways (Figure 1.1). 
Many amino acids can interconvert with glycolytic intermediates, but most amino 
acid metabolic pathways intersect with TCA cycle (Berg et al., 2002; Lunt and Vander 
Heiden, 2011). For example, glutamine, glutamate, arginine, and proline can be 
converted to alpha-ketoglutarate, whereas asparagine and aspartic acid generate 
oxaloacetate. In addition, the branched chain amino acids valine, leucine, isoleucine, and 
the sulfur containing amino acid methionine are broken down to yield acetyl-CoA and/or 
succinyl-CoA (Lunt and Vander Heiden, 2011). Overall, the aforementioned examples 
demonstrate that the metabolic pathways of most amino acids converge on the TCA cycle 
directly, or indirectly though the production of pyruvate (Figure 1.1)  
The matrix-localized TCA cycle couples the oxidation of incoming metabolites to 
the reduction of either nicotinamide adenine dinucleotide (NAD) or flavin adenine 
dinucleotide (FAD) to NADH or FADH2, respectively. Electrons from NADH and 
FADH2 enter the ETC at complexes I and II, respectively (Figure 1.2A). Once associated 
with the ETC, electrons are moved via redox transfer reactions through ubiquinone, 
complex III, cytochrome c, and ultimately to complex IV, where the electrons react with 
oxygen to form water. This transport of electrons drives the translocation of hydrogen 
ions (H+) across the inner mitochondrial membrane (IMM) by complexes I, III, and IV to 












Figure 1.2. Diagram of the electron transport chain (ETC), 
succinate dehydrogenase (SDH), and pyruvate metabolism. 
(A) The process of oxidative phosphorylation by the electron transport chain (ETC). 
Electrons (e-) from NADH generated by the TCA cycle and glycolytic pathway enter the 
ETC and are transferred to complex I, whereas complex II (SDH) couples the oxidation 
of succinate to fumarate to the reduction of FAD to FADH2. Complexes I and II (CI and 
CII) each transfer electrons to ubiquinone (Q), which then passes electrons sequentially 
to Complex III (CIII), cytochrome c (CytC), and Complex IV (CIV). At Complex IV, 
electrons react with oxygen to form water. Complexes I, III, and IV pump protons (H+) 
across the inner mitochondrial membrane (IMM). Protons then move back into the matrix 
through Complex V (CV; ATP-synthase), thus driving oxidative phosphorylation of ADP 
to ATP using inorganic phosphate (Pi). The intermembrane space (IMS) is also shown. 
(B) Mitochondrial pyruvate metabolism. Pyruvate generated during glycolysis is 
transported through the IMM by the mitochondrial pyruvate carrier (MPC) through a 
mechanism dependent on the IMM proton gradient. Mitochondrial pyruvate is either 
converted to oxaloacetate by pyruvate carboxylase (PC), or acetyl-CoA by pyruvate 
dehydrogenase (PDH). The activity of PDH is regulated by pyruvate dehydrogenase 
kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP). (C) The succinate 
dehydrogenase (SDH) complex is shown. The SHDA and SDHB subunits face the 
mitochondrial matrix and are anchored to the IMM by the SDHC and SDHD subunits. 
SDHA contains the FAD moiety that is reduced to FADH2 upon the oxidation of 
succinate to fumarate. SDHB contains three iron sulfur (FeS) clusters, and heme is 
present at the interface between SDHC and SDHD. (Adapted from Berg et al., 2002; 




















concentration gradient. Complex V (ATP-synthase) then couples the movement of H+ 
ions back into the matrix along the electrochemical gradient to drive oxidative 
phosphorylation of adenosine diphosphate (ADP) to ATP (Figure 1.2A) (Alberts et al., 
2002; Berg et al., 2002). 
 
Mitochondrial dysfunction and disease 
ATP is used to fuel almost all aspects of cell biology. As such, defects in 
mitochondrial function are detrimental to cellular function and, thus, commonly linked to 
human disease (Wallace, 2005). Hereditary mitochondrial diseases can be caused by 
mutations in either the mitochondrial genome or in nuclear mitochondrial-protein 
encoding genes (Schapira, 2006). Although each individual form of mitochondrial 
disease is rare, taken together they are quite common with an estimated incidence of 
1/5,000 to 1/10,000 live births (Schaefer et al., 2004; Skladal et al., 2003). Many forms of 
mitochondrial disease are caused by loss-of-function mutations in components of the 
ETC, TCA cycle, or mitochondrial pyruvate metabolic enzymes (Schapira, 2006). These 
diseases are generally characterized by a broad phenotypic spectrum, with the most 
severe defects typically manifested in neuronal and/or muscular tissue (Schapira, 2006; 
Schon and Manfredi, 2003). Work in several genetic model organisms studying 
mitochondrial diseases is consistent with this observation. For example, mice carrying a 
mutation in the complex I subunit-encoding gene Ndufs4 develop age progressive 
encephalomyopathy, characterized by ataxia, neuronal synaptic transmission defects, and 
early lethality (Kruse et al., 2008). Muscle-specific genetic inactivation of the 
cytochrome oxidase assembly gene cox10 causes severe myopathy and muscle weakness, 
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while neuron-specific knockout results in behavioral defects and neuronal cell loss in the 
brain (Diaz et al., 2005; Fukui et al., 2007). Skeletal/cardiac muscle-specific knockout of 
pyruvate dehydrogenase (PDH) alpha subunit causes cardiomyopathy, while its loss 
specifically in neurons results in structural defects in the brain (Pliss et al., 2004; Sidhu et 
al., 2008). Similarly, zebrafish pdhb mutants develop retinal degeneration and visual 
impairment (Maurer et al., 2010). Furthermore, genetic disruption of citrate synthase, 
cytochrome c oxidase, ATP synthase, or succinate dehydrogenase causes 
muscular/neuronal defects in Drosophila (Celotto et al., 2006; Fergestad et al., 2006a; 
Liu et al., 2007; Mast et al., 2008; Walker et al., 2006) (Chapter 4, 5). Overall, the 
similarity between phenotypes observed in human mitochondrial disease and in genetic 
models of these disorders illustrates the evolutionarily conserved role of mitochondria in 
maintaining neuronal and muscular function. This susceptibility of neuronal and 
muscular tissue to mitochondrial dysfunction is thought to be related to their massive 
bioenergetic and biosynthetic demands and potentially an increased sensitivity of neurons 
and muscles to reactive oxygen species (ROS) relative to other tissues (Lax and Jaros, 
2012; Schon and Manfredi, 2003).  
In addition to these specific disorders defined as mitochondrial diseases, 
mitochondrial dysfunction is also associated with common age-related neurological 
diseases, such as Alzheimer’s disease, Parkinson’s disease (PD), and Amyotrophic 
Lateral Sclerosis (ALS) (Schon and Manfredi, 2003). Neuronal tissue from human 
patients and mouse models display abnormal mitochondrial morphology, reduced 
mitochondrial number, reduced energy production, and increased ROS (Hauptmann et al., 
2009; Kong and Xu, 1998; Kopeikina et al., 2011; Moreira et al., 2010; Perier et al., 
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2007; Schapira et al., 1990; Shi et al., 2010; Winklhofer and Haass, 2010; Wong et al., 
1995). However, whether these mitochondrial defects are causative or coincident with the 
initiation or progression of these complex diseases is controversial (Morais and De 
Strooper, 2010). Rare familial forms of Parkinson’s Disease are caused by mutations in 
the genes PARKIN, PINK1, DJ-1, LRRK2, and ATP13A2, all of which have been 
implicated in mitochondrial quality control and/or dynamics (Bonifati et al., 2003; 
Gusdon et al., 2012; Kitada et al., 1998; Narendra et al., 2010; Paisan-Ruiz et al., 2004; 
Ramirez et al., 2006; Winklhofer and Haass, 2010; Zimprich et al., 2004). Similarly, 
mutations in the mitochondrial ROS scavenging enzyme Superoxide Dismutase 1 (SOD1) 
cause ALS in humans and ALS-like phenotypes in mouse models (Rosen et al., 1993; Shi 
et al., 2010). Thus, at least for PD and ALS, there is compelling evidence that is 
consistent with a causative role for mitochondrial dysfunction in disease etiology.  
In addition to degenerative diseases, mitochondrial dysfunction is linked to type 2 
diabetes, suggesting that mitochondria play a critical role in regulating systemic 
metabolic homeostasis (Lowell and Shulman, 2005). For example, skeletal muscle from 
type 2 diabetics exhibits mitochondrial defects, including abnormal morphology, aberrant 
size, reduced number, decreased activity of key OxPHOS enzymes, and defects in ATP 
production (Hojlund et al., 2008; Kelley et al., 2002; Morino et al., 2005; Petersen et al., 
2004; Ritov et al., 2005; Sleigh et al., 2011; Szendroedi et al., 2007). One or more of 
these hallmarks of mitochondrial dysfunction have also been observed in the skeletal 
muscle, cardiac muscle, liver, pancreatic islets, and adipose tissue of genetic and dietary 
rodent models of diabetes (Boudina et al., 2007; Cheng et al., 2009; Choo et al., 2006; 
Koves et al., 2008; Lu et al., 2010; Sparks et al., 2005). Several functional studies have 
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been performed to assay the role of mitochondria in the pancreatic beta cells and the 
liver. Mice carrying a mutation in uncoupling protein 2 (UCP2), which encodes a protein 
expressed in beta cells that uncouples the mitochondrial membrane potential from ATP 
production, exhibit increased islet ATP production and glucose stimulated insulin 
secretion (GSIS—see Chapter 3 for a more extensive discussion of this topic) (Zhang et 
al., 2001). Consistent with these effects, loss of UCP2 results in an amelioration of 
defects in insulin release characteristic of dietary models of type 2 diabetes (Joseph et al., 
2004; Zhang et al., 2001). Conversely, overexpression of UCP2 in rat pancreatic beta 
cells results in defective GSIS (Chan et al., 1999). Taken together, these results 
underscore the critical nature of mitochondrial ATP production in beta cell function. 
Furthermore, genetic inactivation of enzymes involved in mitochondrial pyruvate 
metabolism in hepatocytes or pancreatic beta cells affects processes commonly 
dysregulated in diabetes, such as insulin secretion, insulin sensitivity, lipogenesis, and 
gluconeogenesis (discussed in more detail in Chapter 3) (Choi et al., 2010; Kumashiro et 
al., 2013; Srinivasan et al., 2010). Overall, this evidence suggests that normal 
mitochondrial function is critical for the maintenance of muscles and neurons and, 
further, for the regulation of systemic metabolic homeostasis. 
 
The mitochondrial proteome  
Given the central role of the mitochondrion in cellular function and the 
association of mitochondrial dysfunction with disease, it is critical to gain a 
comprehensive understanding of mitochondrial biology. The identification of all proteins 
that localize to the mitochondrion, i.e., the mitochondrial proteome, provides an 
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important resource to address this problem (Calvo and Mootha, 2010). Mass 
spectrometry-based proteomic approaches were used to identify of all of the proteins 
associated with mitochondria isolated from a wide variety of species, ranging from 
protists to humans (Pagliarini et al., 2003; Pagliarini et al., 2008; Reinders et al., 2006; 
Sickmann et al., 2003; Smith et al., 2007). The number of proteins localized to the 
organelle varies across species, with ~1200 identifiable proteins localized to 
mitochondria in mammals and ~850 in yeast (Pagliarini et al., 2008; Reinders et al., 
2006). Although the distribution of functions assigned to proteins localized to 
mitochondria varies from species to species, it is clear that the largest categories include 
energy metabolism, genome maintenance/transcription, and translation (Figure 1.3) (Lotz 
et al., 2013; Schmidt et al., 2010). Interestingly, ~20% of mitochondrial proteins in yeast 
and 11–36% of mitochondrial proteins in humans have unknown functions, thus 
representing the largest category in the mitochondrial proteome (Figure 1.3) (Pagliarini 
and Rutter, 2013; Schmidt et al., 2010). Approximately 10% of these uncharacterized 
proteins are conserved through evolution from yeast to humans, indicating they may play 
a fundamentally important role in mitochondrial biology (Lotz et al., 2013). Given the 
prevalence of mitochondrial dysfunction in human disease, we also predicted that new 
disease genes would be found within this group. Based on this rationale, the Rutter lab 
began to characterize ~30 proteins of unknown function using budding yeast, 
Saccharomyces cerevisiae, prior to my thesis work (Jared Rutter, personal 
communication). Yeast is a powerful system for genetic studies of mitochondrial function 






Figure 1.3. Functional classification of the mitochondrial proteome. 
The distribution of gene-ontology categories for the ~850 proteins known to localize to 
yeast mitochondria as of 2010 are shown. (Adapted from Reinders et al., 2006 and 








for selective growth screening for mutations that disrupt OxPhos or other mitochondrial 
processes (Barrientos, 2003). The initial studies from the Rutter lab yielded several 
important discoveries in aspects of mitochondrial quality control, ETC supercomplex 
assembly, and SDH complex assembly, as well as the discovery of a novel disease gene 
(Chen et al., 2012; Hao et al., 2009; Heo et al., 2010). As an extension of this research, I 
set out to characterize three conserved mitochondrial proteins of unknown function in 
Drosophila in collaboration with the Rutter lab, to complement their work in yeast. As 
described below, Drosophila is a powerful model to understand the physiological role of 
mitochondria in neuronal and muscular function—and to study the mechanisms 
underlying the regulation of carbohydrate homeostasis. Thus, through this multisystem 
approach, we sought to study cellular and biochemical functions of novel mitochondrial 
proteins in yeast, combined with tissue-specific and physiological functions in 
Drosophila. 
To decide which of these ~30 uncharacterized mitochondrial proteins I would 
study using Drosophila, I focused my attention on genes whose deletion in yeast caused a 
robust growth defect, with the rationale that these would yield a noticeable phenotype 
when mutated in flies. Yeast Mitochondrial pyruvate carrier 1 (Mpc1) mutants display a 
growth defect on media lacking leucine, and Succinate dehydrogenase 7 (Sdh7) and 
Succinate dehydrogenase 8 (Sdh8) mutants display reduced growth on acetate, suggesting 
these genes play a role in cellular metabolism. Based on these data, I decided to focus on 
functionally characterizing the Drosophila orthologs of these genes, which we named 
dMpc1, dSdhaf4, and dSdhaf3. From these studies, we learned that dMpc1 functions in 
mitochondrial pyruvate transport, whereas dSdhaf3 and dSdhaf4 are involved in SDH 
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complex assembly. My thesis research thus focused on the mechanisms of mitochondrial 
pyruvate and succinate metabolism and the physiological roles of these factors, using 
Drosophila as a model system. We also discovered a role for dMpc1 in maintaining 
carbohydrate homeostasis through the insulin signaling pathway, and thus my 
introduction ends with a discussion of these pathways in Drosophila. 
 
Mitochondrial pyruvate transport and metabolism 
Pyruvate occupies a central place in energy metabolism, as its metabolic 
trajectory can be shifted to produce lactate, alanine, acetyl-CoA, or oxaloacetate, 
depending on cellular needs (Gray et al., 2013). While the conversion of pyruvate to 
lactate by lactate dehydrogenase (LDH) and alanine by alanine transaminase (ALT) 
occurs in the cytoplasm; pyruvate-driven acetyl-CoA and oxaloacetate production takes 
place in the mitochondrial matrix, catalyzed by pyruvate dehydrogenase (PDH) and 
pyruvate carboxylase (PC), respectively (Figure 1.2B) (Berg et al., 2002). The PDH 
enzyme complex is localized to the mitochondrial matrix and comprises three parts: the 
pyruvate dehydrogenase subunit, the dihydrolipoyl transacetylase subunit, and the 
dihydrolipoyl dehydrogenase subunit (Patel and Korotchkina, 2006). These components 
act in succession to couple the dehydrogenation of pyruvate with the production of 
acetyl-CoA and NADH from CoA and NAD, through a mechanism involving several 
cofactors, including thiamin pyrophosphate, lipoic acid, and FAD (Patel and Roche, 
1990). PDH is central to cellular energy metabolism as it effectively links glycolysis with 
mitochondrial energy production and fatty acid biosynthesis (Berg et al., 2002). 
Consistent with this pivotal role, PDH activity is tightly regulated to respond to changes 
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in cellular metabolic conditions through its repression by phosphorylation of the pyruvate 
dehydrogenase subunit (Patel and Korotchkina, 2006). This phosphorylation event is 
controlled antagonistically by pyruvate dehydrogenase kinase (PDK) and pyruvate 
dehydrogenase phosphatase (PDP) (Figure 1.2B), which are subject to regulation by 
NAD/NADH, Acetyl-CoA/CoA, and ATP/ADP ratios (Patel and Korotchkina, 2006). 
This regulation links PDH activity to the cellular bioenergetic state, allowing it to 
maintain energy homeostasis (Patel and Korotchkina, 2006). PC is a biotinylated 
mitochondrial matrix enzyme that produces oxaloacetate using pyruvate and Acetyl-CoA 
as substrates through an ATP-dependent mechanism (Jitrapakdee et al., 2008). 
Oxaloacetate produced by PC is used for gluconeogenesis in the liver and kidneys 
through its conversion to phosphoenolpyruvate (PEP) by a rate-limiting enzyme in 
gluconeogenesis, PEP carboxykinase (PEPCK) (Jitrapakdee et al., 2006). Moreover, PC 
facilitates the TCA cycle anaplerosis required for lipogenesis in adipose tissue and the 
synthesis of the neurotransmitter amino acid glutamate in astrocytes (Jitrapakdee et al., 
2006). Thus, mitochondrial pyruvate metabolism is critical for cellular energy production 
and biosynthetic processes across a wide array of cell types. Consistent with these 
fundamental metabolic roles, alterations in mitochondrial pyruvate metabolism can result 
in profound physiological effects. For example, mutations in PC, subunits of PDH, or 
PDP cause diseases characterized by several shared phenotypes, including lactic acidosis, 
developmental abnormalities and neurological defects (Garcia-Cazorla et al., 2006; Maj 
et al., 2005; Patel et al., 2012). Conversely, increasing PDH activity by mutating a PDK 
isoform PDK4 in mice results in beneficial phenotypes, including protection from insulin 
resistance, hyperglycemia, and impaired glucose tolerance induced by a high fat diet.  
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Since pyruvate is produced by the glycolytic pathway in the cytoplasm, it must 
enter the mitochondrion to be utilized by PDH or PC. Pyruvate passes through the outer 
mitochondrial membrane (OMM) via diffusion though the nonselective voltage 
dependent anion channels (VDACs), whereas the mitochondrial pyruvate carrier (MPC) 
facilitates selective pyruvate transport through the inner mitochondrial membrane (IMM) 
(Figure 1.2B) (Gray et al., 2013). Prior to our discovery of the genetic nature of the MPC 
described in chapter 2, in vitro studies using mitochondria isolated from plant, yeast, and 
mammalian cells elegantly defined its biochemical characteristics (Schell and Rutter, 
2013). The kinetics and substrate affinities of the MPC were shown to differ from the 
monocarboxylate transporter (MCT) family of proteins that transport pyruvate and other 
carboxylic acids across the plasma membrane, indicating that a distinct transporter was 
indeed present in the IMM (Halestrap, 1975; Papa et al., 1971; Papa and Paradies, 1974). 
Moreover, the activity of this IMM pyruvate transporter was shown to be pH dependent, 
suggesting that the MPC may function through a H+/pyruvate symporter (or OH–
/pyruvate antiporter) mechanism that could be driven by the IMM H+ concentration 
gradient generated by the ETC (Figure 1.2B) (Halestrap, 1975; Papa and Paradies, 1974). 
Building on these observations, the identification of alpha-cyano-4-hydroxycinnamate 
(CHC) and its derivatives as potent inhibitors of mitochondrial pyruvate transport and the 
demonstration that MPC activity could be reconstituted in liposomes led to several 
attempts at isolating the MPC (Halestrap and Denton, 1974; Nalecz et al., 1986). First, a 
~15 kDa protein was identified in rat heart and liver mitochondria based on the 
characteristic that CHC incubation protected it from labeling by radioactive N-
phenylmaleimide (Thomas and Halestrap, 1981). Since CHCs also protect the MPC from 
  
18 
this thiol-blocking drug, it was concluded that this 15 kDa protein was the MPC (Thomas 
and Halestrap, 1981). A later report from the same authors, however, claimed to identify 
this protein as a subunit of cytochrome oxidase in follow up studies (Hildyard and 
Halestrap, 2003). Following this work, a mixture of ~6 proteins of various sizes (12, 30, 
32, 34, 66, and 74 kDa) purified from castor bean mitochondria were shown to facilitate 
CHC-sensitive pyruvate transport across a liposomal membrane, suggesting that one or 
more of them were the MPC (Brailsford et al., 1986). Then, three studies using 
immobilized CHC to affinity purify and reconstitute the MPC from bovine heart, rat 
liver, and yeast mitochondria were published (Bolli et al., 1989; Capuano et al., 1990; 
Nalecz et al., 1986). In each of the mammalian studies, a ~34 kDa protein was isolated 
that facilitated pyruvate transport in vitro, whereas a mix of 26 kDa and 50 kDa proteins 
were shown to reconstitute pyruvate transport in the yeast paper (Bolli et al., 1989; 
Capuano et al., 1990; Nalecz et al., 1986). The biochemical characteristics of pyruvate 
transport facilitated by the ~34 kDa proteins isolated from mammalian tissues, however, 
differed from that previously described for the MPC and from the pyruvate transporter 
isolated from yeast mitochondria (Bolli et al., 1989; Capuano et al., 1990; Halestrap, 
1975; Nalecz et al., 1986). Moreover, genetic studies were never performed to 
definitively demonstrate that any of these candidate proteins acted as the MPC in vivo. 
Thus, these reports of MPC isolation lacking a shared definitive candidate MPC molecule 
were inconclusive. In 2003, a member of the mitochondrial carrier family (MCF) was 
purported to be the MPC in yeast since its loss abrogated CHC-sensitive mitochondrial 
pyruvate uptake (Hildyard and Halestrap, 2003). This protein, however, was later shown 
to be a specific NAD transporter (Todisco et al., 2006). This result indicates that any 
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effects observed on mitochondrial pyruvate uptake observed by Hildyard and Halestrap 
in 2003 were indirect and likely caused by defects in the NAD-dependent PDH enzyme 
reaction (Todisco et al., 2006). Therefore, although over 40 years of elegant in vitro 
studies had defined the biochemical characteristics of the MPC (reviewed extensively in 
Schell and Rutter, 2013), its genetic identity was still unclear prior to our work described 
in Chapter 2 of this thesis and a copublished study (Herzig et al., 2012).  
 
Succinate dehydrogenase complex assembly and function 
The SDH complex (Complex II) is the only enzyme that acts in both the TCA 
cycle and the ETC and thus plays a unique role in cellular energy metabolism (Rutter et 
al., 2010). SDH couples the oxidation of succinate to fumarate with the reduction of FAD 
to FADH2, which pass electrons through ubiquinone to complex III to drive OxPHOS 
(Figure 1.2A) (Berg et al., 2002). SDH is a tetrameric protein complex containing two 
soluble matrix subunits called SDHA and SDHB in animals (Sdh1 and Sdh2 in yeast), 
and two IMM anchored subunits called SDHC and SDHD in animals (Sdh3 and Sdh4 in 
yeast) (Figure 1.2C)(Sun et al., 2005). The catalytic core of SDH comprises 
SDHA/SDHB, where SDHA contains a covalently bound FAD, and SDHB contains three 
iron sulfur (FeS) clusters. The SDHC/SDHD subunits function to anchor the complex to 
the IMM and contain a heme at their binding interface (Cecchini, 2003). The 
configuration of these redox cofactors (FAD, 3FeS cores, and heme) is arranged such that 




Consistent with the central position of SDH in energy metabolism, defects in 
SDH are linked to human disease. For example, rare mutations in SDH subunit-encoding 
genes have been shown to cause Leigh’s syndrome, infant encephalomyopathy, optic 
atrophy and Leukodystrophy (Alston et al., 2012; Astuti et al., 2001; Bayley et al., 2005; 
Bourgeron et al., 1995; Horvath et al., 2006; Parfait et al., 2000). In addition, SDH is a 
tumor suppressor, as loss-of-function mutations in SDH subunit-encoding genes have 
been linked to susceptibility to familial paraganglioma, pheochromocytoma, renal cell 
carcinoma, and gastrointestinal stromal tumors (Bardella et al., 2011; Baysal et al., 2000; 
Janeway et al., 2011; Niemann and Muller, 2000; Ricketts et al., 2008). Succinate 
accumulation to supraphysiological levels is thought to drive tumorigenesis associated 
with SDH deficiency through the inhibition of 2-oxoglutarate-dependent dioxygenases, 
such as the Jumanji family demethylases and Hypoxia Inducible Factor (HIF) prolyl-
hydroxylase (Bardella et al., 2011). The inhibition of these enzymes is purported to 
contribute to the etiology of SDH deficient tumors, although the exact mechanisms 
involved remain controversial (Bardella et al., 2011). Thus, SDH function appears to be 
critical for neuronal and muscular function, as well as maintaining a normal metabolic 
profile that prevents abnormal signaling or epigenetic events that drive tumorigenesis. 
 Although it is well established that ETC complexes I and IV assemble through a 
stepwise process involving ancillary assembly factors, the mechanisms underlying SDH 
complex assembly have only recently begun to emerge with the discovery of two 
dedicated SDH assembly factors (SDHAFs) in 2009 (Diaz et al., 2011; Fernandez-
Vizarra et al., 2009; Ghezzi et al., 2009; Hao et al., 2009). SDHAF1 (Sdh6 in yeast) was 
identified through genetic studies of patients with infantile leukoencephalopathy 
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characterized by loss of the SDH holocomplex (Ghezzi et al., 2009). The exact function 
of SDHAF1 in SDH complex assembly, however, remained unknown prior to our 
functional analysis (Chapter 5).  SDHAF2 (Sdh5 in yeast) was identified by the Rutter 
lab through the study of mitochondrial proteins with previously unknown functions 
described above (Hao et al., 2009). SDHAF2/Sdh5 directly interacts with SDHA/Sdh1 
and is required for covalent addition of the FAD to that subunit. Loss of Sdh5 in yeast 
and SDHAF2 in mammalian cells results in a complete loss of the SDH holocomplex and 
a concomitant elimination of SDH enzymatic activity. Consistent with these observations, 
mutations in SDHAF2 were identified that cause a form of familial paraganglioma, 
linking its activity to human disease (Hao et al., 2009). Taken together, these two studies 
show that SDH assembly factors are critical for SDH function, and further, demonstrate 
that mutations in SDHAF genes can result in a similar spectrum of diseases to that caused 
by mutations in core SDH subunit-encoding genes. Building on these discoveries, the 
identification of two novel SDHAFs, called SDHAF4 and SDHAF3, are detailed in 
Chapters 4 and 5 of this thesis, respectively. 
 
Drosophila as a model system to study mitochondrial 
function and the regulation of carbohydrate  
homeostasis  
 Drosophila is a powerful genetic model system to study many aspects of biology 
due largely to a short generation time, inexpensive maintenance in the lab, and the wealth 
of genetic tools available to the Drosophila research community (Pandey and Nichols, 
2011). Below, I will describe Drosophila studies relevant to my thesis work, mainly 
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focusing on the role of mitochondria in maintaining neuronal function and architecture 
and the regulation of carbohydrate homeostasis by the insulin-signaling pathway.  
 
Drosophila as a model to study mitochondrial function 
Work in Drosophila has yielded valuable insights into many areas of 
mitochondrial biology, including the role of mitochondria in the regulation of cell cycle 
checkpoints, mitochondrial fusion/fission mechanisms, and the pathways controlling 
mitochondrial motility (Guo et al., 2005; Hales and Fuller, 1997; Mandal et al., 2005; 
Owusu-Ansah et al., 2008; Russo et al., 2009). The field of Drosophila mitochondria 
research most relevant to my thesis, however, is work investigating the role of 
mitochondria in neuronal and muscular function and maintenance. Similar to humans, 
defects in neuronal and muscular tissues are hallmarks of mitochondrial dysfunction in 
Drosophila. Viable flies harboring mutations in a nuclear-encoded mitochondrial 
ribosomal protein technical knock out (tko), citrate synthase knockdown (kdn), adenine 
nucleotide translocase, a cytochrome oxidase subunit levy, Superoxide dismutase 2 
(SOD2), or the mitochondrial genome-encoded ATP-synthase subunit 6 (mtATP6), are all 
sensitive to mechanical shock-induced paralysis, a phenotype termed bang sensitivity 
(Celotto et al., 2006; Celotto et al., 2012; Fergestad et al., 2006a; Fergestad et al., 2008; 
Liu et al., 2007; Zhang et al., 1999). The underlying neuronal mechanism driving bang 
sensitivity is an increased susceptibility to seizures caused by increased neuronal 
hyperactivation (Pavlidis and Tanouye, 1995). Consistent with this idea, most bang 
sensitive mutants display age-progressive neurodegeneration and a reduction in lifespan 
(Fergestad et al., 2006b; Fergestad et al., 2008). Disruption of ATP production and/or 
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increased ROS are associated with these behavioral and neurodegenerative phenotypes, 
although the exact mechanism underlying neuronal cell loss is not known (Celotto et al., 
2012; Fergestad et al., 2006a). Mitotic clones lacking SdhA display neurodegeneration, 
thought to be driven by increased ROS production (Mast et al., 2008). Viable SdhB 
hypomorphic mutants are not sensitive to bang-induced seizures but they do exhibit 
reduced locomotion, aberrant flight muscle mitochondrial morphology, elevated ROS 
production, and sensitivity to oxidative stress (Walker et al., 2006). Drosophila models 
have also been used to understand the etiology of familial Parkinson’s disease. Flies 
harboring mutations in the familial Parkinson’s genes Pink and Parkin display defects in 
mitochondrial function and morphology, combined with reduced locomotion, 
dopaminergic neuron degeneration, and signs of muscular degeneration (Clark et al., 
2006; Greene et al., 2003; Park et al., 2006; Yang et al., 2006). The underlying cause of 
these phenotypes is thought to be a defect in mitochondrial quality control, dynamics, 
and/or motility (Guo, 2010; Park et al., 2009; Poole et al., 2008). Interestingly, reports 
using Drosophila genetic epistasis experiments to study Pink and Parkin were the first to 
show that they function in the same pathway (Clark et al., 2006; Park et al., 2006; Yang 
et al., 2006)—a result that was later confirmed in mammalian cells (Narendra et al., 
2010). Moreover, forward genetic studies of Pink and Parkin have identified genetic 
modifiers of these phenotypes, thus revealing potential pathways through which these 
genes affect mitochondrial quality control and tissue degeneration (Fernandes and Rao, 
2011). Taken together, these studies establish Drosophila as a powerful model to study 
the genetic pathways and molecular mechanisms underlying the nervous system and 
muscular defects caused by mitochondrial dysfunction. 
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Drosophila as a model to study carbohydrate homeostasis  
The insulin signaling pathway is a major regulator of carbohydrate homeostasis in 
humans (Hers, 1990; Schrayyef and Gerich, 2010). Defects in this pathway lead to 
diabetes mellitus, a disease characterized by chronic hyperglycemia (Inzucchi, 2012). 
The insulin signaling pathway is conserved in flies, where it controls growth in larvae 
and metabolism in both larvae and adults (Teleman, 2010; Grewal, 2009). Here I provide 
a brief introduction to the insulin signaling pathway as a foundation for my discussion of 
the role of dMPC1 in regulating carbohydrate homeostasis in Chapter 3. 
 There are eight Drosophila insulin-like peptides (DILPs) in the fly genome 
(Nassel et al., 2013). Of these, DILP2, DILP3, and DILP5 are produced in the insulin 
producing cells (IPCs) of the brain, which are functionally analogous to mammalian 
pancreatic beta cells (Nassel et al., 2013). DILPs are secreted into the circulation in 
response to feeding, where they bind to the sole insulin receptor (InR) ortholog present in 
flies in peripheral tissues (Geminard et al., 2009; Kim and Rulifson, 2004; Nassel et al., 
2013). Activation of the InR results in its autophosphorylation and the recruitment of 
Phosphoinositide 3-kinase (PI3K) to the membrane, which ultimately drives the 
phosphorylation and activation of the kinase Akt (Teleman, 2010). Akt subsequently 
phosphorylates and inhibits the nuclear translocation of the transcription factor FOXO, 
thus affecting FOXO target genes (Alic et al., 2011; Hwangbo et al., 2004; Teleman, 
2010). DILP signaling likely regulates metabolism through FOXO-dependent and -
independent transcriptional changes, as well as nontranscriptional mechanisms (Teleman, 
2010). The exact downstream mechanisms by which DILP signaling regulates 
carbohydrate metabolism, however, remain only partially understood (Teleman, 2010). In 
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addition, a signaling molecule analogous to mammalian glucagon called adipokinetic 
hormone (AKH) functions in opposition to the DILP signaling pathway by promoting 
catabolic metabolism under nutrient deprivation (Bharucha et al., 2008; Van der Horst, 
2003). Taken together, the opposing regulation and functions of DILP and AKH 
signaling maintain a balance of anabolic and catabolic pathways in the animal. 
Several studies have demonstrated a role for the DILP signaling pathway in 
regulating carbohydrate homeostasis. For example, circulating and/or stored 
carbohydrates were shown to accumulate as a result of disrupting DILP secretion or 
ablating IPCs (Haselton et al., 2010; Rulifson et al., 2002). Consistent with these results, 
deletion of dilp genes or downstream DILP signaling components, such as InR or a PI3K 
ortholog dp110, also leads to an elevation of carbohydrates (Murillo-Maldonado et al., 
2011; Shingleton et al., 2005). Conversely, mutants for negative regulators of insulin 
signaling like the lipocalin Neural lazarillo (Nlaz), PTEN, TORC, or the ortholog of the 
insulin-like growth factor binding protein-acid labile subunit dALS, display reduced 
carbohydrate levels (Arquier et al., 2008; Hull-Thompson et al., 2009; Oldham et al., 
2002; Wang et al., 2008). These studies provide strong evidence that DILP signaling is 
central to maintaining carbohydrate homeostasis in vivo, analogous to the role of insulin 
in mammals, and suggest that Drosophila may provide a powerful model to study the 
cellular and molecular mechanisms underlying diabetes pathophysiology. Several lines of 
experimentation have provided further support for this proposal. For example, although 
trehalose is the major circulating sugar present in larvae, glucose and trehalose are 
present at nearly equal levels in adult flies (Figures 3.2A and 3.2B) (Barry et al., 
manuscript in preparation). Consistent with this observation, disrupting insulin signaling 
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in adults causes hyperglycemia similar to that observed in humans, as well as 
hypertrehalosemia, which is specific to insects (Haselton et al., 2010). Moreover, insulin 
signaling is both necessary and sufficient for the clearance of circulating glucose from 
hemolymph in adult flies, suggesting DILP signaling promotes glucose uptake in vivo 
(Haselton et al., 2010; Haselton and Fridell, 2010). These results demonstrate that 
disrupting DILP signaling in flies leads to hyperglycemia and reduced glucose tolerance, 
which are two defining characteristics of diabetes in the clinic (Inzucchi, 2012).  
In addition, a number of recent studies have led to the exciting and important 
conclusion that Drosophila may provide a genetic model to study the mechanisms of 
glucose stimulated insulin secretion (GSIS). In mammals, GSIS is a process characterized 
by a series of steps in pancreatic beta cells that link the oxidation of circulating glucose to 
insulin secretion through ATP production, plasma membrane depolarization, and cellular 
calcium uptake (Prentki et al., 2013). Although amino acids, but not glucose, were shown 
to trigger DILP secretion from the IPCs of Drosophila larvae, recent evidence from our 
lab and others indicates that glucose is sufficient to stimulate DILP secretion from adult 
IPCs, analogous to pancreatic beta cells (Geminard et al., 2009). For example, IPCs 
isolated from adult flies depolarize and take up Ca2+ when incubated with glucose in vitro 
(Fridell et al., 2009; Kreneisz et al., 2010). Moreover, adult IPCs express subunits of the 
KATP-dependent channel known to be critical for GSIS in mammals (Fridell et al., 2009; 
Kreneisz et al., 2010). Consistent with this observation, adult IPCs respond to 
pharmacological KATP-dependent channel inhibitors used to promote insulin secretion in 
patients with diabetes (Fridell et al., 2009; Kreneisz et al., 2010).  Finally, glucose 
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feeding is sufficient to trigger DILP secretion from the IPCs of adult flies (Barry et al., 
manuscript in preparation).  
Interestingly, a Drosophila model of diet-induced type 2 diabetes has also been 
recently reported. A diet containing high sugar levels was shown to cause insulin 
resistance and hyperglycemia in wild type flies (Musselman et al., 2011). This diet 
promotes cardiac dysfunction and an increased susceptibility to tumors, similar to 
complications associated with diabetes (Hirabayashi et al., 2013; Na et al., 2013). Insulin 
resistance in Drosophila promotes changes in fatty acid metabolism and is regulated by 
the lipocalin Nlaz (Musselman et al., 2013; Pasco and Leopold, 2012). In mammals, 
alterations in lipid homeostasis and lipocalin signaling have been implicated in insulin 
resistance, suggesting that some mechanisms underlying insulin sensitivity may be 
conserved from flies to mammals (Law et al., 2010; Samuel and Shulman, 2012). Taken 
together, these recent findings all suggest that Drosophila provides a suitable model to 
study the molecular mechanisms underlying diabetes etiology. 
 
Thesis outline 
The identification and functional analysis of the MPC, SDHAF3, and SDHAF4 is 
presented in Chapters 2–5. This work, which was done in close collaboration with several 
other groups, has revealed novel regulators of mitochondrial energy metabolism and new 
aspects of physiology in Drosophila. Moreover, in at least one case, we linked our 
discovery to the identification of a novel human disease gene. 
In Chapter 2, we report the identification and functional characterization of the 
mitochondrial pyruvate carrier. In this study, we characterized two related proteins called 
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MPC1 and MPC2 that physically interact with each other to form a oligomeric complex 
embedded in the mitochondrial inner membrane. Drosophila MPC1 (dMPC1) mutants 
display phenotypes consistent with altered carbohydrate metabolism, including sensitivity 
to a sugar-only diet and elevated carbohydrate levels. Loss of dMPC1 also causes a 
defect in pyruvate metabolism, as dMPC1 mutants display elevated pyruvate levels 
combined with a reduction of TCA cycle intermediates and ATP. Building on these 
results, we demonstrate that Mpc1 is required for pyruvate uptake in isolated yeast 
mitochondria. Consistent with these observations in yeast and flies, knockdown of MPC1 
or MPC1 in human cells causes a defect in pyruvate oxidation. Importantly, our 
identification of a CHC-resistant point mutation in yeast Mpc1 suggests that Mpc1 is 
either the target of the drug, or in close proximity to its target, thus linking our work to 
previous biochemical studies of the MPC. Interestingly, we found that previously 
described patients displaying a disease characterized by a defect in mitochondrial 
pyruvate uptake carry loss-of-function mutations in MPC1. Overall, this chapter 
demonstrates that the conserved MPC complex is, or is a component of, the previously 
uncharacterized mitochondrial pyruvate carrier. As a co-first author of this work, I 
performed all of the Drosophila experiments presented in this chapter. 
Chapter 3 represents an extension of our analysis of the defects in carbohydrate 
homeostasis observed in dMPC1 mutants. This work demonstrates that dMPC1 mutants 
display hallmarks of diabetes, including toxicity associated with increased dietary sugar, 
hyperglycemia, elevated fasting glucose levels, and impaired glucose tolerance. 
Moreover, we show that defects in peripheral insulin signaling accompany these 
phenotypes. Preliminary results suggest that the reduction in peripheral insulin signaling 
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may be caused by a defect in DILP secretion from the IPCs. Future directions aimed at 
determining the mechanisms by which the MPC promotes glucose homeostasis and 
insulin signaling activity in Drosophila are also described.  
Chapters 4 and 5 are complementary studies in which we identified two novel 
SDH assembly factors, called SDHAF4 (Chapter 4) and SDHAF3 (Chapter 5), and 
performed a mechanistic characterization of the previously discovered protein SDHAF1 
(Chapter 5). Loss of SDHAF3 or SDHAF4 results in reduced assembly and activity of 
SDH in yeast, flies, and human cells. Accompanying this defect, flies or yeast cells 
mutant for either SDHAF3 or SDHAF4 accumulate succinate and display reduced levels 
of fumarate and malate.  Further, we show that Drosophila SDHAF4 mutants display a 
reduced lifespan, seizure susceptibility, neurodegeneration, and sensitivity to oxidative 
stress. Similar, but weaker, phenotypes are present in dSDHAF3 mutants. All of these 
assembly factors appear to affect redox homeostasis through protein-protein interactions 
with SDH subunits to promote SDH complex assembly. SDHAF3 and SDHAF1 
physically interact with the SDHB subunit to protect FeS clusters from ROS, whereas 
SDHAF4 physically interacts with the flavinated SDHA subunit to prevent auto-
oxidation. Together, these studies provide new insights into the mechanisms of SDH 
complex assembly and reveal novel candidate causative genes for diseases characterized 
by SDH deficiency. As a co-first author on chapter 4, I performed all Drosophila 
experiments in this study. My contribution to chapter 6 is smaller, however, as I 
generated the dSDHAF3 mutants and transgenic flies carrying the UAS-dSDHAF4 
construct, both of which were subsequently characterized by Wendou Yu. All other 
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PDH activity was almost normal in mpc1D cells
grown in rich medium [when the E2 subunit was
lipoylated (Fig. 2C)]. Thus, the MPC proteins ap-
peared to act upstream of PDH and may function
in the transport of pyruvate into mitochondria.
We therefore measured uptake of 14C pyruvate
in mitochondria isolated fromWT,mpc1D,mpc2D,
mpc3D, and mpc2Dmpc3D cells grown in lactate
medium (Fig. 3A). The specificity of uptake was
assessed by the use of UK5099, an inhibitor of
the mitochondrial pyruvate carrier (14). Uptake of
pyruvate in WT mitochondria was sensitive to
the proton ionophore carbonyl cyanide m-chloro
phenyl hydrazone (CCCP) (Fig. 3B). Mitochon-
dria from mpc1D and mpc2Dmpc3D cells showed
decreased pyruvate uptake (Fig. 3, A and B), de-
spite a normal mitochondrial membrane poten-
tial (fig. S5). Surprisingly, deletion ofMPC3 alone
impaired pyruvate uptake in mitochondria, where-
as mitochondria from the mpc2D mutant trans-
ported pyruvate normally. Because this result did
not correlate with the phenotypes of mpc2D and
mpc3D single mutants grown in SD, we inves-
tigated the expression of Mpc2 and Mpc3 in SD
and lactate media. In SD, yeast expressed mainly
Mpc2, whereas in lactate medium, they mainly
expressed Mpc3 (Fig. 3C). This expression pat-
tern could be explained, at least in part, by the
presence of binding sites for Gcn4 (a transcrip-
tion factor activated by amino acid starvation)
upstream of MPC2 (15). This raises the possi-
bility that under certain growth conditions, these
two proteins might have specific, nonredundant
functions.
We next assessed whether mouse MPC1
(mMPC1) and MPC2 (mMPC2) could restore
growth of yeast cells lacking a functional pyru-
vate transporter (Fig. 4, A and B). mMPC1 alone
restored growth ofmpc1D cells, but mMPC2 failed
to restore growth of the double-deletion strain
of its orthologous genes MPC2 and MPC3.
However, growth of the triple-deletion strain
mpc1Dmpc2Dmpc3D or of mpc2Dmpc3D cells
was restored by coexpression of both mMPC1
and mMPC2 (Fig. 4A). Thus, mMPC1 and
mMPC2 together functionally complement the
absence of pyruvate transport. We next expressed
mMPC1 andmMPC2, alone and in combination,
in the bacterium Lactococcus lactis (Fig. 4C),
which has been successfully used to express and
characterize mitochondrial transporters (16). No
pyruvate uptake was observed in bacteria ex-
pressing either protein alone compared with the
empty vector control. However, a fourfold in-
crease in pyruvate uptake was detected when
mMPC1 and mMPC2 were coexpressed (Fig. 4,
D and E). This uptake was sensitive to the mito-
chondrial pyruvate carrier inhibitor UK5099 and
to 2-deoxyglucose, which collapses the proton elec-
trochemical gradient (Fig. 4E) (17). Moreover,
artificially increasing the membrane potential
by lowering the pH in the import buffer from
7.2 to 6.2 significantly increased pyruvate uptake
(two-tailed t test, P < 0.05) (Fig. 4E). Thus, coex-
pression of mMPC1 and mMPC2 in bacteria is
sufficient to allow import of pyruvate with similar
properties to the mitochondrial pyruvate carrier
(3). We therefore conclude that the mitochondrial
pyruvate carrier is composed of Mpc1 and either
Mpc2 or Mpc3 in yeast and of MPC1 andMPC2
in mammals.
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A Mitochondrial Pyruvate Carrier
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Pyruvate constitutes a critical branch point in cellular carbon metabolism. We have identified
two proteins, Mpc1 and Mpc2, as essential for mitochondrial pyruvate transport in yeast,
Drosophila, and humans. Mpc1 and Mpc2 associate to form an ~150-kilodalton complex in the
inner mitochondrial membrane. Yeast and Drosophila mutants lacking MPC1 display impaired
pyruvate metabolism, with an accumulation of upstream metabolites and a depletion of
tricarboxylic acid cycle intermediates. Loss of yeast Mpc1 results in defective mitochondrial
pyruvate uptake, and silencing of MPC1 or MPC2 in mammalian cells impairs pyruvate oxidation.
A point mutation in MPC1 provides resistance to a known inhibitor of the mitochondrial
pyruvate carrier. Human genetic studies of three families with children suffering from lactic
acidosis and hyperpyruvatemia revealed a causal locus that mapped to MPC1, changing single
amino acids that are conserved throughout eukaryotes. These data demonstrate that Mpc1
and Mpc2 form an essential part of the mitochondrial pyruvate carrier.
Pyruvate occupies a pivotal node in the reg-ulation of carbon metabolism as it is theend product of glycolysis and a major sub-
strate for the tricarboxylic acid (TCA) cycle in
mitochondria. Pyruvate lies at the intersection
of these catabolic pathways with anabolic path-
ways for lipid synthesis, amino acid biosynthesis,
and gluconeogenesis. As a result, the failure to
correctly partition carbon between these fates
lies at the heart of the altered metabolism evi-
dent in diabetes, obesity, and cancer (1, 2). Owing
to the fundamental importance of pyruvate, the
mitochondrial pyruvate carrier (MPC) has been
studied extensively (3, 4). This included the dis-
covery that a-cyanocinnamate analogs, such as
UK-5099, act as specific and potent inhibitors
of carrier activity (5). In spite of this character-
ization, however, the gene or genes that encode
the mitochondrial pyruvate carrier remain un-
known (6, 7).
As part of an ongoing effort to characterize
mitochondrial proteins that are conserved through
evolution, we initiated studies of theMPC protein
family (originally designatedBRP44 andBRP44L





in humans) (8). This family contains three mem-
bers in Saccharomyces cerevisiae, encoded by
YGL080W, YHR162W, and YGR243W, hereafter
referred to asMPC1,MPC2, andMPC3, respec-
tively.Mpc2 andMpc3 are 79% identical in amino
acid sequence and appear to be the product of
a recent gene duplication event. Mpc1, Mpc2,
and Mpc3 colocalize with mitochondria (Fig. 1A
and fig. S2A), consistent with published mito-
chondrial proteomic studies (9, 10). The mito-
chondrial localization of Mpc1 and Mpc2 was
confirmed by biochemical fractionation (Fig. 1B).
Mpc1, Mpc2, and Mpc3 were enriched in mito-
chondrial membranes (fig. S2B), consistent with
the presence of predicted transmembrane domains
in their sequences (fig. S1).Mpc1 andMpc2were
resistant to protease treatment unless the mito-
chondrial outer membrane was ruptured (Fig. 1B
and fig. S2C), implying that they are embedded
in the mitochondrial inner membrane. Chromato-
graphic purification of tagged variants of Mpc1
and Mpc2, followed by mass spectrometry, re-
vealed that Mpc2 and Mpc3 were among the
major interacting proteins of Mpc1, and Mpc1
and Mpc3 were among the major interacting
proteins of Mpc2 (table S1). Consistent with this,
immunoprecipitation of tagged Mpc1 copurified
Mpc2 and vice versa (Fig. 1C, lanes 3 and 4). In
addition, Mpc2 can interact with itself (Fig. 1C,
lane 8), whereas anMpc1 homotypic interaction
was not detected (Fig. 1C, lane 7). Blue native–
polyacrylamide gel electrophoresis showed that
both Mpc1 and Mpc2 migrated as part of an
~150-kD complex (fig. S2D). Loss of Mpc2
prevented Mpc1 from migrating in this complex,
whereas an mpc1D strain showed elevated Mpc2
complex formation (fig. S2E). We conclude that
Mpc1 and Mpc2 form a multimeric complex
embedded in the mitochondrial inner mem-
brane, with Mpc2 likely being the major struc-
tural subunit.
Mutant yeast strains were subjected to a va-
riety of growth conditions. Thempc1D andmpc2D
cells displayed mild growth defects on non-
fermentable carbon sources like glycerol, with
greater effects on glucose medium (fig. S3) and
a strong growth defect in the absence of leucine
(Fig. 1D). In contrast, mpc3Dmutant displayed
no apparent growth phenotypes. Yeast,Drosoph-
ila, or human MPC1 orthologs, but not human
MPC2, could rescue the mpc1D growth pheno-
type (Fig. 1E), indicating that Mpc1 function is
conserved through evolution.
To analyze the physiological function of
MPCs in a multicellular animal, we extended
our studies to the Drosophila ortholog of MPC1
(dMPC1; encoded by CG14290), which also lo-
calized to mitochondria (fig. S4). Analogous to
yeast mpc1D mutants, dMPC1 mutants (fig. S5)
were viable on standard food, but sensitive to a
carbohydrate-only diet, with rapid lethality after
transfer to a sucrosemedium (Fig. 2A).Whereas
the amount of adenosine 5′-triphosphate (ATP)
was reduced in dMPC1mutants (Fig. 2C), along
with triacylglycerol (TAG) and protein (fig. S6,
B and C), the amounts of carbohydrates were el-
evated, including the circulating sugar trehalose
(Fig. 2D), glucose (Fig. 2E), fructose, and gly-
cogen (fig. S6, A and D). These results suggest
that dMPC1 mutants are defective in carbohy-
drate metabolism and may consume stored fat
and protein for energy. Consistent with this, the
lethality of dMPC1mutants on the sugar diet was
rescued by expression of the wild-type gene in
tissues that depend heavily on glucose metabo-
lism: the fat body, muscle, and neurons (Fig. 2B).
Metabolomic analyses revealed that the con-
centration of pyruvate was highly elevated, where-
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Fig. 1. Mpc1 and Mpc2 are evolutionarily conserved mitochondrial inner-membrane proteins. (A) Mpc1
labeled with green fluorescent protein (Mpc1-GFP) and mitochondrial targeted red fluorescent protein
(MtRFP) coexpressed in yeast cells. DIC, differential interference contrast. (B) Intact mitochondria, hypotonic-
swollen mitoplasts, and TritonX-100–solubilized mitochondria from a strain expressing Mpc1-V5 and
Mpc2-His6/HA2 with (+) or without (–) proteinase K incubation. An immunoblot of extracts using the
indicated antibodies with the whole-cell lysate (WCL) and postmitochondrial supernatant (PMS) is shown.
Mge1, Cyb2, and Fzo1 are matrix, intermembrane space, and outer-membrane proteins, respectively. (C)
Immunoprecipitations from mitochondrial extracts from mpc1D mpc2D cells expressing Mpc1 and Mpc2
tagged as indicated. Immunoblot of either immunoprecipitate (IP:HA) or input is shown (HA, hemag-
glutinin). QCR1 and 2 (ubiquinol–cytochrome c reductase complex core protein 1 and 2) along with Cox II
(cytochrome c oxidase subunit 2) are controls for the specificity of the immunoprecipitation. (D) Serial
dilutions of the indicated yeast strains spotted on synthetic media lacking leucine and grown at 30°C for
24 hours. (E) Serial dilutions of indicated strains spotted on synthetic media lacking leucine and grown at
30°C for 48 hours. wt, wild type; EV, empty vector.
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depleted in dMPC1 mutants on the sugar diet
(Fig. 2F). Similarly, the amounts of glycine and
serine, which can interconvert with glycolytic in-
termediates, were elevated in the mutants on
the sugar diet (fig. S6E), whereas glutamate, as-
partate, and proline, which can interconvert with
TCA cycle intermediates, were depleted under
these conditions (fig. S6F). Consistent with this,
metabolomic analysis ofmpc1D andmpc2D yeast
mutants revealed elevated pyruvate concentrations
(Fig. 3A), depletion of malate (fig. S7), depleted
acetyl–coenzyme A (CoA), and elevated CoA
concentrations (Fig. 3B). Taken together, these
results suggest that MPC1 mutants are unable
to efficiently convert cytosolic pyruvate to mito-
chondrial acetyl-CoA to drive the TCA cycle and
ATP production.
These phenotypes could arise from either
a defect in mitochondrial pyruvate uptake or
the conversion of mitochondrial pyruvate into
acetyl-CoA by the pyruvate dehydrogenase (PDH)
complex. Yeast lacking Mpc1, however, had
nearly wild-type PDH activity, unlike the strong
decrease seen in pda1Dmutants (Fig. 3C), which
lack PDH function (11). A decrease in PDH ac-
tivity also does not explain the growth defect of
mpc1D mutants, which is more severe than that
of the pda1D mutant (fig. S8). However, com-
bining thempc1D allele with a deletion formae1,
which encodes a malic enzyme that converts
malate to pyruvate in the mitochondrial matrix
(12), revealed a profound growth defect on glucose
medium that was completely rescued by plasmid
expression of either MAE1 or MPC1 (Fig. 3D).
Notably, mitochondria from the mpc1D mutant
displayed almost no uptake of 14C-pyruvate, which
could be fully rescued by plasmid expression of
wild-type MPC1 (Fig. 3E). Moreover, Mpc1
appears to be a key target for UK-5099, which
is an inhibitor of themitochondrial pyruvate carrier
(5). The mae1D mpc1D double mutant displayed
reduced growth on glucose medium lacking leu-
cine, and this phenotype could be effectively res-
cued by transgenic expression of wild-type MPC1
in the absence, but not the presence, of UK-5099
(Fig. 3F). By screening for MPC1 mutants that
could grow in the presence of UK-5099, we re-
covered an Asp118→Gly (D118G) substitution
in Mpc1 that conferred UK-5099 resistance (Fig.
3F).Moreover, whereas 14C-pyruvate uptake into
mitochondria expressing wild-type MPC1 was
almost completely inhibited by UK-5099, efficient
pyruvate uptake that is resistant to UK-5099 was
recovered upon expression ofMPC1-D118G (Fig.
3G). We conclude that Mpc1 is a key component
of the mitochondrial pyruvate carrier that cor-
responds to the activity studied for decades by
Halestrap and others (5, 13).
Depletion ofMPC1 in mouse embryonic fibro-
blasts (fig.S9A)causedamodest decrease inpyruvate-
driven oxygen consumption under basal conditions,
and a stronger reduction in the presence of carbon-
yl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP), which stimulates maximal respiration
(Fig. 4A). Similar results were also seen upon
silencingMPC2 (Fig. 4B and fig. S9A). This sup-
pression of pyruvate oxidation, which occurred
without affecting components of the oxidative phos-
phorylation machinery (fig. S9, B and C), sug-
gests that mammalian Mpc1 and Mpc2 mediate
mitochondrial pyruvate uptake in a manner sim-
ilar to that seen in yeast and Drosophila.
We have previously described a French-
Algerian family with two offspring that exhibited
a devastating defect in mitochondrial pyruvate
oxidation (14) (Fig. 4C, family 1). We subsequent-
ly discovered two additional families, each with
one affected child who displayed a similar, but
less severe, phenotype (Fig. 4C, families 2 and 3).
Linkage analysis and homozygosity mapping
allowed us to focus on one candidate region on
chromosome 6 (163,607,637 to 166,842,083,
GRCh37/hg19). This interval contained 10 poten-
tial candidate genes: PACRG, QKI, C6orf118,
PDE10A, SDIM1, T,PRR18, SFT2D1,RPS6KA2,
and BRP44L, which is the human MPC1. DNA
sequencing of the exons and intron/exon bound-
aries of the MPC1 gene in fibroblasts from the
affected patients in families 2 and 3 revealed the
samemolecular lesion, c.236T→A, causing a pre-
dicted p.Leu79→His (L79H) alteration (Fig. 4D).
Analysis of DNA from family 1 revealed a dis-
tinct sequence change, c.289C→T,which resulted
in a predicted p.Arg97→Trp (R97W) mutation
(Fig. 4D). Both of the affected residues are con-
served through evolution betweenMPC1 orthologs,
and Arg97 is conserved among both MPC1 and
MPC2 orthologs (fig. S1).
Cells from the affected individuals in families
1 and 2 exhibited impaired basal and FCCP-
stimulated pyruvate oxidation (Fig. 4E), whereas
glutamine-driven oxygen consumption was nor-
mal or elevated, demonstrating that they have
not acquired a generalized impairment of mito-
chondrial respiration (Fig. 4E). As expected, ex-
pression of wild-type humanMPC1 in the cells
from family 2 (Fig. 4F) or family 1 (Fig. 4G) ei-
ther completely or partially rescued the defect
in FCCP-induced pyruvate oxidation. Moreover,
expression of theMPC1-Leu79His allele was less
effective at suppressing the yeast mpc1D growth
defect relative to wild-type human MPC1 (Fig.
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Fig. 2. dMPC1 is required for pyruvate metabolism in Drosophila. (A) Percentage of living control
(dMPC1+) or dMPC1 mutant (dMPC– ) flies after transfer to standard laboratory medium (std. food) or to
media containing only sugar. (B) Percentage of living dMPC1+ or dMPC– flies carrying the indicated GAL4
and UAS transgenes on sugar media after 8 days. (C to E) Relative concentration of ATP (C), trehalose (D),
and glucose (E) in extracts from dMPC1+ or dMPC– flies on the indicated diet after either 2 days (D and E)
or 3 days (C). (F) Relative abundance of pyruvate and TCA cycle intermediates in dMPC1+ or dMPC– flies
after 2 days on the indicated diet as measured by gas chromatography–mass spectrometry. *P < 0.05,
**P < 0.01, and ***P < 0.001 (Student’s t test). Data are shown as mean T SEM.





Fig. 4. MammalianMPC1 andMPC2 are required for
normal pyruvate metabolism. (A and B) Pyruvate-
driven respiration in mouse embryonic fibroblasts
under basal and FCCP-stimulated conditions in cells
transfected with either control (Cont) small interfer-
ing RNAs (siRNAs) or three different siRNAs (si 1–3)
targeted to either MPC1 (A) or MPC2 (B). P values
relative to control. (C) Pedigrees of families 1, 2, and
3. Circles indicate females; squares, males; and dia-
monds, unknown sex. Black indicates deceased and
white, living. Arrows mark individuals from whom fi-
broblasts were obtained. (D) The protein region of
MPC1 containing the predicted amino acid substi-
tutions from all three families aligned by ClustalW.
Single-letter abbreviations for the amino acid residues
are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G,
Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro;
Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
Saccharomyces cerevisiae, Drosophila melanogas-
ter, Homo sapiens, Caenorhabditis elegans, Danio
rerio, Arabidopsis thaliana. (E) Pyruvate- (left) and
glutamine- (right) supported respiration of fibroblasts
harboring either L79H or R97WMPC1mutations. (F)
Pyruvate-supported respiration of either a control or
an L79H patient cell line after transduction with the
indicated vector. (G) Pyruvate-supported respiration
of either a control or an R97W patient cell line after
transduction with the indicated vector. (H) Serial di-
lutions of wt or mae1D mpc1D yeast strains carrying
the indicated plasmid grown onmedium lacking uracil
for plasmid selection at 30°C for 40 hours. Both long
(L) and short (S) forms of R97W were used (with or
without exon 4). ***P < 0.001, **P < 0.01, *P < 0.05,
†P < 0.10; NS, not significant (Student’s t test). Data
are shown as mean T SEM.
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Fig. 3. MPC1 is required for mitochondrial pyruvate uptake. (A) Relative
abundance of pyruvate in the indicated strains. P values relative to wt. (B)
Relative abundance of acetyl-CoA and CoA in the indicated strains. (C) Mito-
chondrial pyruvate dehydrogenase activity in the indicated strains. P value
relative to wt and mpc1D. (D) Serial dilutions of the indicated strain on
glucose medium grown at 30°C for 48 hours. (E) Uptake of 14C-pyruvate into
mitochondria purified from either wt or mpc1D cells containing the indi-
cated plasmid. P value relative to wt + EV and mpc1∆ + MPC1. (F) Mae1D
mpc1D cells transformed with the indicated plasmid and plated on media
containing or lacking combinations of leucine or UK-5099. (G) Uptake of
14C-pyruvate into mitochondria isolated from the mpc1D strain containing
the indicated plasmid in the presence or absence of UK-5099. ***P < 0.001,
**P < 0.01, *P < 0.05; NS, not significant (Student’s t test). Data are shown
as mean T SEM.





essentially inactive (Fig. 4H), suggesting thatMPC1
function is evolutionarily conserved from yeast
to humans.
The data presented here demonstrate that the
Mpc1-Mpc2 complex is an essential component
of the mitochondrial pyruvate carrier in yeast,
flies, and mammals. This is consistent with ex-
periments performed in rat liver, heart, and castor
beans, which implicated proteins of 12 to 15 kD
in mitochondrial pyruvate uptake (15)—similar
to the molecular masses ofMpc1 (15 kD), Mpc2
(14 kD), and Mpc3 (16 kD). Although these
individual sizes are relatively small, Mpc1 and
Mpc2 form a complex of ~150 kD, suggesting
that an oligomeric structure mediates pyruvate
transport. The demonstration thatMpc1 andMpc2
are sufficient to promote pyruvate uptake in a
heterologous system provides further evidence that
they constitute an essential pyruvate transporter
(16). Finally, the degree to which carbohydrates
are imported into mitochondria and converted
into acetyl-CoA is a critical step in normal glu-
cose oxidation as well as the onset of diabetes,
obesity, and cancer. Thus, like PDH, which is con-
trolled by allostery and posttranslational modifi-
cation (17), the mitochondrial import of pyruvate
is likely to be precisely regulated (18, 19). The
identification of Mpc1 and Mpc2 as critical for
mitochondrial pyruvate transport provides a new
framework for understanding this level of meta-
bolic control, as well as new directions for po-
tential therapeutic intervention.
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An Abundance of Rare Functional
Variants in 202 Drug Target Genes
Sequenced in 14,002 People
Matthew R. Nelson,1*† Daniel Wegmann,2* Margaret G. Ehm,1 Darren Kessner,2
Pamela St. Jean,1 Claudio Verzilli,3 Judong Shen,1 Zhengzheng Tang,4 Silviu-Alin Bacanu,1
Dana Fraser,1 Liling Warren,1 Jennifer Aponte,1 Matthew Zawistowski,5 Xiao Liu,6 Hao Zhang,6
Yong Zhang,6 Jun Li,7 Yun Li,4 Li Li,1 Peter Woollard,3 Simon Topp,3 Matthew D. Hall,3
Keith Nangle,1 Jun Wang,6,8 Gonçalo Abecasis,5 Lon R. Cardon,9 Sebastian Zöllner,5,10
John C. Whittaker,3 Stephanie L. Chissoe,1 John Novembre,2†‡ Vincent Mooser9‡
Rare genetic variants contribute to complex disease risk; however, the abundance of rare variants
in human populations remains unknown. We explored this spectrum of variation by sequencing
202 genes encoding drug targets in 14,002 individuals. We find rare variants are abundant
(1 every 17 bases) and geographically localized, so that even with large sample sizes, rare variant
catalogs will be largely incomplete. We used the observed patterns of variation to estimate
population growth parameters, the proportion of variants in a given frequency class that are
putatively deleterious, and mutation rates for each gene. We conclude that because of rapid
population growth and weak purifying selection, human populations harbor an abundance of rare
variants, many of which are deleterious and have relevance to understanding disease risk.
Understanding the genetic contribution tohuman disease requires knowledge ofthe abundance and distribution of func-
tional genetic diversity within and among pop-
ulations. The “common-disease rare-variant”
hypothesis posits that variants affecting health
are under purifying selection and thus should
be found only at low frequencies in human pop-
ulations (1–3). This hypothesis has become
increasingly credible because very large genome-
wide association studies of common variants
have explained only a fraction of the known her-
itability of most traits (4, 5). Investigating the role
of rare variants for complex trait mapping has
led to tests that aggregate rare variants (6) and
determine the abundance, distribution, and phe-
notypic effects of rare variants in human popu-
lations (7, 8).
Population genetic models predict that mu-
tation rates, the strength of selection, and de-
mography affect the abundance of rare variants,
although the relative importance of each is a
long-standing question (9–11). To understand
rare variant diversity in humans, we sequenced
202 genes in a sample of 14,002 well-phenotyped
individuals (table S1). These genes represent
approximately 1% of the coding genome and
approximately 7% of genes considered current
or potential drug targets (12) and are enriched
for cell-signaling proteins and membrane-bound
transporters (table S2). A total of 864 kb were
targeted, including 351 kb of coding and 323 kb
of untranslated (UTR) exon regions (database S1).
More than 93% of target bases were successfully
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Materials and methods 
Yeast strains 
 Saccharomyces cerevisiae haploid strain BY4741 (MATa his3 leu2 met15 ura3) 
was used as the parental wild-type strain in the mae1Δ mpc1Δ spot tests and JRY472 
(W303a MATa his3 leu2 met15 trp1 ura3) was used as the strain for all other 
experiments. Single deletion mutations were created in diploid strains by the standard 
PCR-based homologous recombination method using KanMX4 (kanamycin resistance), 
NatMX4 (nourseothricin resistance), or HphMX4 (hygromycin B resistance) cassettes to 
replace the entire gene, followed by sporulation and tetrad dissection to isolate the 
desired haploid knockout. Double and triple deletion mutants were created by standard 
crosses. Deletion strains were verified by PCR.  
 
Yeast plasmids 
 Nontagged and tagged yeast DNA fragments with the promoter, coding, and 
terminator sequences were inserted into low-copy centromeric expression vectors or 
high-copy 2µ expression vectors to enable endogenous level or overexpression 
expression. Coding sequences were tagged at the 3’ end with coding sequences for either 
Green Fluorescent Protein (GFP), a tandem affinity purification-tag that consist of a His6 
tag and either two HA tags, or a single V5 tag. The human BRP44 and BRP44L and 
Drosophila CG14290 genes were inserted into pRS416 (URA3) with a GPD promoter to 
create a constitutively transcribed construct. For expression of the patient-derived 
mutants, cDNA was used as a template to insert the patient sequences into pRS416 
(URA3) with the native promoter for yeast MPC1. 
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Assessment of yeast MPC1 sub-mitochondrial localization 
This experiment was done following a protocol adapted from Boldogh and Pon 
(Boldogh and Pon, 2007). Mitochondria harvested from the indicated strain expressing 
Rcf1-His6/HA3 were washed once with SH buffer (0.6 M sorbitol and 20 mM Hepes-
KOH, pH 7.4) to remove protease inhibitors.  Fifty micrograms of mitochondria were 
incubated in the isotonic SH buffer or hypertonic H buffer (20mM Hepes-KOH) with and 
without 1% Triton X-100.  To initiate protease digestion, 1µg of Protease K was added 
and incubated on ice for 20–30 minutes. One microliter of 200 mM PMSF was added into 
the reaction mixtures to stop protease activity, and lysate was denatured in Laemmli 
buffer and resolved on a 12% SDS-PAGE, followed by immunoblot.  To assess the 
solubility of MPC proteins, soluble and membrane fractions of the intact mitochondria 
homogenized by sonication were separated by centrifugation and precipitated in 15% 
TCA.  
 
Blue-native polyacrylamide gel electrophoresis (BN-PAGE) 
BN-PAGE was done as described previously (Wittig et al., 2006).  Seventy-five 
µg of mitochondria harvested from the strain indicated was resuspended in lysis buffer 
(50 mM NaCl, 5 mM 6-aminocaproic acid, 50 mM imidazole, 1 mM AEBSF, and 
protease inhibitor cocktail) and solubilized in 1% digitonin.  The lysate was resolved on a 
8–18% gradient native PAGE gel using a PROTEAN® II xi Cell gel running system (Bio-
rad).  Immunoblot was performed by soaking the gel in transfer buffer (192 mM glycine, 
25 mM Tris-base, 5% methanol, and 0.1% SDS) for 1 hour and transferring it onto a 
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PVDF membrane in a Trans-Blot® transfer cell (Bio-rad).  Membrane was blocked in 5% 
nonfat milk/TBST and probed with antibodies as indicated.  
 
Drosophila stocks 
The transposable P-element insertion P(XP)CG14290[d00809] was used to generate 
dMPC1 mutant alleles by imprecise excision. Two deletion alleles (dMPC11  and 
dMPC12)  and a precise excision were isolated and verified by PCR and sequencing. For 
all experiments, dMPC1– denotes dMPC11/dMPC12 transheterozygotes and dMPC1+ 
denotes animals that are homozygous for the precise excision allele and thus wild-type 
for dMPC1 function. To generate the UAS-dMPC1 construct, the dMPC1 cDNA (BDGP 
Gold GH10244) was sequenced, excised by digestion with XhoI and EcoRI, and cloned 
into the pUAST vector. To generate the UAS-MPC1-eGFP construct, eGFP was amplified 
from pPelican using the primers 5’-CTCGAGGTGAGCAAGGGCGAGG-3’ and 5’-
GGTACCTTACTTGTACAGCTCGTCCATG-3’, cut with XhoI and KpnI and cloned 
into pUAST to create pUAST-eGFP. The dMPC1 cDNA was then amplified by PCR to 
exclude the stop codon using primers 5’-CGGAATTCAACTTTCGGAGTG 
ACAACACG-3’ and 5’-CGCTCGAGGGCTGCCGCCTGCTGCTCCTTAGAC-3’, cut 
with XhoI and EcoRI and cloned into pUAST-eGFP.  All vectors used for generating 
transgenic lines were verified by restriction digestion and DNA sequencing. Transgenic 
lines were generated using standard P-element mediated transformation. All GAL4 lines 
were obtained from the Bloomington Stock Center. Mex-GAL4, CG-GAL4 and Elav-
GAL4 transgenes on the second chromosome were crossed into the dMPC11 and mutant 
background using balanced crossing schemes. Tubulin-GAL4, Mef2-GAL4, and UAS-
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dMPC1 on the third chromosome were recombined onto either the dMPC11 or dMPC12 
chromosome. The presence of dMPC1 deletion alleles in the transgenic lines was verified 
by PCR. 
 
Assessment of Drosophila MPC1 mitochondrial localization 
Fat body from adult Tubulin-GAL4/+; UAS-dMPC1-eGFP/+ animals was 
dissected in PBS and incubated for 30 minutes in 100 nM Mitotracker Orange 
CMTMROS (Invitrogen M7510). Following several washes, tissue was mounted in PBS. 
Imaging was performed using a Leica TCS SP2 confocal microscope using an excitation 
wavelength of 488 nm for eGFP and 543 nm for Mitotracker Orange CMTMROS. 
Emission spectra analyzed were 500–550 nm for eGFP and 550–620 nm for Mitotracker 
Orange CMTMROS. A Z-stack of 25 slices was imaged for each setting sequentially. 
The maximum intensity projection was generated in Image-J and used to generate an 
overlay. A 400 x 400 pixel region was enlarged and shown to focus on subcellular 
features. 
 
Drosophila dietary treatments 
Flies were maintained on standard Bloomington stock center medium at 25˚C in a 
12:12 light:dark cycle. For diet switching experiments, animals were allowed to eclose 
for 4 days and were then transferred to standard media supplemented with yeast paste and 
allowed to mature for 5 days. Males were collected and transferred in groups of 10–20 to 
vials containing the same food, or to vials containing 10% sucrose, 1% agar in PBS. 
Lethality was assayed by counting immobile flies that were not responsive to touch. For 
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survival assays, at least 40 flies of each genotype/dietary condition were assayed per 
experiment and each experiment was repeated two to three times. Representative data are 
shown.  
 
Drosophila metabolic assays 
For ATP measurements, adult male flies were homogenized in extraction buffer 
(6 M guanidine-HCL, 100mM Tris, 4 mM EDTA) and boiled for 5 minutes. 
Homogenates were spun down and diluted 1:750 in ATP assay buffer (25mM Tris, 
100uM EDTA) without GuCl essentially as described (Park et al., 2006), and ATP was 
measured using a luminescence-based assay (ATP Determination Kit, Invitrogen). ATP 
was measured 3 days after transfer to either standard food or the sugar diet as indicated. 
To measure glycogen, glucose, TAG, and protein, male adult flies were homogenized in 
cold PBS, and metabolites were measured essentially as described (Palanker et al., 2009), 
except that lysates used for glycogen, glucose, and TAG determination were heat treated 
at 70˚C for 10 minutes immediately after homogenization. Amyloglucosidase (Sigma) 
and a glucose assay kit (GO kit, Sigma) were used for glycogen and glucose 
determination. TAG was measured using Triglyceride Reagent and Free Glycerol 
Reagent (Sigma). Protein was measured using Bradford’s reagent (Bio-Rad). For 
trehalose determination, male adult flies were homogenized in trehalase buffer and 
trehalose levels were measured as previously described (Tennessen et al., 2011) using a 
porcine trehalase and a glucose assay kit (GO kit, Sigma). TAG, trehalose, glucose, 
glycogen, and protein levels were measured 2 days after transfer to either the standard 
food or sugar diet as indicated. In all experiments, five flies were pooled per biological 
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replicate and 5–6 biological replicates were assayed per condition/genotype. Combined 
results from at least three independent experiments are shown.   
 
Drosophila metabolomics sample preparation 
For GC/MS analysis, male adult flies were transferred to either standard food or 
the sugar diet for 2 days, after which, they were washed multiple times in PBS and snap 
frozen in liquid nitrogen. Frozen flies were transferred to tubes containing 1.4 mm 
ceramic beads, and 500 uL of cold (-20˚C) 90% MeOH was added and the flies 
pulverized using a MP Bio FastPrep 24 bead mill. The tubes were quickly transferred to  
-20˚C and incubated for 1 hour.  Following this cell debris was removed by 
centrifugation. A second extraction step was performed on the pellet using cold (-20˚C) 
60% MeOH.  The supernatants were combined and dried en vacuou. Samples were then 
analyzed by GC/MS as described below. For each experiment, 15 flies were pooled per 
biological replicate and 5–6 biological replicates were assayed per condition/genotype. 
Combined results from three independent experiments are shown.   
 
Yeast metabolomics sample preparation 
 Starter cultures were inoculated with a single colony into either YPD for glycolytic 
conditions or YPE for respirative conditions and grown overnight. These cultures were 
used to inoculate 80 mL of SD media containing the nutrients needed to supplement the 
auxotrophies. The initial inoculation was OD600 of 0.01 for YPD and 0.1 for YPE. 10 mL 
of this culture was transferred into eight 25 x 150 mm culture tubes containing three 3 
mm glass beads. Eight biological replicates of each strain were used per experiment. The 
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cultures were grown to an OD600 of 1 and harvested using the method of Canelas (Canelas 
et al., 2009). Briefly, 5 mL of culture was added to 20 mL of -40˚C MeOH followed by 
centrifugation at 5000 x g for 3 minutes at -20˚C. The supernatant was removed and the 
pellet gently washed with 2 mL of -40˚C 80% MeOH (aq) and centrifuged. The wash was 
removed and 5 mL of boiling 75% EtOH	  (aq) was immediately added, vortexed then 
incubated at 90˚C for 5 minutes. Cell debris was removed by centrifugation at 5000 x g 
for 3 minutes. The supernatant was removed to new tubes and dried under vacuum. A 
total of six biological replicates per group were prepared for GC/MS analysis and four 
biological replicates per group were prepared for LC/MS analysis. 
 
GC/MS analysis  
 All GC/MS analysis was performed with a Waters GCT Premier mass spectrometer 
fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 autosampler. Dried 
samples were suspended in 40µL of a 40 mg/mL O-methoxylamine hydrochloride in 
pyridine and incubated for 1 hour at 30˚C. 20µL of this solution with MSTFA was added 
to autosampler vials and incubated for 30 minutes at 37˚C while shaking. 1µL of sample 
was injected to the inlet which was held at 250˚C. The gas chromatograph was set to an 
initial temperature of 95˚C for 1 minute followed by a 40˚C/min ramp to 110˚C and a 
hold time of 2 minutes. This was followed by a second 5˚C/min ramp to 250˚C, then a 
third ramp to 350˚C, and a final hold time of 3 minutes. A 30 m Restek Rxi-5 MS column 
with a 5-m long guard column was employed for analysis. Data were collected by 
MassLynx 4.1. Data analysis for known metabolites was performed using QuanLynx. To 
find possible unknown metabolites MarkerLynx was used for peak picking, and these 
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data were exported to SIMCA-P ver. 12.0.1 where PCA and PLS-DA analysis was 
performed. All data were saved to an Excel spread sheet for further analysis. 
 
LC/MS analysis  
 Samples were analyzed using a Phenomenex (Torrence, CA) 3.0 mm x 150 mm 
Gemini-NX C18 (5µm) column with a Phenomenex Security Guard column filled with the 
same packing material. The chromatographic system consisted of an integrated Shimadzu 
HPLC system consisting of two LC-10AD pumps, column oven and a CBM-20A 82	  
controller. A PE200 autosampler with a cooling unit set to 4˚C was used for sample 
handling. A PE Sciex API 365 mass spectrometer modified with an Ionics EP 10+ source 
was used for analyte detection. A mobile phase consisting of solvent A (water with 15 
mM ammonium formate/6.5 mM N-dibutylamine) and solvent B (methanol/6.5 mM N-
dibutylamine) was used for elution of samples. The initial condition was 5% B with an 
initial hold time of 3 minutes followed by a ramp to 73% B over 21 min. A second ramp 
to 90% B was employed over the next minute with a 1 minute hold. The column was 
brought back to 5% B over 2 minutes and reequilibrated for 9 minutes. The flow rate was 
0.3 mL/min at 24˚C. Mass spectrometer transition optimization was performed using a 
syringe pump. For each metabolite optimized it was dissolved in buffer A as a 1 mg/mL 
solution. Infusion was performed at 20µL/min while 10% B/90% A buffer was coinfused 
using the HPLC at 0.3 mL/min. Samples were prepared as follows: to prevent the 
exogenous oxidation of GSH it was derivatized using 2-vinyl pyridine. To each sample 
was added 48µL of 10 mM K2PO4 pH 7 and 2µL of 2-VP. A brief sonication using a 
water bath was performed to fully elute each sample. After 30 minutes of incubation at 
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room temperature 50µL of buffer A was added followed by 10 minutes of centrifugation 
at 20000 x g. 90µL of this was transferred to an autosampler vial and immediately 
transferred to the autosampler, which was held at 4˚C until analysis. After analysis each 
metabolites peak height was recorded in Excel. 
 
Mitochondrial isolation 
Yeast mitochondria were isolated using a simplified version of the method 
described by Boldogh and Pon (2007). Briefly, yeast were grown in synthetic 2% 
raffinose media to an A600~3.0 and collected. The cells were pelleted, washed with sterile 
water, re-pelleted, and then frozen at -80˚C. Mitochondrial isolation began by thawing 
the cells on ice, digesting the cell wall with lyticase (Sigma) for 1 hour to generate 
spheroplasts. Following 40 minutes in regeneration buffer, spheroplasts were lysed using 
a Dounce homogenizer. The mitochondria were further purified through several high and 
low speed centrifugation steps.  
 
Pyruvate uptake 
Mitochondria used for pyruvate uptake experiments were extracted from live 
cells, kept on ice, and used within 5 hours of harvest without freezing.  An estimate of 
mitochondrial concentration was calculated using A280. Samples were then diluted to 
yield equal mitochondrial mass and centrifuged at 10000 rpm for 10 minutes to pellet 
mitochondria. The supernatant was then removed, and the mitochondrial pellet was 
resuspended in respiratory buffer (120 mM KCl, 5 mM KH2PO4, 1 mM EGTA, and 3 
mM HEPES pH 7.4) and placed on ice.  To initiate pyruvate uptake, 50 µL of 
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mitochondria was added to 100 µL of room temperature respiratory buffer at pH 6.8 in a 
microcentrifuge tube. The final concentration of the reaction mixture included 0.05 mM 
unlabeled malate along with 0.1 mM labeled pyruvic acid mixture (0.01 mM 14C-
pyruvate and 0.09 mM unlabeled pyruvate). The reaction was carried out at room 
temperature with constant stirring using a micro stir bar. Immediately following the 
addition of mitochondria to the reaction buffer the timer was started and 50 µL samples 
were taken and spotted onto binderless glass fiber filters (0.5 to 0.7 µm pore size) at 1, 2, 
or 3 min timepoints. The filter was then rinsed with 3 mL of ice cold TBS using an 
aspirator to draw the wash buffer through the filter and dry it. The filter was then placed 
in a scintillation vial containing Ultima Gold MV for liquid scintillation counting. Blank 
samples in which the 50 µL of mitochondria was replaced with the buffer used to 
resuspend the mitochondria were taken at corresponding timepoints, and these blank 
values were subtracted from the experimental data. Five biological replicates were 
analyzed per group. 
 
Drug inhibitor studies 
Pyruvate uptake was carried out as above with the following modifications. Prior 
to initiating the reaction, individual mitochondrial samples were incubated in 0.2 mM 
UK-5099 or DMSO (vehicle) for 2 min at room temperature with constant stirring. 
Following incubation, 100 µL of buffer containing radiolabeled pyruvate was added and 
the timer was started, and samples were collected as described above. Results shown are 




Screen for UK-5099-resistant mutants 
A plasmid library harboring MPC1 mutants was generated by PCR mutagenesis 
using methods previously described (Cadwell and Joyce, 1994). mpc1Δ mpc3Δ mae1Δ 
triple mutant yeast cells were transformed with the MPC1 mutant library and plated onto 
SD-Ura-Leu supplemented 500 uM UK-5099. Plates were incubated at 30˚C for 72 
hours, and mutant plasmids were isolated from viable colonies, amplified in E. coli, and 
then transformed into naive mpc1Δ mpc3Δ mae1Δ triple mutant yeast cells to confirm the 
conferral of resistance to UK-5099. An MPC1 mutant containing a D118G substitution 
was recovered from this screen. To quantify UK-5099 resistance conferred by the D118G 
substitution, uniform suspensions of mpc1Δ mpc3Δ mae1Δ triple mutant yeast cells were 
transformed with 2 µg empty vector, plasmid harboring wild-type MPC1, or plasmid 
harboring MPC1 D118G, and then plated onto either SD-Ura, SD-Ura-Leu, or SD-Ura-
Leu plus 500 uM UK-5099.  
 
Immunoprecipitation 
JRY472 mpc1Δ mpc2Δ was transformed with plasmids expressing tagged proteins 
(MPC1-HA, MPC1-V5, MPC2-HA, and MPC2-V5) or untagged MPC1 or MPC2 as 
controls. These strains were then grown to log phase in selective synthetic media 
containing 2% raffinose. Following harvest, mitochondria were isolated as above and 
stored at -80˚C. For immunoprecipitation, 2 mg of total mitochondria was solubilized in 
500 µL XWA buffer containing 150 mM NaCl, 0.8% digitonin, and protease and 
phosphatase inhibitors for 1 hour at 4˚C with gentle agitation. The debris was then 
pelleted and the supernatant was saved, one aliquot for input and the remainder being 
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used for the IP. 20 µL/10 mg of HA-Agarose beads were rinsed and incubated with the 
supernatant from above at 4˚C with gentle agitation for 2 hours. The HA-agarose beads 
were then washed 5 times with buffer as above with 0.1% digitonin.  Following the final 
wash the supernatant was aspirated and the beads resuspended in 1X SDS loading buffer 
and incubated at 95˚C for 10 minutes. 60 uL was then loaded to a 15% SDS 
polyacrylamide gel and separated by electrophoresis. Following transfer to a 
nitrocellulose membrane, anti-HA and anti-V5 primary antibody were used in 
combination with fluorescent anti-mouse and anti-rabbit secondary antibodies 
respectively. Protein bands were visualized using an Odyssey imager (Licor Biosciences). 
 
Pyruvate dehydrogenase activity assay 
The indicated strains were grown to stationary phase at 30˚C in selective media 
containing 2% raffinose. Once in stationary growth phase the strains were harvested and 
pelleted at 3000 g for 5 minutes and washed once with sterile water. Following 
resuspension, concentration was determined by A600 and used to dilute to an OD of 1.0 in 
1 liter of synthetic media containing 2% glucose. After 3 hours of growth the strains were 
harvested and mitochondria were isolated as described above.  Mitochondria were diluted 
to 4 mg/mL and sonicated on ice at an amplitude of 1.0, 3 seconds on and 9 seconds off 
for a total sonication time of 60 seconds. Debris was pelleted by centrifugation at 10,000 
rpm for 1 minute. Sonicated mitochondrial samples were then subjected to a coupled 
enzymatic assay with a spectrometric readout modified from the assay explained by 
Hinman and Blass (Hinman and Blass, 1981). Briefly, purified sonicated mitochondria 
was used to start the pyruvate dehydrogenase reaction in 50mM potassium phosphate 
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buffer pH 7.8, 0.2mM thiamine diphosphate, 2.5mM NAD+, 0.1mM CoA, 1mM MgCl2, 
0.3mM dithiothreitol, 5mM pyruvate, with coupling molecules 0.6mM 2(p-iodophenyl)-
3-p-nitrophenyl-5-phenyl-tetrazolium chloride and 6.5µM phenazine methosulfate. The 
reaction proceeded with intermittent shaking at 25˚C and absorbance readings at 495 nm 
are taken every 30 seconds over 30 minutes. Rates are determined by calculating the 
change in absorbance in the linear range per unit of time. Pyruvate dehydrogenase 
activity is calculated by subtracting the rate of absorbance change in samples supplied 
with 5 mM pyruvate from identical samples lacking pyruvate. The molar absorption of 
INT (12.4 mM-1 cm-1) (Hinman and Blass, 1981) was used to calculate the amount of 
NADH in nanomoles per milligram of protein per minute. Three biological replicates 
were analyzed per group. 
 
Fluorescence colocalization 
The indicated strains were transformed with a vector for expression of a C-
terminally GFP-tagged Mcp1, Mcp2, or Mcp3 shown to rescue the relevant phenotype 
along with a Mito-RFP plasmid. These cells were grown in selective synthetic media with 
2% glucose to an A600 = 1.0. The cells were then observed using a Zeiss Axioplan 2 
Imaging microscope (Carl Zeiss). 
 
Mammalian cell culture 
Mouse embryonic fibroblasts (MEFs) were isolated on day-13 post coitum. MEFs 
were transformed by viral transduction with SV40 Large-T antigen (pLNX SV-40) and 
selection with hygromycin (200 ug/ml).  Transformed MEFs were maintained in DMEM 
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with 10% FBS, 2 mM glutamax, and 1% primocin (Invivogen).  Human skin fibroblasts 
(HSFs) were isolated as previously described (Brivet et al., 2003) and immortalized by 
viral transduction with hTERT (Addgene Plasmid 1773) and selection with hygromycin 
(20 ug/ml). For rescue experiments, HSFs were reconstituted with empty vector or MPC1 
by viral transduction and selection with puromycin (1 ug/ml). HSFs were maintained in 
DMEM with 15% FBS, 2 mM glutamax, and 1% primocin. All viral transductions were 
performed with pseudotyped retroviral supernatants generated by cotransfection of 293T 
cells with Vsv-G, Gag-Pol, and a retroviral targeting vector harboring cDNA for the gene 
of interest. MPC1 cDNA was cloned into (Not1/BamHI) and delivered by the pQCXIP 
retroviral vector (Clontech).  
Knockdown of MPC1 and MPC2 was performed by treating cells with 20 nM 
siRNA using the Lipofectamine RNAiMax transfection reagent, according to the 
manufacturers instructions (Invitrogen). The All-Stars nontargeting siRNA (Qiagen) was 
used as the control for siRNAs targeting MPC1 and MPC2, which were designed with the 
Dharmacon siDesign Center tool (http://www.dharmacon.com/designcenter 
/DesignCenterPage.aspx). Sequences of the sense strands of targeting siRNAs, which 
include a 3’ tt DNA overhang are as follows. MPC1: (1) UCAACUACGAGAUGAG 
UAAtt, (2) GGGAAAACACAGAAUGCUAtt, and (3) CCAUGUAACAAACG 
AAGUAtt. MPC2: (1) CCGAUAAGGUGAUGCUAAAtt, (2) UGGAUAAAGUGG 
AGUUGUUtt, and (3) ACCAAGAACUCAAAUCUAAtt. Cells were subjected to 





Measurements of mammalian cellular respiration 
Oxygen consumption of MEFs and HSFs was measured with the XF-24 Seahorse 
Bioanalyzer. The day prior to assays, cells were seeded at densities between 20–30k 
(MEFs) and 15–25K (HSFs) per well of Seahorse XF-24 plates. At the time of seeding, 
12-well plates were seeded proportionally to 1) enable normalization of oxygen 
consumption data and 2) provide protein lysates for analysis by Western Blot. One hour 
prior to assays, cells were incubated, after 1 wash, with DMEM without glucose, 
bicarbonate, or phenol red (SIGMA, D5030), but with either pyruvate at 20 mM (MEFs) 
or 2 mM (HSFs), or glutamine at 2 mM (HSFs).  Basal Oxygen consumption was 
measured in the incubation media. FCCP-stimulated respiration was measured after 
injection of FCCP to a final concentration of either 0.5 uM (MEFs) or 1.0 uM (HSFs). 
For both basal and FCCP-stimulated respiration, a measurement loop was repeated 3 
times: 1 minute mixing, 2 minutes waiting, and 3 minutes measuring oxygen 
consumption. Oxygen consumption data were normalized to total protein. Total protein 
values were obtained by measuring the protein content, by BCA, of the proportionally 
seeded wells within 12-well plates and multiplying by the fraction of cells loaded per 
well in the Seahorse XF-24 plates. Five to eleven biological replicates were analyzed per 
group in each experiment. 
 
Human genetic mapping 
A severe defect of mitochondrial pyruvate oxidation has been found previously in 
three unrelated consanguineous families of Algerian descent. Key features of the index 
case in family 1 have been previously reported (Brivet et al., 2003). This female patient 
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developed a severe neonatal encephalopathy with lactic acidosis and died at 19 months 
after progressive neurological deterioration. Pyruvate dehydrogenase deficiency was 
ruled out as in other cases of families 2 and 3. These patients were less severely affected 
and presented essentially with psychomotor retardation without regression and epilepsy 
in family 2 or peripheral neuropathy in family 3. Currently these patients are alive aged 
5–14 years. 
Samples were subjected to a whole genome scan using The GeneChip Human 
Mapping 250k NspI arrays (Affymetrix, Santa Clara, CA, USA). Homozygosity regions 
were defined when more than 35 consecutive SNPs were homozygous, using HomoSNP 
software (http://bips.u-strasbg.fr/HomoSNP/ updated from [Stoetzel et al., 2007]). We 
selected candidate intervals when homozygous regions were observed for all affected 
individuals but not for unaffected ones. Homozygous haplotypes were then checked to be 
either identical for all four affected individuals (hypothesis of a common shared 
mutation), or identical for both affected individuals of family 1 on one side and identical 
for the two more mildly affected patients from families 2 and 3 on the other side 
(hypothesis of one mild and one more severe mutation). Parametric multipoint linkage 
analysis was performed in family 1 using software ALLEGRO 1.2 via the 
easyLINKAGE Plus V5.02 interface (Gudbjartsson et al., 2000) and assuming autosomal 
recessive inheritance, full penetrance, and a disease allelic frequency of 0.0001. 
Homozygosity mapping using the three affected families allowed for the 
identification of four candidate regions, each containing more than 35 consecutive 
homozygous SNPs in all four affected individuals, but not in unaffected probands from 
family 1. Haplotype-coherence checking permitted us to discard two regions. Out of the 
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two remaining candidate regions, the one located on chromosome 7 was 400 kb in length 
(84,106,464-84,587,114, GRCh37/hg19) and supported the initial hypothesis that a 
common mutation was shared by all four affected individuals since all homozygous 
haplotypes were identical. This region contained a single gene (SEMA3A), which did not 
appear to be a functionally relevant candidate.  The second region was located on 
chromosome 6 and of total length 3.2 Mbp (163,607,637-166,842,083, GRCh37/hg19). 
Haplotypes therein suggested the existence of two different mutations at the same locus, 
one carried by the more severely affected patients from family 1 and the other by the 
more mildly affected patients from families 2 and 3.  Interestingly, an independent 
multipoint analysis on family 1 highlighted five regions of linkage reaching the maximal 
expected LOD score of 2.05 (taking into account first cousin consanguinity), one of them 
encompassing the entire homozygosity region on chromosome 6. While the LOD score of 
2.05 is lower than required for definitive mapping to a single locus, it is the maximal 
LOD score given the structure of Family 1 that has confirmed first cousin consanguinity. 
Five other regions in family 1 showed the same LOD score, but the candidate region on 
chromosome 6 was the only one consistent with homozygosity mapping in the two other 
families. Improving the confidence in linkage analysis or segregation of mutations would 
have required the analysis of other family members, who were not accessible to the 
investigators, despite several attempts to recontact family 2. This interval on chromosome 
6 contained 10 potential candidate genes: PACRG, QKI, C6orf118, PDE10A, SDIM1, T, 





Human MPC1 alleles 
The c.289C>T mutation in MPC1 in family 1, which caused the predicted 
p.Arg97Trp substitution, also caused an altered splicing pattern of the pre-mRNA, 
leading to the formation of a truncated mRNA that lacked exon 4 in mutant fibroblasts 
(Fig. S2.10).  Sequence analysis of the other probands from family 1 revealed that the 
two parents were heterozygous for the c.289C>T mutation and the two unaffected 
children did not carry the mutation (Fig. S2.4C).  Similarly, the two affected children in 
family 3 were both homozygous for the c.236T>A mutation, which caused the predicted 
p.Leu79His substitution, and the two parents were both heterozygous (Fig. S2.4C).  
Sequence analysis of MPC1 from 80 unaffected donors revealed no evidence of 
mutations in this gene. Further, the c.236T>A mutation has not been observed in the 
more than 5200 individuals (European Americans and African Americans) whose exome 
data are reported in the exome variant server database.  
 
Primers for amplification of aspects of the MPC1 and MPC2 genes 
The following primers were used to amplify aspects of the MPC1 and MPC2 
genes (Table S2.1). Amplification of MPC1 exons and MPC1 cDNAs and ORFs was 
performed with the Hot-Start Phusion Polymerase (Thermo-Fisher) with the inclusion of 
Betaine to a final concentration of 1M, and all with annealing temperatures of 72˚C. 
Primers for the MPC1 ORF include NotI (5’) and EcoR1 (3’) restriction endonuclease 
sites that were utilized for cloning. Quantitative PCR (qPCR) was performed with a 




Table S2.1. Primers used for quantitative PCR. 
 
Amplicon Primer Sequence 
hsMPC1 Exon 1 FWD CCAGCCCCAGCCGTTTTACGGCAG 
  REV CTGAAAGGCGCCCACTGTCACCG 
hsMPC1 Exon 2 FWD GGCACAAACCACCCATGCCCAGC 
  REV GCTGTCACAGAGCTCGTGTCTAGGC 
hsMPC1 Exon 3 FWD GTGTCTGGGGTCCTGGGCATTGATTTC 
  REV 
GCAAGCAGGAGCTCTACTATGTTGAAAGT
CC 
hsMPC1 Exon 4 FWD CAGCCTACTCTTGCTCGGAAATATGTTCC 
  REV CCAGTCCCGCAGCACTCCCTC 
hsMPC1 cDNA FWD GCCGGGGTGTCATTGGCTCT 
  REV GTGACTCAGCAGCAGCTGGCAAT 
hsMPC1 ORF FWD 
GATCGCGGCCGCACCATGGCGGGCGCGT
TG 
  REV 
GATCGGATCCTTATGCAGATGCCGTTTTA
GTCATCTC 
mmMPC1 qPCR FWD GCACGGCCATGGCTGGAGC 
  REV GCAACAGAGGGCGAAAGTCATCCG 
mmMPC2 qPCR FWD CCGCTTTACAACCACCCGGCA 






Mass spectrometric identification of Mpc1 and Mpc2 interacting proteins. 
Eluates from TAP purification of Mpc1-His6/HA2 were subjected to trypsin 
digestion and mass spectrometric protein identification (Table S2.2 and S2.3).  Proteins 
that were absent from a negative control purification and are annotated as mitochondrial 
are shown, along with the Peptide-Spectral Matches (PSMs).  Size of the protein is also 
shown as this correlates with the number of possible tryptic peptides that can be detected.  
 
Statistical analysis 
Quantitative results were analyzed for statistically significant effects. P-values 
were determined by Student’s t test using Microsoft Excel. All quantitative data are 

















Table S2.2. Mpc1 TAP purification. 
 
Protein	   PSMs	   Protein	  Length	  (aa)	  
Ygl080	  (Mpc1)	   9	   139	  
Mpm1	   7	   252	  
Gut2	   7	   649	  
Ygr243	  (Mpc3)	   5	   146	  
Fmp24	   4	   501	  
Yhr162	  (Mpc2)	   4	   129	  
 
 
Table S2.3. Mpc2 TAP purification. 
	   	   	  Protein	   PSMs	   Protein	  Length	  (aa)	  
Mdl2	   28	   773	  
Yhr162	  (Mpc2)	   24	   129	  
Ygl080	  (Mpc1)	   17	   130	  
Nde1	   6	   560	  
Cor1	   5	   457	  
Ygr243	  (Mpc3)	   5	   146	  
Gut2	   4	   649	  

















Figure S2.1. MPC1 and MPC2 amino acid alignments. 
Mpc protein family sequences were aligned and plotted using the Clustal W and 
Boxshade programs. The Mpc1 and Mpc2 protein subfamilies were aligned separately 
first to show conservation within the subfamilies. Yeast Mpc2 (2) and Mpc3 (3), both 
members of the Mpc2 family, are shown. Subfamily alignments were then aligned 
manually, to show conservation between the subfamilies. TMHMM and MEMSAT3 
transmembrane prediction software predicted the presence of two transmembrane 
domains in the MPC proteins (shown above) whereas MEMSAT-SVM predicted three 
















Mpc protein family sequences were aligned and plotted using the Clustal W and 
Boxshade programs. The Mpc1 and Mpc2 protein sub-families were aligned 
separately first, to show conservation within the sub-families. Yeast Mpc2 (2) and 
Mpc3 (3), both members of Mpc2 family, are shown. Sub-family alignments were 
then aligned manually, to show conservation between the sub-families. TMHMM and 
MEMSAT3 transmembrane prediction software predicted the presence of two 
transmembrane domains in the MPC proteins (shown above) whereas MEMSAT-






















































































Figure S2.2. Additional characterization of MPC1 and MPC2/MPC3 in yeast.  
(A) Mpc2-GFP and Mpc3-GFP coexpression with mitochondrial targeted RFP (mtRFP). 
(B) Soluble and membrane fractions extracted from sonicated mitochondria were 
analyzed by immunoblot. Mpc proteins were detected by HA antibody. Aco1 is a soluble 
matrix protein and Sdh1 is a membrane-associated matrix protein. Asterisk indicates a 
nonspecific signal. (C) Intact mitochondria, hypotonic-swollen mitoplasts, and 1% 
TritonX-100–solubilized mitochondria of a strain expressing Mpc3-His6/HA3 were 
treated either with (+) or without (-) Proteinase K and analyzed by immunoblot.  Mge1, 
Tim10, and Fzo1 are matrix, intermembrane space, and outer membrane proteins, 
respectively.  Asterisk indicates a cleaved form of Mge1. (D) Mitochondria extracted 
from strains harboring either EV or plasmids expressing Mpc1-V5 and Mpc2-HA were 
solubilized by 1% digitonin and resolved by BN-PAGE followed by immunoblotting 
with HA and V5 antibodies. (E) Mitochondria extracted from strains harboring plasmids 
expressing Mpc1-HA in the presence or absence of Mpc2 (left) or Mpc2-HA in the 
presence or absence of Mpc1 (right) were solubilized by 1% digitonin and resolved by 
BN-PAGE followed by immunoblotting with an HA antibody. The Mpc1-HA blot was 
exposed for substantially longer than the Mpc2-HA blot.  The remaining Mpc1 assembly 




(A) Mpc2-GFP and Mpc3-GFP coexpression with mitochondrial targeted RFP (mtRFP). (B) Soluble 
and membrane fractions extracted from sonicated mitochondria were analyzed by immunoblot. Mpc 
proteins were detected by HA antibody. Aco1 is a soluble matrix protein and Sdh1 is a membrane-
associated matrix protein. Asterisk indicates a non-specific signal. (C) Intact mitochondria, 
hypotonic-swollen mitoplasts, and 1% TritonX-100–solubilized mitochondria of a strain expressing 
Mpc3-His6/HA3 were treated either with (+) or without (-) Proteinase K and analyzed by 
immunoblot.  Mge1, Tim10, and Fzo1 are matrix, intermembrane space, and outer membrane 
proteins, respectively.  Asterisk indicates a cleaved form of Mge1. (D) Mitochondria extracted from 
strains harboring either EV or plasmids expressing Mpc1-V5 and Mpc2-HA were solubilized by 1% 
digitonin and resolved by BN-PAGE followed by immunoblotting with HA and V5 antibodies. (E) 
Mitochondria extracted from strains harboring plasmids expressing Mpc1-HA in the presence or 
absence f Mpc2 (left) or Mpc2-HA in the p esence or absence of Mpc1 (right) were solubilized by 
1% digitonin and resolved by BN-PAGE followed by immunoblotting with an HA antibody. The 
Mpc1-HA blot was exposed for substantially longer than the Mpc2-HA blot.  The remaining Mpc1 
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Figure S2.3. Yeast MPC mutant growth defects.  
Serial dilutions of wild type (wt), and the indicated mutant strains were spotted on 
synthetic complete media, synthetic media containing glycerol, or YPAD media and 
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Serial dilutions of wild type (wt) and the indicated mutant strains were spotted on 
synthetic complete media, synthetic media containing glycerol, or YPAD media 







Figure S2.4. Drosophila MPC1 is localized to mitochondria.  
The adult fat body was dissected from animals expressing a UAS-dMPC1-eGFP 
construct under the control of the ubiquitous driver Tubulin-GAL4 and subsequently 










The adult fat body was dissected from animals expressing a UAS-dMPC1-eGFP 
construct under the control of the ubiquitous driver Tubulin-GAL4, and 
subsequently stained with the mitochondria-specific dye Mitotracker Orange. 































Figure S2.5. Drosophila MPC1 alleles.  
(A) The P-element P(XP)CG14290[d00809], located in the 5’UTR of dMPC1, was 
excised to generate the dMPC11 and dMPC12 deletion alleles, which are 999 and 1,352 
base pairs in length, respectively. A strain in which P(XP)CG14290[d00809] was excised 
precisely is utilized in this study as a genetically-matched control (dMPC1+). All alleles 
were verified by PCR and DNA sequencing. (B) Northern blot analysis performed using 
RNA isolated from the wild type Drosophila laboratory strain w1118 , homozygotes for 
the dMPC1 precise excision (dMPC1+) and transheterozygotes for the dMPC11/dMPC12 
deletion alleles. RNA was isolated using TriPure extraction reagent (Roche), and the 
resulting northern blots were probed with radiolabeled oligonucleotides targeted to 
dMPC1 and the loading control Ribosomal protein 49 (rp49). dMPC1 expression levels 
are equal to wild type  in the precise excision strain, whereas dMPC1 expression is 






(A) Th P-elem nt P(XP)CG14290[d00809], located in the 5’UTR of dMPC1, was 
excised to generate the dMPC11 and dMPC12 deletion alleles, which are 999 and 
1,352 base pairs in length, respectively. A strain in which P(XP)CG14290[d00809] 
was excised precisely is utiliz d in this stu y as a genetically-matched control 
(dMPC1+). All alleles were verified by PCR and DNA sequencing. (B) Northern 
blot analysis performed using RNA isolated from the wild type Drosophila 
laboratory strain w1118 , homozygotes for the dMPC1 precise excision (dMPC1+) and 
transheterozygotes for the dMPC11/dMPC12 deletion alleles. RNA was isolated 
using TriPure extraction reagent (Roche) and the resulting northern blots were 
probed with radiolabeled oligonucleotides targeted to dMPC1 and the loading 
control Ribosomal protein 49 (rp49). dMPC1 expression levels are equal to wild 
type  in the precise excision strain, whereas dMPC1 expression is eliminated in 






















Figure S2.6. dMPC1 mutants display metabolic defects.  
(A–C) Relative abundance of glycogen (A), TAG (B), or protein (C) in extracts from 
dMPC1+ or dMPC– flies on either a standard laboratory medium (std. food) or a medium 
containing only sugar after 2 days. (D–F) Relative abundance of fructose (D), amino 
acids metabolized through glycolysis (E) and amino acids metabolized through the TCA 
cycle (F) in flies on the indicated diet for two days measured by GC/MS. *p < 0.05, **p 


































































































(A-C) Relative abundance of glycogen (A), TAG (B), or protein (C) in extracts from 
dMPC1+ or dMPC– flies on either a standard laboratory medium (std. food) or a medium 
containing only sugar after two days. (D-F) Relative abundance of fructose (D), amino acids 
metabolized through glycolysis (E) and amino acids metabolized through the TCA cycle (F) 
in flies on the indicated diet for two days measured by GC/MS. *p<0.05, **p<0.01 and 









































Figure S2.7. Yeast MPC mutant metabolomic analysis. 
Relative abundance of various metabolites in the indicated strains was measured by 
GC/MS metabolomics. *p < 0.05; **p < 0.01; ***p < 0.001 relative to wt (Student's t 














































































































Relative abundance of various metabolites in the indicated strains was 
measured by GC-MS metabolomics. *p<0.05; **p<0.01; ***p<0.001 relative 
to wt (Student's t test). Data displayed as mean±SEM.


















Figure S2.8. Yeast MPC1 and PDA1 double mutant analysis.  
Serial dilutions of the indicated strains carrying the indicated centromeric expression 











































pda1∆ mpc1∆ + EV/EV
pda1∆ mpc ∆ + PDA1/EV
pda1∆ mpc ∆ + PDA1/MPC1
wt+ V/EV
FIg. S8. 
Serial dilutions of the indicated strains carrying the indicated centromeric expression 
plasmids were plated on medium lacking leucine and grown at 30°C for 72 hours.








Figure S2.9. Controls for mammalian experiments.  
(A) Relative levels of MPC1 and MPC2 mRNA after treatment of mouse embryonic 
fibroblasts (MEFs) with a nontargeting control or siRNAs targeting mouse MPC1 or 
MPC2. Cont. = control (nontargeting siRNA) (B–E) Western blots for tubulin, ATP5A 
(Complex V), UQCRC2 (Complex III), MCT01 (Complex IV), SDHB (Complex II), and 
NDUFB8 (Complex I) performed on cell lysates of (B) MEFs subjected to MPC1 or 
nontargeting knockdown (cont.), (C) MEFs subjected to MPC2 or nontargeting 
knockdown, (D) HSFs harboring the wild-type and L79H MPC1 alleles after retroviral 
reconstitution with empty vector or wild-type MPC1 or (E) HSFs harboring the wild-type 
and R97W MPC1 alleles, after retroviral reconstitution with empty vector or wild-type 
MPC1. *p < .05; **p < .01 and ***p < .001 relative to controls (Student's t test). Data 








(A) Relative l vels of MPC1 and MPC2 mRNA after treatment of mous  
embryonic fibroblasts (MEFs) with a non-targeting control or siRNAs targeting 
mouse MPC1 or MPC2. Cont.=control (non targeting siRNA) (B-E) Western blots 
for tubulin, ATP5A (Complex V), UQCRC2 (Complex III), MCT01 (Complex IV), 
SDHB (Complex II), and NDUFB8 (Complex I) performed on cell lysates of (B) 
MEFs subjected to MPC1 or non-targeting knockdown (cont.), (C) MEFs subjected 
to MPC2 or non-targeting knockdown, (D) HSFs harboring the wild-type and 
L79H MPC1 alleles after retroviral reconstitution with empty vector or wild-type 
MPC1 or (E) HSFs harboring the wild-type and R97W MPC1 alleles, after 
retroviral reconstitution with empty vector or wild-type MPC1. *p<.05; **p<.01 





































































































































Figure S2.10. Amplification of the MPC1 cDNA from patient samples.  
Amplification of cDNA harboring the MPC1 ORF derived from human skin fibroblasts 
that were isolated from a control patient and patients manifesting impaired pyruvate 
metabolism from families 1, 2, and 3. Amplification of cDNAs from families 1, 2, and 3 
resulted in amplicons of the expected size (arrow) that upon sequencing were found to 
harbor mutations matching those observed when sequencing their MPC1 genes (Family 
1: C289T/R97W; Families 2 and 3: T236A/L79H). Amplification of cDNA from family 
1 also produced an unexpected short amplicon (arrowhead). Sequencing revealed that the 
short MPC1 mRNA is misspliced and skips exon 4. Exon 4 skipping results in a 2 base 
pair frame-shift that codes for an Ala58Gly mutation and is followed by a premature stop 





Control Family 1 Family 2 Family 3
Fig. S10. 
Amplification of cDNA harboring the MPC1 ORF derived from human skin fibroblasts 
that were isolated from a control patient and patients manifesting impaired pyruvate 
metabolism from families 1, 2, and 3. Amplification of cDNAs from families 1, 2, and 3 
resulted in amplicons of the expected size (arrow) that upon sequencing were found to 
harbor mutations matching those observed when sequencing their MPC1 genes (Family 
1: C289T/R97W; Families 2 and 3: T236A/L79H). Amplification of cDNA from family 1 
also produced an unexpected short amplicon (arrowhead). Sequencing revealed that the 
short MPC1 mRNA is mis-spliced and skips exon 4. Exon 4 skipping results in a 2 base 
pair frame-shift that codes for an Ala58Gly mutation and is followed by a premature stop 
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DROSOPHILA MPC1 MUTANTS DISPLAY DEFECTS IN  
CARBOHYDRATE HOMEOSTASIS AND  
HALLMARKS OF DIABETES 
 














Circulating glucose concentrations are maintained at a relatively constant level by 
the insulin-signaling pathway. Aberrant glucose homeostasis is the main feature of 
diabetes, which is characterized by chronic hyperglycemia and defective insulin 
signaling. We describe here a role for the mitochondrial pyruvate carrier (MPC) in the 
regulation of glucose homeostasis and the prevention of diabetes-like phenotypes. 
dMPC1 mutant flies, which lack MPC function, are sensitive to dietary sugar levels and 
display hyperglycemia, elevated sorbitol, and other metabolic defects. Hyperglycemia 
can be rescued by specific expression of dMPC1 in the fat body of dMPC1 mutants.  
Moreover, dMPC1 mutants are glucose intolerant and display reduced activation of 
insulin signaling in peripheral tissues, possibly caused by a defect in insulin secretion, 
thus recapitulating key phenotypes associated with diabetes. Taken together, our results 
support a model in which mitochondrial pyruvate transport facilitates a metabolic state 




Circulating glucose levels must be maintained within optimal parameters to 
prevent tissue dysfunction and damage (Negre-Salvayre et al., 2009). This state of 
euglycemia is achieved through the homeostatic balance of cellular carbohydrate uptake, 
storage, synthesis, and catabolism (Schrayyef and Gerich, 2010). Carbohydrate 
homeostasis is primarily regulated by the insulin-signaling pathway, which controls 
cellular glucose uptake, glycogen synthesis, glycogenolysis, and gluconeogenesis in key 
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metabolic tissues (Schrayyef and Gerich, 2010; Siddle, 2011). Defects in carbohydrate 
homeostasis can manifest as diabetes, a disease characterized by a chronic elevation of 
blood sugar levels (Inzucchi, 2012). Type 2 diabetes, which is defined by peripheral 
insulin resistance and hyperglycemia, currently affects ~25 million people in the US and 
represents the seventh leading cause of death nationwide (WHO, 2013). With the spread 
of dietary excess and a sedentary lifestyle, the increasing incidence of type 2 diabetes is 
expected to continue at its alarming pace (CDC, 2011). Thus, it is critical that we better 
understand the basic genetic and molecular mechanisms underlying the regulation of 
glucose homeostasis and how misregulation of these pathways can lead to diabetes.  
Glucose homeostasis is controlled by the secretion of insulin from pancreatic beta 
cells in response to an increase in circulating glucose (Schrayyef and Gerich, 2010). This 
process, called glucose-stimulated insulin signaling (GSIS), is characterized by a set of 
steps that link the oxidative catabolism of glucose to insulin secretion through ATP 
production and cellular ionic changes. Following a meal, circulating glucose is 
transported across the beta cell plasma membrane through the glucose transporter 
GLUT2, rapidly converted to glucose-6-phosphate by glucokinase, and metabolized 
through glycolysis and the TCA cycle to drive ATP synthesis by the electron transport 
chain. This spike in ATP results in an increased ATP/ADP ratio, which inhibits the KATP-
dependent channel. The resulting membrane depolarization drives the activation of 
voltage gated calcium channels, thus increasing the intracellular Ca2+ concentration. 
Ultimately, this Ca2+ spike, along with metabolites generated by increased flux of the 
TCA cycle called coupling factors, trigger insulin secretion (Maechler, 2012; Prentki et 
al., 2013). Once secreted into the circulation, insulin activates the insulin receptor in 
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peripheral tissues, such as the liver and skeletal muscle, to activate PI3K and other 
signaling pathways, driving glucose uptake, metabolism, and storage to maintain 
euglycemia (Siddle, 2011). 
In the fruit fly, Drosophila melanogaster, circulating sugar levels are regulated by 
a signaling pathway orthologous to insulin signaling in humans. Analogous to insulin 
production by beta cells in the pancreas, several Drosophila Insulin Like Peptides 
(DILPS) are produced in the Insulin Producing Cells (IPCs) of the brain and secreted in 
response to dietary nutrients (Geminard et al., 2009; Kim and Rulifson, 2004; Nassel et 
al., 2013). Also similar to beta cells, IPCs in adult flies express the Kir6 and Sur1 
subunits of the KATP-dependent ion channel that is involved in GSIS (Fridell et al., 2009). 
Consistent with this, drug antagonists of the KATP-dependent channel used to promote 
insulin secretion in diabetic patients are functional in Drosophila (Fridell et al., 2009; 
Kim and Rulifson, 2004; Kreneisz et al., 2010). Moreover, IPCs isolated from adult flies 
depolarize in response to glucose in vitro, suggesting that DILP secretion in Drosophila 
adults may be regulated by a similar glucose-sensing mechanism as that used in 
mammals (Fridell et al., 2009; Kreneisz et al., 2010). Consistent with this model, work 
from our lab has shown that feeding adult flies glucose alone is sufficient to trigger DILP 
secretion (Barry et al., manuscript in preparation). Circulating DILPs activate the Insulin 
Receptor ortholog (InR) in peripheral tissues, including the fat body, which is the fly 
tissue analogous to both the liver and white adipose tissue (Arrese and Soulages, 2010; 
Teleman, 2010). DILP binding to the InR ultimately drives the activation of PI3K, the 
phosphorylation of Akt, and repression of the transcription factor FOXO, thus altering the 
transcriptional profile of many metabolic genes (Alic et al., 2011; Hwangbo et al., 2004; 
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Teleman, 2010). DILP signaling regulates aspects of carbohydrate homeostasis in 
peripheral tissues required to maintain euglycemia through these transcriptional changes 
and nontranscriptional mechanisms (Alic et al., 2011; Slack et al., 2011; Yamamoto and 
Tatar, 2011).    
Disruption of DILP signaling at multiple levels can lead to metabolic defects in 
Drosophila (Nassel et al., 2013). For example, ablation of the IPCs during development 
or adulthood results in alterations in TAG storage and an accumulation of glucose, 
glycogen, and trehalose, which is a disaccharide of glucose that is present in insects 
(Haselton et al., 2010; Rulifson et al., 2002). Moreover, genetic disruption of Dilp genes, 
InR, or a PI3K ortholog dp110, results in a similar elevation of carbohydrate levels 
(Arquier et al., 2008; Murillo-Maldonado et al., 2011; Shingleton et al., 2005; Zhang et 
al., 2009). Similarly, disruption of DILP secretion from IPCs also results in 
hyperglycemia (Fridell et al., 2009). Consistent with this observation, Drosophila 
mutants for Hepatocyte Nuclear Factor 4 (dHNF4) recapitulate a monogenic form of 
diabetes called Maturity Onset Diabetes of the Young 1 (MODY1), which is 
characterized by defective GSIS and hyperglycemia (Barry et al., manuscript in 
preparation; Gardner and Tai, 2012; Yamagata et al., 1996). Interestingly, a recent report 
has shown that increasing dietary sucrose levels to high levels leads to insulin resistance 
and hyperglycemia in wild type flies (Musselman et al., 2011). In follow up studies, some 
of the mechanisms underlying insulin resistance in humans were shown to be conserved 
in this Drosophila model of diet-induced diabetes, including dysregulated lipocalin 
signaling and alterations in lipid metabolism (Law et al., 2010; Musselman et al., 2013; 
Pasco and Leopold, 2012; Samuel and Shulman, 2012). Thus, studies in Drosophila 
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provide a simple system to understand the genetic and molecular mechanisms governing 
insulin secretion, insulin resistance, and the regulation of glucose homeostasis. 
The glycolytic product pyruvate is positioned at a central node in cellular 
metabolism, as it can be converted to alanine, lactate, acetyl-CoA, or oxaloacetate, 
depending on cellular metabolic requirements (Berg et al., 2002). The transport of 
pyruvate across the inner mitochondrial membrane is critical for fueling the TCA cycle 
through its conversion to acetyl-CoA or oxaloacetate by the mitochondrial enzymes 
pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC), respectively (Gray et al., 
2013). Consistent with this central role in cellular metabolism, alterations in pyruvate 
utilization can affect glucose homeostasis. For example, liver-specific disruption of PC 
reduces hepatic gluconeogenesis, and loss of either PDH or PC promotes hepatic insulin 
sensitivity (Choi et al., 2010; Kumashiro et al., 2013). In addition, disrupting PDH in beta 
cells reduces insulin secretion, demonstrating that the oxidation of glucose-derived 
pyruvate is required for GSIS in vivo (Srinivasan et al., 2010). Taken together, these 
studies suggest that mitochondrial pyruvate metabolism may represent a critical step in 
the regulation of glucose homeostasis, insulin resistance, and insulin secretion, all of 
which are processes known to be dysregulated in the context of diabetes (Inzucchi, 2012). 
We recently discovered the identity of the mitochondrial pyruvate carrier (MPC), 
which functions upstream of PDH and PC by facilitating mitochondrial pyruvate import 
from the cytosol (Bricker et al., 2012). Interestingly, there is evidence that manipulation 
of the MPC could be a strategy for treatment for type 2 diabetes as a novel 
PPAR gamma-sparing thiazolidinedione derivative that inhibits MPC activity was 
recently identified (Colca et al., 2013; Divakaruni et al., 2013). This MPC-binding drug 
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can improve insulin sensitivity in flies and cultured human pancreatic islets, but it is not 
clear if these benefits are the result of MPC inhibition (Colca et al., 2013; Rohatgi et al., 
2013). With these recent pharmacological discoveries, it is clear that a better 
characterization of the role of the MPC in the regulation of glucose homeostasis is 
required.  
In a previous set of experiments, we generated mutations in the Drosophila 
ortholog of MPC1 (dMPC1), an essential subunit of the MPC (Bricker et al., 2012).  
These mutants are viable to adulthood but display elevated carbohydrate and pyruvate 
levels, reduced overall ATP production, and a marked sensitivity to amino acid and lipid 
starvation (Bricker et al., 2012). Using these mutants, we set out to understand the role of 
mitochondrial pyruvate import in the regulation of glucose homeostasis in vivo though 
genetic studies in Drosophila melanogaster. We determined that dMPC1 mutants exhibit 
multiple hallmarks of diabetes, including a sensitivity to dietary sugar levels, glucose 
intolerance, and elevated circulating glucose under both fed and fasted conditions. 
Accompanying these phenotypes, we found that dMPC1 mutants display defects in 
insulin signaling, possibly due to a defect in DILP secretion from the IPCs. Furthermore, 
we determined that dMPC1 is required in the fat body to maintain euglycemia when flies 
are challenged with dietary sugar. Thus, our work defines a role for pyruvate metabolism 
in carbohydrate homeostasis in Drosophila and provides a simple, genetically tractable 
system for future studies of the role of mitochondrial pyruvate import in the regulation of 







Tubulin-Gal4 and Mef2-Gal4 were obtained from the Bloomington stock center. 
Lsp2-Gal4-3.1 (Lazareva et al., 2007) was a gift from Daniela Drummond-Barbosa 
(Johns Hopkins Bloomberg School of Medicine) and Dilp2-Gal4 (Wu et al., 2005) was a 
gift from Ping Shen (University of Georgia). UAS-dMPC1, dMPC1 mutants 
(dMPC11/dMPC12 transheterozygotes), and dMPC1+ precise-excision control strains 
were described previously (Bricker, et al., 2012). 
 
Dietary treatments 
All flies were maintained at 25˚C. To alter dietary sugar concentrations, media 
was prepared with a constant 10% yeast concentration, and either low sugar (2% 
sucrose), intermediate sugar (10% sucrose) or high sugar (18%) concentrations in water. 
To assay the effect of dietary sugar concentration on metabolite levels, animals were 
raised on standard Bloomington stock center media and transferred to the indicated diet 
within 2–4 days of eclosion, and metabolites were measured within 8–12 days of transfer. 
For lifespan analysis, males were transferred to the indicated diet within 1 day of 
eclosion. Flies were then transferred to new vials every 2–5 days and dead flies were 
counted and removed. To assay sugar-induced developmental delay, animals were 
allowed to lay on egg caps topped with yeast paste, the resulting progeny were 
transferred at the first instar stage to the indicated diets, and the number of pupariated 





To directly measure circulating glucose, ~30 adult females were poked in the 
thorax with a tungsten needle and centrifuged at 13,000 g through DNA columns (Zymo-
Spin IIIC #C1006-50) twice in a centrifuge at 4˚C. Hemolymph was then diluted 1/200 in 
PBS and heat treated at 70˚C for 10 minutes to inactivate enzymes, and the glucose 
concentration was measured as described previously (Bricker et al., 2012). Whole-animal 
glucose, trehalose, triacylglycerol (TAG), glycogen, and protein measurements were 
performed using colorimetric assays and all other metabolites were measured by gas 
chromatography/mass spectrometry as described previously (Bricker et al., 2012). 
 
Glucose tolerance test 
Male adult flies were aged 5–9 days on standard Bloomington stock center media, 
starved overnight on starvation media (1% agar in H2O), fed 10% glucose/1% agar for 2 
hours, and subsequently transferred to starvation media for 2 or 4 hours. Glucose 
measurements were performed at each time point as described previously (Bricker et al., 
2012). 
 
Assays for activation of peripheral insulin signaling 
 Flies were aged for 8–12 days on high sugar media prior to western or northern 
blot analysis. To assay Akt phosphorylation, flies were homogenized and protein from 
the equivalent of ½ of a fly was resolved by SDS-PAGE and immunoblotted using 
standard methods with antibodies to Phospho-Akt (Cell Signaling #4691 – 1:1000 
dilution), Pan-Akt (Cell Signaling #4054 – 1:1000 dilution), and Beta-Tubulin 
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(Chemicon MAB380 – 1:100,000 dilution), followed by chemo-luminescent detection. 
4eBP and rp49 mRNA levels were assayed by northern blot analysis using radiolabeled 
probes generated using templates amplified using the following primers: 4eBP – 5’-
TGAAGAATCTCCGTGGCTCC-3’ and 5’-GACCGAGAGAACAAACAAGGTG-3’, 
rp49 – 5’-ATTAACCCTCACTAAAG-3’ and 5’-AATACGACTCACTATAG-3’. 
Experiments were repeated several times and representative data is shown.  
 
DILP2 secretion assay 
Flies aged 5–9 days were starved overnight followed by 2 hours of feeding on 
high sugar media (10% yeast/18% sucrose). Brains were dissected from starved or fed 
animals in cold PBS and fixed for 20 minutes at room temperature (4% 
paraformaldehyde in PBS). Following several washes in PAT (PBS + 0.5% TritonX-
1000) brains were incubated with an antibody targeted to DILP2 (polyclonal antibody 
generated against the peptide MVCEEYNPVIPH) in PAT+5% normal donkey serum 
(NDS) at 1:500 concentration for 48 hours at 4˚C. Brains were then washed in PAT and 
subsequently incubated for 48 hours with Cy2-conjugated secondary antibody in 
PAT+5% NDS at 4˚C. Brains were mounted in Slowfade GoldTM (Invitrogen) and 
imaged using an Olympus FV1000 confocal microscope. Z stack images were taken 
through the entire depth of fluorescence of the IPCs from all brains using identical 
settings. IPCs were traced in maximum intensity projections and the mean gray value was 






Prism software was used to graph all quantitative data and perform statistical 
analysis. P values for pairwise comparisons were calculated using a Student’s t test. P 
values for Kaplan Meyer survival curves were calculated using a log rank test. All 
quantitative data is shown as mean ± SEM. 
 
Results 
Drosophila MPC1 mutants are sensitive to dietary sugar levels 
Work from our lab has demonstrated that flies exhibiting defects in carbohydrate 
homeostasis can be sensitive to the abundance of sugar in their diet (Barry et al., 
manuscript in preparation). In addition, low carbohydrate diets have been utilized to treat 
human patients with disorders of pyruvate metabolism (Wexler et al., 1997). Thus, we 
sought to determine if dMPC1 mutants are sensitive to dietary sugar levels. To do so, we 
assayed the developmental timing and adult lifespan of flies fed a diet in which we varied 
sucrose levels, from low (2%) to intermediate (10%) or high (18%) concentrations in the 
presence of a constant amount of yeast (10%). The yeast in this food provides the amino 
acids and lipids required for the dMPC1 mutants to survive for longer than ~4 days 
(Bricker et al., 2012).  These sucrose concentrations were used such that the highest 
concentration (18%) is well below the amount (34%) previously shown to cause insulin 
resistance in wild-type flies (Musselman et al., 2011), and the intermediate level is close 
to that found in normal Drosophila growth media. Control flies raised on these diets 
experience a developmental delay correlated with increasing dietary sucrose 
concentrations (Figure 3.1A), whereas dMPC1 mutants display a similar, but more severe 
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sugar-induced delay (Figure 3.1B). Adult controls transferred to intermediate or high 
sugar diets after eclosion live longer than those on low sugar food, consistent with 
previous reports (Figure 3.1C) (Bass et al., 2007; Skorupa et al., 2008). Conversely, this 
profile is reversed in dMPC1 mutant adults, with flies on the low sugar diet living 
longest, and flies on the high sugar food dying most rapidly (Figure 3.1D). Taken 
together, these results suggest that dMPC1 mutants are sensitive to dietary sugar load, 
especially during the adult stage. 
 
Defects in carbohydrate and lipid homeostasis in dMPC1 mutants 
on a high-sugar diet 
The sensitivity of dMPC1 mutants to a high-sugar diet is consistent with an 
inability to maintain metabolic homeostasis in response to increased sugar intake. To 
better understand the metabolic changes induced by the high dietary sugar load, we 
quantified several key metabolites in dMPC1 mutant adults fed either the low or high 
sugar diet for 10 days. Interestingly, whole animal trehalose and glucose levels are 
normal in dMPC1 mutants on the low sugar diet, and significantly elevated on the high 
sugar medium (Figures 3.2A and 3.2B). Glycogen levels are increased in dMPC1 mutants 
on the low sugar diet, with a further elevation on the high sugar medium (Figure 3.2C). 
Conversely, TAG levels are normal in dMPC1 mutants on the low sugar food, and 
reduced in mutants on the high sugar diet (Figure 3.2D). Moreover, dMPC1 mutants 
exhibit a significant accumulation of the sugars inositol, erythrose, and ribose as well as 
the sugar alcohols sorbitol, mannitol, threitol, and xylitol (or ribitol) when maintained on  
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Figure 3.1. dMPC1 mutants are sensitive to dietary sugar levels. 
(A–B) Precise-excision controls or dMPC1 mutant (dMPC1–) first instar larvae were 
transferred to media containing low (2%), intermediate (Int; 10%), or high (18%) sugar 
concentrations and the number of pupariated flies was counted daily. N > 105 flies per 
genotype under each feeding condition. Mean ± SEM is shown. Median time to 
pupariation (days) for each genotype/condition are as follows—Control low = 4.15; 
Control intermediate = 4.55; Control high = 5.35; Mutant low = 4.48; Mutant 
intermediate = 5.07; Mutant high = 6.46.  (C–D)  The percentage of surviving adult 
control or dMPC1– flies fed the low, intermediate, or high sugar diet was assayed every 
2–5 days. N > 115 male flies per genotype under each feeding condition. Mean ± SEM is 
shown. Median lifespan (days) for each genotype/condition–Control low = 48; Control 
intermediate = 57; Control high = 60; Mutant low = 35; Mutant intermediate = 29; 
Mutant high = 22. P values for each possible comparison were calculated using a log rank 
test and are as follows–Control low vs. control intermediate or high: p < 0.0001. Control 
intermediate vs. high: p = .223. Mutant low vs. mutant intermediate: p = 0.0005. Mutant 
low vs. mutant high: p < 0.0001. Mutant intermediate vs. mutant high: p < 0.0001. All 






Figure 3.2. Altered carbohydrate and lipid homeostasis in 
dMPC1 mutants. 
Control or dMPC1 mutant (dMPC1–) adults were aged 8–12 days on the low or high 
sugar diet and whole animal metabolite levels were measured. The abundance of (A) 
trehalose, (B) glucose, (C) glycogen, or (D) triacylglycerol (TAG) normalized to protein 
is shown. N = 5–6 samples per genotype. Mean ± SEM is shown. P values calculated by 






the high sugar diet (Figure 3.3). The sorbitol accumulation is particularly interesting 
because the conversion of excess intracellular glucose to sorbitol through the polyol 
pathway is thought to promote neuropathy in diabetic patients (Brownlee, 2001). In 
addition, we observe a similar sorbitol accumulation in a Drosophila model of MODY1 
(Barry et al., manuscript in preparation).  In contrast, pyruvate accumulates to similar 
levels in dMPC1 mutants on both diets (Figure 3.3). These metabolic changes on the high 
sugar diet demonstrate that dMPC1 mutants are unable to maintain carbohydrate and lipid 
homeostasis in response to changes in dietary sugar and, furthermore, that these defects 
are independent of changes in pyruvate accumulation.  
 
dMPC1 mutants display elevated circulating glucose, increased 
fasting glucose, and glucose intolerance 
Since we observe a sensitivity to dietary sugar and an elevation of glucose and 
sorbitol in dMPC1 mutants, we wanted to determine if dMPC1 mutants exhibit clinically-
defined characteristics of diabetes. To do this, we first verified that the increase in 
dMPC1 glucose observed in previous experiments does indeed correspond to an increase 
in the circulating levels of glucose in the hemolymph (Figure 3.4A). Building on that 
observation, we asked if dMPC1 mutants exhibit impaired fasting glucose and impaired 
glucose tolerance, similar to diabetic patients (Inzucchi, 2012). To address this question, 
we designed a Drosophila oral glucose tolerance test that measures the dynamics of 
postprandial glucose clearance over time. Using this assay, we identified that dMPC1 






















Figure 3.3. Accumulation of sugars and sugar alcohols in dMPC1 
mutants is influenced by dietary sugar. 
Control or dMPC1 mutant (dMPC1–) adults were aged 8–12 days on the low or high 
sugar diet and whole animal small metabolite levels were measured by Gas 
chromatography/mass spectrometry. The abundance of (A) pyruvate, (B) ribose, (C) 
inositol, (D) erythrose, (E) sorbitol, (F) mannitol, (G) threitol, or (H) xylitol (or ribitol – 
cannot differentiate between these two in our analysis) is shown. N = 3 biological 
replicates per genotype. Mean ± SEM is shown. P values comparing mutants to controls 
under either condition were calculated by Student’s t test. *p < 0.05, **p < 0.01, and 
























Figure 3.4. Hallmarks of diabetes in dMPC1 mutants. 
(A) Hemolymph glucose concentrations of either control or dMPC1 mutant (dMPC1–) 
adult flies aged 10 days on high sugar media were determined N = 4 per genotype. (B) 
Control or dMPC1– flies were aged 5–9 days on standard laboratory media and starved 
overnight for 16 hours. After starvation, whole-animal glucose abundance normalized to 
protein was determined. N = 5 per genotype. (C) Control or dMPC1–  flies were aged 5–9 
days on standard laboratory media, starved overnight for 16 hours, placed on 10% 
glucose for 2 hours, and subsequently restarved for either 2 or 4 hours. At each timepoint, 
whole-animal glucose abundance normalized to protein was assayed. N = 5 biological 
replicates per genotype at each timepoint. Mean ± SEM is shown. P values were 










following a glucose meal (Figures 3.4B and 3.4C). Taken together, these results establish 
that dMPC1 mutants display several key hallmarks of diabetes. 
 
Insulin signaling defects in dMPC1 mutants 
Given the diabetes-like phenotypes observed in dMPC1 mutants, we predicted 
that they might also exhibit defects in insulin signaling. To test this prediction, we 
assayed the phosphorylation state of Akt and the expression level of 4eBP, a target gene 
of the transcription factor FOXO (Figure 3.5A)(Alic et al., 2011; Demontis and Perrimon, 
2010; Teleman et al., 2008). If insulin signaling is reduced in peripheral tissues, we 
expect to observe a reduction in Akt phosphorylation and overexpression of 4eBP due to 
derepression of FOXO.  Consistent with this prediction, dMPC1 mutants display reduced 
levels of phosphorylated Akt and increased 4eBP mRNA levels (Figures 3.5B and 3.5C). 
Taken together, these results indicate that dMPC1 is required for normal insulin signaling 
activity in peripheral tissues. 
 
Partial disruption of DILP2 secretion in dMPC1 mutants 
Reduced insulin signaling in the tissues of dMPC1 mutants could be caused by a 
defect in the secretion of DILPs from the IPCs. We hypothesize that mitochondrial 
pyruvate import would be required for DILP secretion if the release of DILPs from IPCs 
is controlled by a mechanism similar to GSIS in mammalian beta cells (Prentki et al., 
2013; Srinivasan et al., 2010). To address this possibility, we dissected the brains from 
dMPC1 mutants following an overnight fast and subsequent refeeding, and assayed the 


















Figure 3.5. Reduction of peripheral insulin signaling activity in 
dMPC1 mutants. 
(A) A simplified diagram of the Drosophila insulin-signaling pathway. (B–C) Control or 
dMPC1 mutant adults were aged 8–12 days on the high sugar diet and (B) 
phosphorylated Akt (phospho-Akt), total Akt, and Tubulin protein levels were 
determined by western blot analysis, or (C) 4eBP and rp49 mRNA levels were assayed 






immunofluorescence. In control IPCs, there is a reduction in DILP2 staining upon 
refeeding due to the secretion of accumulated DILP2, as expected (Figures 3.6A and 
3.6B). In contrast, dMPC1 mutants display an accumulation of DILP2 to higher levels 
under both fasted and fed conditions, and DILP2 secretion is partially reduced (Figures 
3.6A and 3.6B). Thus, although this data is still preliminary, our results indicate that 
dMPC1 is required for proper DILP secretion by the IPCs.  
 
dMPC1 is required in the fat body to regulate glucose homeostasis 
To determine the tissue specific roles of dMPC1 in glucose homeostasis, we 
measured glucose levels in dMPC1 mutant flies expressing wild type dMPC1 in critical 
metabolic tissues. To do this, we combined a Gal4 driver that is expressed ubiquitously 
(Tubulin-Gal4), in the fat body (Lsp2-Gal4), the IPCs (Dilp2-Gal4), or the muscle (Mef2-
Gal4), with a UAS-dMPC1 transgene. Despite the observed defect in DILP secretion in 
dMPC1 mutants, dMPC1 expression in the fat body, but not the IPCs or muscles, is 
sufficient to rescue hyperglycemia to the same degree as ubiquitous rescue. These results 
indicate dMPC1 functions mainly within the fat body to regulate circulating glucose 
levels (Figure 3.7). 
 
Discussion 
Circulating glucose levels are controlled through the coordination of carbohydrate 
uptake and metabolism by the insulin-signaling pathway in metabolic tissues (Schrayyef 
and Gerich, 2010). We show here that genetic disruption of mitochondrial pyruvate 
















Figure 3.6. Reduced DILP secretion from IPCs in dMPC1 mutants. 
5–9 day old control or dMPC1 mutant (dMPC1–) males were starved overnight (16 hr.) 
and subsequently fed on high sugar media (10% yeast/18% sucrose) for 2 hours. Brains 
dissected from flies after starvation or subsequent feeding were stained with a Dilp2 
antibody. (A) DILP2 staining of representative brains. (B) Quantification of DILP2 
staining intensity. N = 6–8 brains per genotype/condition. Mean ± SEM is shown. P value 


























Figure 3.7. Fat body-specific rescue of dMPC1 ameliorates 
hyperglycemia in dMPC1 mutants. 
Whole animal glucose levels of controls (dMPC1+) or mutant (dMPC1–) flies carrying 
the indicated GAL4 transgenes in the presence of a UAS-dMPC1 construct after 10 days 
on high sugar media.  GAL4 driver expression patterns: Tubulin (Tub) = ubiquitous; 
Lsp2 = fat body; Dilp2 = insulin producing cells; Mef2 = muscle. Mean ± SEM is shown. 






new insights into the basic role of mitochondrial pyruvate metabolism in whole-organism 
physiology. In addition, we have established a new genetic model that can be used to  
better understand how changes in pyruvate utilization can affect insulin signaling and 
cause diabetes. 
 
Hallmarks of diabetes in dMPC1 mutants  
We have identified defects associated with diabetes through our phenotypic 
analysis of dMPC1 mutants. dMPC1 mutants are sensitive to dietary sugar levels, as 
increased sugar correlates with hyperglycemia and a reduction in lifespan. This trend is 
similar to that observed in the dHNF4 mutant model of MODY1, although the dHNF4 
mutants have a shorter life span under any dietary condition than dMPC1 mutant flies 
(Barry et al., manuscript in preparation). This may be due to the fact that dHNF4 mutant 
flies, which exhibit a similar degree of hyperglycemia as that seen in dMPC1 mutants, 
also display defects in the regulation of many genes involved in beta-oxidation and the 
immune response (Barry et al., manuscript in preparation). Our results also translate to 
humans, as a reduction in dietary carbohydrate levels has been shown to help diabetic 
patients regulate glycemia and overall health (Kirk et al., 2008). In addition to chronic 
hyperglycemia, dMPC1 mutants fed a high-sugar diet display an elevation in fasting 
glucose levels and reduced glucose clearance in an oral glucose tolerance test. These are 
key criteria that result in a diabetes diagnosis in the clinic (Inzucchi, 2012). Moreover, 
these data demonstrate that dMPC1 mutants display a defect at the level of cellular 
glucose uptake or retention. Consistent with these defects, we observed reduced 
peripheral insulin signaling activity, another hallmark of diabetes (Inzucchi, 2012).  
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We predict that the hyperglycemia observed in dMPC1 mutants is indirect, 
however, and ultimately caused by defects in mitochondrial pyruvate import. There are 
two hypotheses to explain the defects in glucose homeostasis observed in dMPC1 
mutants. First, pyruvate metabolic disruption could cause a general back up of glycolytic 
intermediates, which could alter the equilibrium of metabolites to reduce the rate at which 
glucose can be transported across the plasma membrane and phosphorylated (Figure 
3.8A). In this model, insulin-signaling defects play a minor role in causing 
hyperglycemia (Figure 3.8A). Our alternative hypothesis is that the observed reduction in 
peripheral tissue insulin signaling may be the major factor causing hyperglycemia 
(Figures 3.8B, 3.8C, and 3.8D). Our metabolomic analysis is inconsistent with the first 
model (Figure 3.8A) as pyruvate levels are not affected by alterations in dietary sugar 
concentration. In addition, we do not observe an accumulation of detectable glycolytic 
intermediates positioned in the pathway between glucose and pyruvate, including 
glucose-6-phosphate, fructose-6-phosphate, 3-phosphoglycerate, or 2-phosphoglycerate 
(data not shown). Thus, we predict that the hyperglycemia caused by a loss of dMPC1 is 
largely driven by the defect in insulin signaling in peripheral tissues (Figures 3.8B, 3.8C, 
and 3.8D). 
 
Models for the role of the mitochondrial pyruvate carrier in the 
regulation of DILP signaling 
There are two potentially overlapping models to explain the insulin signaling 
defects in dMPC1 mutants. Defective DILP secretion from the IPCs may reduce the 















Figure 3.8: Models for the role of the MPC in the regulation of insulin 
signaling and glucose homeostasis. 
(A) MPC promotes glycolytic flux and influences glycemia through mitochondrial 
pyruvate import. In this model, abnormal flux caused by dMPC1 causes a back up of 
glycolytic intermediates, such that equilibrium is shifted away from cellular glucose 
import and Akt phosphorylation in the fat body. Effects on insulin signaling are caused 
indirectly, possibly by chronic hyperglycemia, instead of glycemia being influenced by 
MPC-mediated activation of insulin signaling. (B) MPC promotes DILP secretion cell 
autonomously. In this model, MPC1 facilitates DILP secretion through a metabolic GSIS 
pathway similar to that of mammals, or by some other mechanism. In dMPC1 mutants, 
reduced circulating DILPs cause a reduction in the activity of fat body insulin activation, 
and thus hyperglycemia and other diabetic phenotypes. (C) MPC promotes DILP 
secretion non-cell autonomously. This model is similar to that shown in A, except that 
MPC1 functions in the fat body to promote signaling events that control DILP secretion 
from the IPCs. In this model, metabolic alterations in the dMPC1 fat body lead to 
signaling, either by decreased Unpaired2 (Upd2) expression, increased DILP6 
expression, or changes in some other signaling pathway to block DILP secretion. (D) 
MPC promotes insulin sensitivity. In this model, MPC1 functions primarily in the fat 
body to promote a metabolic state that is protective against insulin resistance. In dMPC1 
mutants, alteration of lipogenesis, signaling pathways known to affect insulin sensitivity, 
and/or another mechanism promotes insulin resistance. Insulin resistance in the fat body 











tissues (Figures 3.8B and 3.8C). Alternatively, peripheral DILP resistance could decrease 
the ability of metabolic tissues to efficiently respond to circulating DILPS (Figure 3.8D). 
Disrupting DILP secretion from IPCs has been shown to cause hyperglycemia (Fridell et 
al., 2009). IPCs express the Sur1 and Kir6 subunits of the KATP-dependent potassium 
channel and thus undergo depolarization and Ca2+ influx in response to glucose 
incubation ex vivo (Fridell et al., 2009; Kreneisz et al., 2010). Moreover, glucose feeding 
alone is sufficient to trigger DILP secretion from the IPCs during adulthood (Barry et al., 
manuscript in preparation). Taken together, these studies raise the possibility that IPCs 
may undergo GSIS utilizing a similar glucose sensing mechanism to that seen in 
mammals (Prentki et al., 2013). If GSIS is controlled by metabolic glucose sensing in 
flies, then we would predict that mitochondrial pyruvate import would be required for 
DILP secretion. Consistent with this prediction, we identified a defect in DILP secretion 
from the IPCs of dMPC1 mutants. It is unclear, however, if this reduction in DILP 
secretion is caused by a cell autonomous defect in the IPCs due to effects on glucose 
sensing or general cellular IPC dysfunction, or non-cell autonomously through a role for 
the MPC in the fat body. Our data demonstrating that hyperglycemia is rescued by 
specific expression of dMPC1 in the fat body, but not the IPCs of dMPC1 mutant flies, 
are consistent with the second model (Figure 3.8C). There is precedent for this kind of 
mechanism, as nutrient sensing pathways in the fat body have been shown to remotely 
control DILP secretion from the IPCs by production of secreted signaling molecules such 
as Unpaired 2, Dilp6, or other molecules (Figure 3.8C) (Bai et al., 2012; Geminard et al., 
2009; Rajan and Perrimon, 2012). In addition, the functional significance of the observed 
DILP secretion defect in the reduced activation of insulin signaling in dMPC1 mutant 
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tissues remains unknown. This question and the mechanism by which DILP secretion is 
affected by a loss of dMPC1 will be explored in future studies. The alternative, but not 
mutually exclusive explanation for the reduction in peripheral insulin signaling seen in 
the peripheral tissues of dMPC1 mutants is insulin resistance (Figure 3.8D). Altered lipid 
homeostasis is thought to be a major underlying mechanism that drives insulin resistance 
in mammals (Samuel and Shulman, 2012). Mitochondrial pyruvate import and 
subsequent conversion to acetyl-CoA would be expected to be critical for carbohydrate-
driven fatty acid synthesis (Berg et al., 2002). Consistent with this prediction, we 
observed an accumulation of TAG in wild-type flies upon transfer to the high sugar diet 
and found that this response is reduced in dMPC1 mutants. Fat body lipogenesis was 
recently shown to be an important protective factor for flies fed a high sugar diet 
(Musselman et al., 2013). Thus, it is possible that altered lipogenesis in dMPC1 mutants 
could affect DILP sensitivity and toxicity associated with high dietary sugar levels 
(Figure 3.8, D). Alternatively, decreased lipogenesis could also result from impaired 
insulin signaling, consistent with the role of insulin as an anabolic hormone. Whether the 
peripheral tissues in dMPC1 mutants display bona fide insulin resistance, however, is 
unknown and will provide a focus for future studies. 
 
The role of pyruvate metabolism in normal glucose homeostasis 
and diabetes 
Mitochondrial pyruvate metabolism is important in tissues critical for the 
regulation of glucose homeostasis in mammals, including the pancreatic beta cells and 
liver. Flux analysis has shown that pyruvate is almost exclusively used to drive the TCA 
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cycle in beta cells, with ~60% of pyruvate converted to acetyl-CoA by PDH, and ~40% 
converted to oxaloacetate by PC (Khan et al., 1996; Schuit et al., 1997). PC-derived 
oxaloacetate, along with citrate, malate and isocitrate, is cycled through cytoplasmic 
enzymes to regenerate pyruvate (Jensen et al., 2008). This cycling is thought to be 
important for the production of metabolic coupling factors that promote maximal GSIS 
(Jensen et al., 2008). Recent evidence, however, suggests that this process is more active 
in rodents than humans and may not be functionally relevant to human GSIS (MacDonald 
et al., 2011). Conversion of pyruvate to acetyl-CoA by PDH is critical for ATP 
production using glucose as an oxidative substrate (Berg et al., 2002).   Consistent with 
this role, GSIS is reduced in mice that carry mutations in PDH in their beta cells, thus 
resulting in impaired glucose tolerance and hyperglycemia (Srinivasan et al., 2010). This 
GSIS defect in PDH-deficient beta cells is presumably due to a diminished ability to 
generate the increase in cellular ATP required to inhibit the KATP-dependent channel and, 
thus, promote the depolarization event that drives insulin secretion (Prentki et al., 2013).  
In the liver, mitochondrial pyruvate is utilized by PDH and PC for lipogenesis and 
gluconeogenesis (Holness and Sugden, 1990; Merritt et al., 2011). Consistent with these 
critical roles in liver physiology, defects in pyruvate utilization affect liver glucose 
metabolism and insulin signaling. For example, a specific loss of PDH or PC in the liver 
results in improved glycemia and insulin sensitivity (Choi et al., 2010; Kumashiro et al., 
2013). Interestingly, these phenotypes are the opposite of those observed in dMPC1 
mutant flies, where we would also expect a reduction in the availability of mitochondrial 
pyruvate used as a substrate for both PDH and PC. This disparity could be due to the fact 
that we are studying whole-body dMPC1 mutants, while mammalian studies of PDH and 
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PC have focused on tissue-specific genetic disruption (Choi et al., 2010; Kumashiro et 
al., 2013). Improved insulin sensitivity associated with a hepatic loss of PDH or PC is 
thought to be driven by reduced hepatic or adipose tissue lipogenesis; however, this 
mechanism has not been tested directly (Choi et al., 2010; Kumashiro et al., 2013).  
Interestingly, the MPC may be a clinically relevant drug target for the treatment 
of type 2 diabetes. A thiazolidinedione derivative was recently discovered that binds to 
the MPC via an interaction with the MPC2 subunit (Colca et al., 2013). This drug, which 
was shown to inhibit mitochondrial pyruvate transport in vitro, ameliorates insulin 
resistance in flies and isolated human beta cells (Colca, et al., 2013; Divakaruni et al., 
2013; Rohatgi et al., 2013). Whether inhibition of the MPC is the mechanism underlying 
how this drug affects insulin sensitivity, however, is unknown. Thus, it is clear that the 
metabolic fate of pyruvate is critical in the regulation of glucose homeostasis, and defects 
in pyruvate utilization affect aspects of diabetes pathophysiology. dMPC1 mutants 




Future studies will be focused on determining the mechanism underlying the 
defects in insulin signaling and glucose homeostasis in dMPC1 mutants. To do so, we 
will perform experiments to differentiate between the DILP secretion and DILP 
resistance models (Figures 3.8B and 3.8C). First, we will verify that dMPC1 is required 
for DILP secretion by repeating our secretion assay. In this experiment, we will drive 
secretion by glucose feeding so that we can define any observed defects as due to a block 
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in GSIS. If the secretion defect is reproducible, then we will determine if it is of 
functional significance. To do this, we will drive the expression of a temperature-
sensitive ion channel, TRPA1, specifically in the IPCs of dMPC1 mutants (Hamada et al., 
2008). This tool will allow us to bypass the DILP secretion defect in dMPC1 mutants by 
forcing IPC depolarization and consequent DILP secretion in a temporally controlled 
manner. In these animals, readouts of peripheral insulin signaling activity 
(phosphorylated Akt and 4eBP mRNA levels) and glucose levels will be assayed and 
compared to relevant controls. Alternatively, the low threshold voltage-gated NaChBac 
Na+ channel from bacteria that has been shown to constitutively increase neuronal 
excitability could be expressed in IPCs as described previously (Geminard et al., 2009; 
Rajan and Perrimon, 2012). Although this latter strategy for forcing DILP secretion has 
been shown to rescue a DILP secretion defect, it is somewhat limited because it does not 
allow temporal control of DILP secretion. 
 If forced DILP secretion is sufficient to fully or partially rescue defects in dMPC1 
mutants, then we will determine the nature of this regulation of DILP secretion by the 
MPC. To do so, we will determine if DILP secretion from IPCs is regulated by dMPC1 
cell autonomously or non-cell autonomously. We will express dMPC1 in the IPCs or the 
fat body of dMPC1 mutants using the GAL4/UAS system and assay for DILP secretion 
from the IPCs. Since fat body dMPC1 rescue is sufficient to rescue hyperglycemia in 
dMPC1 mutants, we expect that dMPC1 in the fat body will also rescue DILP secretion. 
If this hypothesis is correct, then it will be interesting to measure the expression of fat 
body signaling molecules previously shown to regulate DILP secretion non-cell 
autonomously such as Unpaired2 and DILP6 (Bai et al., 2012; Rajan and Perrimon, 
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2012). Alternatively, GSIS may be regulated by the MPC cell autonomously. The 
interpretation gained from this result, however, would depend on the experiment 
described above to determine if forced DILP secretion from the IPCs is sufficient to 
rescue hyperglycemia and defects in peripheral insulin signaling in dMPC1 mutants. 
 If a DILP secretion defect is not the exclusive cause of the insulin signaling defect 
and hyperglycemia in dMPC1 mutants, then we will test for insulin resistance. To do this, 
we will inject bovine insulin into starved adult dMPC1 mutant flies (Haselton and Fridell, 
2011). Since bovine insulin was shown to activate insulin signaling in Drosophila tissues, 
we can measure Phospho-Akt levels and 4eBP expression in injected animals to 
determine the sensitivity of peripheral tissues to exogenous insulin (Haselton et al., 2011; 
Musselman et al., 2011). This approach will bypass any DILP secretion defect present in 
dMPC1 mutants. If peripheral tissues display insulin resistance, then we will determine 
what metabolic or signaling pathways contribute to this defect. Since lipogenesis was 
previously shown to protect flies from an insulin resistance-inducing diet (Musselman et 
al., 2013), and dMPC1 mutants display reduced accumulation of TAG when fed high 
sugar, we will directly measure glucose incorporation into fatty acids by flux analysis. If, 
as expected, flux of glucose-derived carbon to fatty acid synthesis is altered in dMPC1 
mutants, then we could validate the functional relevance of this defect by RNA-mediated 
silencing of king tubby (ktub) in the dMPC1 mutant fat body as described (Musselman et 
al., 2013). In addition to these metabolic studies, we could determine whether any 
signaling pathways previously shown to regulate insulin sensitivity are affected in 
dMPC1 mutants. To do this, we could measure the expression of several molecules 
known to regulate DILP sensitivity in dMPC mutants, including the InR antagonists 
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ImPL2 and SDR and the lipocalin Nlaz (Honegger et al., 2008; Okamoto et al., 2013; 
Pasco and Leopold, 2012). Based on these results, we could test the functional relevance 
of any expression changes with double mutant and/or overexpression studies. 
 Finally, it is possible that hyperglycemia is not entirely caused by the defect in 
insulin signaling in dMPC1 mutants (Figure 3.8A). If this is the case, then we will 
investigate the metabolic mechanisms driving altered glucose homeostasis in dMPC1 
mutants. If the equilibrium of glycolytic intermediates is altered, it may be possible to 
bypass these defects by overexpressing lactate dehydrogenase in the fat body of dMPC1 
mutants. This enzyme converts cytosolic pyruvate to lactate and thus may enhance 
glycolytic flux (Yang et al., 1999). Alternatively, we can overexpress upstream rate-
limiting enzymes in glycolysis, such as hexokinase and/or phosphofructokinase, to 
promote glucose uptake and retention (Tennessen et al., 2011). Circulating glucose will 
be measured in dMPC1 mutants employing these two strategies for altering glycolytic 
flux independently and in combination. In addition, we will assay for rescue of insulin 
signaling defects in these experiments.  
 Our current data and potential future results combined provide a better 
understanding of the role of mitochondrial pyruvate metabolism in the maintenance of 
glucose homeostasis. More specifically, dMPC1 mutants allow us investigate the role of 
the MPC in the regulation of insulin signaling and diabetic phenotypes in vivo. This 
understanding is particularly important as it was recently shown that the MPC is a target 
of PPAR gamma-sparing thiazolidinedione derivatives that improve insulin sensitivity in 
rodent and fly models. Therefore, our work will likely yield valuable insight into the 
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Succinate dehydrogenase (SDH) occupies a central place in cellular energy 
production, linking the tricarboxylic cycle with the electron transport chain. These critical 
functions are consistent with the causal role of SDH loss of function in a subset of cancer 
and neuromuscular disorders. In spite of these unique activities, only two factors have 
been identified that are required for proper SDH assembly and the prevention of disease. 
Herein we characterize a novel evolutionarily conserved mitochondrial protein 
designated Sdh8/SDHAF4, using yeast, Drosophila, and mammalian cells. We show that 
Sdh8 interacts specifically with Sdh1 in the mitochondrial matrix, facilitating its 
association with Sdh2 and the subsequent assembly of the SDH holocomplex. These roles 
for Sdh8 are critical for preventing motility defects and neurodegeneration in Drosophila 
as well as the excess ROS generated by free Sdh1. These studies provide insights into the 
mechanisms by which SDH is assembled and raise the possibility that some forms of 




Mitochondria are dynamic organelles that are essential for many cellular 
processes including metabolism, signal transduction, and apoptosis. Consistent with these 
broad cellular functions, mitochondrial dysfunction is associated with a wide range of 
human diseases, including diabetes, neurodegeneration, and cancer. These important 
roles have led to comprehensive characterization of the mitochondrial proteome, 
identifying more than 1,000 nuclear-encoded proteins (Mercer et al., 2011; Pagliarini et 
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al., 2008; Sickmann et al., 2003).  In spite of these efforts, however, many mitochondrial 
proteins remain uncharacterized, including proteins that are conserved throughout 
eukaryotic evolution. We are studying this subset of proteins as part of a systematic effort 
to comprehensively understand mitochondrial physiology. Herein, we describe the 
function of one of these evolutionarily conserved proteins and demonstrate that it is 
essential for proper succinate dehydrogenase (SDH) complex assembly and activity in 
yeast, flies, and mammalian cells.  
SDH is unique in that it functions in both the tricarboxylic acid (TCA) cycle and 
the electron transport chain (ETC), wherein it is referred to as Complex II. SDH links the 
oxidation of succinate to fumarate in the TCA cycle with the reduction of ubiquinone to 
ubiquinol in the ETC, which contributes to the establishment of the mitochondrial 
membrane potential and ATP synthesis.  SDH is a heterotetrameric protein complex that 
is embedded in the inner mitochondrial membrane (IMM), with its catalytic domain 
facing the mitochondrial matrix.  The complex is anchored to the IMM by two integral 
membrane proteins, Sdh3 (SDHC in humans) and Sdh4 (SDHD), which coordinate a 
heme cofactor at their interface. The Sdh3/Sdh4 dimer binds the peripheral membrane 
protein Sdh2 (SDHB), which tethers the catalytic Sdh1 (SDHA) subunit to the complex. 
Sdh1 harbors a covalently bound FAD cofactor that is required for the oxidation of 
succinate (Hao et al., 2009; Robinson et al., 1994). The two electrons that result from this 
activity are channeled through the three iron-sulfur clusters in Sdh2 to ubiquinone, which 
interacts with SDH via the Sdh3/Sdh4 membrane anchor (Rutter et al., 2010).   
The assembly of complexes like SDH presents the cell with the problem of 
coordinating the synthesis and stepwise interactions of individual subunits to form an 
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intricate membrane bound complex.  This problem is exacerbated in the case of ETC 
complexes as individual subunits contain redox-active cofactors that can perform 
inappropriate and deleterious reactions when they are not properly secluded within the 
native complex.  As a result, a number of dedicated factors assist the assembly of these 
complexes by facilitating cofactor insertion, preventing nonproductive interactions, and 
stabilizing assembly intermediates.  
While the importance of assembly factors for Complex I and Complex IV is well 
established (Diaz et al., 2011; Fernandez-Vizarra et al., 2009), dedicated SDH assembly 
factors have only recently begun to emerge with the discovery of SDHAF1 (Sdh6 in 
yeast) and SDHAF2 (Sdh5) (Ghezzi et al., 2009; Hao et al., 2009).  Human patients with 
loss of function mutations in SDHAF1 or SDHAF2 display reduced SDH complex levels 
and activity and present with infantile leukoencephalopathy and neuroendocrine tumors, 
respectively (Ghezzi et al., 2009; Hao et al., 2009). This is consistent with the spectrum 
of diseases that associate with mutations affecting the core subunits of SDH—SDHA, 
SDHB, SDHC, and SDHD (Bardella et al., 2011; Rutter et al., 2010)—and with a series of 
additional diseases that are characterized by loss of SDH activity, but which lack 
mutations in known SDH genes (Jain-Ghai et al., 2013; Pantaleo et al., 2014). Disruption 
of the yeast orthologs for SDHAF1 or SDHAF2 (SDH5 or SDH6) prevents respiratory-
dependent growth, with a clear defect in SDH activity.  While the precise mechanism by 
which Sdh6 supports SDH biogenesis has remained elusive, Sdh5 was shown to be 
required for the covalent attachment of the FAD cofactor to Sdh1 (Ghezzi et al., 2009; 
Hao et al., 2009). The current model proposes that Sdh1 is flavinated by Sdh5 and then 
binds iron-sulfur loaded Sdh2, which then docks onto the pre-assembled membrane 
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bound Sdh3-Sdh4 dimer to form the holocomplex (Rutter et al., 2010). We hypothesized 
that the complexity of this assembly process likely necessitates the action of additional 
dedicated assembly factors and that the genes encoding these factors may contribute to 
the currently idiopathic SDH-associated genetic diseases.  
With the goal of discovering new human disease genes and gaining a better 
understanding of SDH assembly and activity, we have focused on our ongoing functional 
elucidation of uncharacterized mitochondrial proteins. These studies led us to identify an 
evolutionarily conserved SDH assembly factor, Ybr269, which we have renamed Sdh8 in 
yeast and SDHAF4 in higher organisms. Utilizing yeast, flies, and mammalian cells, we 
have defined the molecular function of the SDHAF4 protein family in SDH assembly and 




 The following stocks were obtained from the Bloomington Stock Center: 
ElaV-Gal4 (Luo et al., 1994), Daughterless-Gal4 (Wodarz et al., 1995), 
Frt82B,CoVatend/TM6B (Mandal et al., 2005), SdhB[12081]/CyO (Walker et al., 2006) and 
SdhA[HP21216]/CyO. Sdhaf4 mutants and transgenic lines were generated as described 
below. All fly stocks were maintained at 25˚C on standard cornmeal/molasses/agar food 






Generation of dSdhaf4 mutant lines 
DSdhaf4 mutants were generated by targeting the second exon of dSdhaf4 using 
TALENs, as described (Cermak et al., 2011; Dahlem et al., 2012; Hu et al., 2013). The 
specificity of potential TALEN target sequences was determined using Target Finder 
(https://tale-nt.cac.cornell.edu) and a BLAST analysis. TALEN pairs were designed and 
constructed by the Mutation Generation and Detection Core Research Facility at the 
University of Utah (http://www.cores.utah.edu/) with the following specifications: Left 
binding site—5’-CGAGATCAAGGAACCAAA-3’; Right binding site—5’-
AATGGCCTTCCAGAAGA-3’; Spacer—5’-GACGCGCACCGAGAAGCT-3’. The 
TALEN Golden Gate kit described by Cermak et al. was used with modifications, and 
TALENs were assembled as described by Dahlem et al. and Hu et al. Plasmid DNAs 
carrying the dSdhaf4 TALEN construct were then purified with a Qiagen maxi-prep kit 
and concentrated by ethanol precipitation. RNAs were generated by digesting the 
TALEN construct with NotI, repurifying, and directing in vitro transcription using the 
AmpliScribe SP6 High Yield Transcription Kit (Epicentre), followed by the ScriptCap 
m7G Capping System (Epicentre). The TALEN RNAs were concentrated and 250 µg/ml 
of each RNA was combined in 0.1X PBS. We used the obligate heterodimer architecture 
DDD/RRR and injected ~200 Canton S embryos. ~35 surviving injected G0 animals were 
crossed individually to a strain carrying a CyO balancer. ~5 F1 progeny males from each 
cross were then outcrossed to a strain carrying a CyO balancer marked with GFP, and 
individual strains were isolated. Flies were screened for mutations in dSdhaf4 by high 
resolution melt analysis (Dahlem et al., 2012). Two putative mutant strains (dSdhaf41 and 
dSdhaf42) were verified by DNA sequencing. Flies carrying a wild type dSdhaf4 locus 
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derived from the same G0 animals as the dSdhaf41 and dSdhaf42 alleles were carried 
through the same series of crosses and used as genetically matched controls. This control 
is labeled dSdhaf4+ or dSdhaf4+/+ in all figures. The transposable P-element insertion 
pCG7224KG07581 was also used to generate a dSdhaf4 allele by imprecise excision. The 
dSdhaf43 allele, which was verified by Southern blotting, PCR and DNA sequencing, 
contains an unexcised fragment of the pCG7224KG07581 element. A precise excision was 
also isolated (dSdhaf4Ex32+) and is used as a control for dSdhaf43 in all relevant 
experiments.  All mutant and control genotypes analyzed are in a w1118 background. 
 
Generation of transgenic fly lines 
To generate UAS-dSdhaf4 rescue construct, the CG7224 cDNA (GH 06541) was 
excised using XhoI and BglII and inserted into a pUAST vector. To generate the UAS-
hSdhaf4 construct, the hSdhaf4 cDNA was PCR amplified from pJR3455A, which 
contains an hSdhaf4 cDNA amplified from HepG2 cells using the primers 5’-CGAG 
ATCTATGACCCCATCGAGGCTT-3’ and 5’-CGCTCGAGTTAAAAATCAA 
TACAGCGTCCTTTT-3’. This amplicon was then cut with BglII and XhoI and cloned 
into an pUAST-AttB plasmid. All plasmids used to generate transgenic lines were 
verified by restriction digestion and DNA sequencing. UAS-dShdaf4 transgenic lines 
were generated using standard P-element mediated transformation, and UAS-hSdhaf4 
transgenic lines were targeted to AttP2 by site-directed transformation (Bateman et al., 
2006; Pfeiffer et al., 2010). Elav-Gal4, UAS-dSdhaf4, and UAS-hSdhaf4 on the third 
chromosome were crossed into the dSdhaf41 or dSdhaf42 background using balanced 
crossing schemes. Da-Gal4 on the third chromosome was recombined onto the same 
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chromosome as the dSdhaf42 allele. The presence of the dSdhaf4 mutant alleles in 
transgenic lines was verified by DNA sequencing and complementation tests.  
 
Drosophila genetic interactions 
To assay whether combining the lethal allele of SdhA or the viable hypomorphic 
allele of SdhB with dSdhaf4 mutations affects viability, the SdhA[HP21216] or SdhB[12081] 
insertions were recombined with the either dSdhaf41 or dSdhaf42 alleles. Flies carrying 
these recombinant chromosomes, dSdhaf41 allele alone, Sdh allele alone, or a wild type 
chromosome over an SM5 balancer marked with Cy– were intercrossed in various 
combinations. All crosses were performed in triplicate. The number of expected progeny 
resulting from these crosses was calculated based on mendelian ratios. To determine if 
the expected number of progeny of non-SM5 chromosomes reached adulthood, the total 
number of eclosed Cy+ adult flies was counted, and that number was compared to 1/2 or 
1/3 of the total number of progeny depending on whether a 1:1 or 1:2 ratio was expected. 
The N values for genetic interactions shown between dSdhaf4 and SdhA/B represent the 
total number of progeny counted from the pertinent cross. Since CoVa[tend] mutation is on 
the third chromosome, dSdhaf41/SM5;CoVa[tend]/TM3 or dSdhaf4+/SM5;CoVa[tend]/TM3 
flies were crossed to dSdhaf42/dSdhaf42 or dSdhaf4+/dSdhaf4+ flies, respectively. A 
normal 1:1 distribution of Cy–:Cy+  flies were observed (Data not shown), so only the 
Cy+ flies were counted. Since TM3 is marked with Sb–, the total number of Cy+;Sb– or 
Cy+;Sb+ flies was counted and compared to the 1:1 ratio expected. The N values shown 
for the genetic interaction experiment concering dSdhaf4 and CoVa represent the total 




Drosophila lifespan analyses 
For lifespan measurements, flies were allowed to eclose for one day and were 
separated into vials containing ~20 flies. Every 2–4 days dead flies were 
counted/removed and surviving flies transferred to new food vials. >100 flies were 
assayed for each genotype. For starvation assays, 2–4 day old females were transferred to 
starvation media (1% agar in H2O), and the number of surviving flies was assayed every 
12 hours. >90 flies were assayed per genotype. To measure sensitivity to hyperoxia, vials 
containing 2–4 day old females were placed in polyethylene bags (Scienceware 12”x16”), 
which were subsequently filled with 100% O2 and sealed using a Quick Seal bag sealer. 
Bags were refilled with fresh O2 2–3 times daily and the number of surviving flies was 
assayed every 24 hours. >40 flies were assayed per genotype. A similar degree of 
hyperoxia sensitivity was observed in dSdhaf mutants placed in a styrofoam box with a 
continuous flow of 100% O2 as described (Walker et al., 2006); however, we could not 
maintain this experimental paradigm long enough to assay the full lifespan of controls 
(data not shown). Survival during hyperoxia was assayed at room temperature, whereas 
flies for all other lifespan experiments were kept at 25˚C. Experiments on female flies are 
presented for all survival curves, but similar results were observed when assaying males 
(data not shown).  
 
Drosophila metabolomic analysis and enzyme activity assays 
Adult male flies were aged 5–7 days, washed with PBS, and snap frozen in liquid 
nitrogen. Metabolites were extracted from frozen flies and GC/MS was performed as 
previously described (Bricker et al., 2012). Succinate dehydrogenase activity was 
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measured in mitochondrial extracts as previously described, by examining the reduction 
of iodonitrotetrazolium at 500 nm in the presence of succinate (Celotto et al., 2011). 
Citrate synthase activity was measured in mitochondrial extracts by examining the 
reduction of 5,5’-5 dithiobis-2-nitrobenzoic acid in the presence of oxaloacetate and 
acetyl-CoA, as previously described (Tang et al., 2009). Enzyme activity per gram of 
mitochondrial protein was calculated.  
 
Drosophila paralytic assays 
Bang sensitivity was measured as previously described (Ganetzky and Wu, 1982). 
Flies were collected in groups of 5–8 females per vial and allowed to recover from CO2 
anesthesia for at least 2 hours. Flies were then vortexed for 15 seconds and the time it 
takes to return to a standing position was assayed. At least 3 vials were assayed per 
condition in each experiment, and all experiments were repeated at least twice. 
Experiments on female flies are presented, but similar results were observed when 
assaying males (data not shown). 
 
Electron microscopy 
Heads were removed from 8–12 day old female flies, the proboscis was removed, 
and heads were fixed overnight in EM grade 3% glutaraldehyde/3% paraformaldehyde in 
PBS at 4˚C. After fixation, heads were rinsed three times in 10 mM cacodylate buffer and 
postfixed in 2% OsO4 for 2 hours at room temperature. The heads were then washed in 
the same buffer, followed by a wash in dH2O, and then poststained in 1% uranyl acetate 
for 1 hour at room temperature. After washing with dH2O, heads were dehydrated in a 
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graded series of acetone (25%, 50%, 75%, 90% and 3 x 100% for 20 min each step), and 
then infiltration was conducted over 3 days followed by embedding in epoxy resin 
(Embed 812, Electron Microscopy Sciences). For the infiltration step, specimens were 
incubated in 30% resin and acetone for 6 hours, then in placed in 70% resin and acetone 
overnight. The next day, the specimens were placed into 90% resin and acetone for 8 hrs 
and 100% resin for another overnight incubation. On the following day, after two 
incubations in freshly prepared 100% resin over 6 hrs, specimens were embedded and 
polymerized at 60˚C for 48 hrs. Ultrathin (70 nm) sections were obtained with diamond 
knife (Diatome) and an ultratome Leica UC6  (Leica Microsystems, Bannockburn,IL). 
Grids with sections were poststained with saturated uranyl acetate in dH2O for 20 min 
and with lead citrate for 10 min and imaged at 120kV using a Technai T 12 electron 
microscope. N = 3 flies assayed per genotype. 
 
Immunoblotting 
The following antibodies were used for immunoblotting: anti-SdhA (Abcam 
137756; rabbit polyclonal to human SdhA), anti-SdhB (Abcam 14714; mouse 
monoclonal to human SdhB), anti-Atp synthase α (Abcam 14748; mouse monoclonal to 
bovine Atp5) and anti-beta Tubulin (Chemicon MAB380; mouse monoclonal), anti-
VDAC (Abcam 15895), anti-Sdh1 (rabbit polyclonal to yeast Sdh1; was a generous gift 
from Dennis Winge), anti-Sdh2 (rabbit polyclonal to yeast Sdh2; was a generous gift 





SdhA/Sdh1 flavination assay 
To visualize flavinated SdhA, mitochondrial extracts were fractionated by SDS-
PAGE and the gel was incubated for 20 minutes in 10% acetic acid. Autofluorescent 
flavo-SdhA was imaged using an ethidium bromide filter, as previously described (Hao et 
al., 2009). The gel was stained with Coomassie Blue to visualize total protein as a control 
for loading in Drosophila experiments.  In yeast experiments, immunoblot for Sdh1 was 
used to control for loading. 
 
Yeast strains and growth conditions 
Saccharomyces cerevisiae (BY4741 MATa, his3 leu2 met15 ura3) and 
Saccharomyces cerevisiae (W303a MATa, his3 leu2 met15 trp1 ura3) were used as the 
wild-type strains where indicated.  Each mutant was derived from a BY4741 or W303 
diploid using a standard PCR-based homologous recombination method.  Each haploid 
was generated by sporulation and tetrad dissection.  The genotypes of all strains used in 
this study are shown (Table 4.1).  Yeast transformation was performed by the standard 
TE/LiAc method and transformed cells were recovered and grown in synthetic complete 
glucose (SD) medium lacking the appropriate amino acid(s) for selection purposes.  
Medium used in this study includes YPA and synthetic minimal medium supplemented 
with 2% glucose, 2% raffinose, 2% glycerol, 2% ethanol, or 2% acetate. 
Growth assays were performed using synthetic minimal media supplemented with the 
appropriate amino acids and indicated carbon source.  Overnight cultures were back-




Table 4.1. Yeast strains used in this study. 
Strain Genotype Source 
WT (BY4741) Mat A his3 leu2 ura3 met15 Open 
Biosystems 
sdh1Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX 
This Study 
sdh2Δ Mat A his3 leu2 ura3 met15 
sdh2::kanMX 
This Study 
sdh4Δ Mat A his3 leu2 ura3 met15 
sdh4::natMX 
This Study 
sdh8Δ Mat A his3 leu2 ura3 met15 
sdh8::hygMX 
This Study 
sdh1Δsdh2Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh2::kanMX 
This Study 
sdh1Δsdh4Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh4::natMX 
This Study 
sdh1Δsdh8Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh8::hygMX 
This Study 
sdh2Δsdh4Δ Mat A his3 leu2 ura3 met15 
sdh2::kanMX  sdh4::natMX 
This Study 
sdh2Δsdh8Δ Mat A his3 leu2 ura3 met15 
sdh2::kanMX  sdh8::hygMX 
This Study 
sdh4Δsdh8Δ Mat A his3 leu2 ura3 met15 
sdh4::natMX  sdh8::hygMX 
This Study 
sdh1Δsdh2Δsdh4Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh2::kanMX  sdh4::natMX 
This Study 
sdh1Δsdh2Δsdh8Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh2::kanMX  sdh8::hygMX 
This Study 
sdh1Δsdh4Δsdh8Δ Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh4::natMX  sdh8::hygMX 
This Study 
sdh2Δsdh4Δsdh8Δ Mat A his3 leu2 ura3 met15 




Mat A his3 leu2 ura3 met15 
sdh1::his3MX  sdh2::kanMX  sdh4::natMX  
sdh8::hygMX 
This Study 
WT (W303) Mat A his3 leu2 ura3 met15 trp1 David Stillman 
sdh1Δ Mat A his3 leu2 ura3 met15 trp1 
sdh1::kanMX   
This Study 
sdh2Δ Mat A his3 leu2 ura3 met15 trp1 
sdh2::kanMX 
This Study 
sdh5Δ Mat A his3 leu2 ura3 met15 trp1 
sdh5::kanMX 
This Study 
sdh8Δ Mat A his3 leu2 ura3 met15 trp1 
sdh8::hygMX 
 
sdh1Δsdh8Δ Mat A his3 leu2 ura3 met15 trp1 
sdh1::kanMX sdh8::hygMX 
This Study 
sdh2Δsdh8Δ Mat A his3 leu2 ura3 met15 trp1 
sdh2::kanMX  sdh8::hygMX 
This Study 
sdh5Δsdh8Δ Mat A his3 leu2 ura3 met15 trp1 






The plasmids expressing internal His6HA3 or GFP tagged Sdh8 were generated by 
PCR amplification of SDH8 (NC_001134.8) flanked by its upstream promoter and 
downstream terminator regions off genomic DNA.  The untagged gene along with its 
regulatory elements were ligated into pRS415 using XhoI and SpeI.  Sewing PCR was 
used to add NheI and SalI restriction sites between the codons encoding residues N82 and 
S83 of SDH8.  The His6HA3 tag, which was chemically synthesized, and the GFP tag, 
which was amplified by PCR, were each ligated between N82 and S83 using the NheI 
and SalI yielding the final SDH8-His6HA3 and SDH8-GFP constructs.  The sequence of 
each construct was confirmed by sequencing (Genewiz).       
Human and Drosophila SDHAF4 were cloned such that the expression of each 
gene was under the control of the SDH8 promoter.  Sewing PCR was used to clone the 
SDH8 promoter and terminator separated by NheI and SalI restriction sites into pRS415.  
SDHAF4 from each species was PCR amplified from cDNA and ligated between the 
SDH8 promoter and terminator using NheI and SalI. Sdh1H90A and Sdh1H90S  constructs 
were generated by sewing PCR.  The mutants were ligated into pRS416 using XhoI and 
XmaI.  Both constructs were expressed under the control of the native SDH1 promoter 
and terminator.   
 
Isolation of yeast mitochondria 
Yeast cells were harvested in midlog phase.  Preparation of crude mitochondria 
was as described previously (Boldogh and Pon, 2007).  Cell pellet was washed once with 
ddH2O and incubated in TD buffer (100 mM Tris-SO4, pH 9.4 and 100 mM DTT) f
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min at 30˚C.  Spheroplasts were obtained by incubating cells in SP buffer (1.2 M Sorbitol 
and 20 mM potassium phosphate, pH 7.4), supplemented with 0.3 mg/mL lyticase for 1 
hour at 30˚C to remove the cell wall.  Spheroplasts were gently washed once and 
homogenized in ice-cold SEH buffer (0.6 M sorbitol, 20 mM HEPES-KOH, pH 7.4, 2 
mM MgCl2, 1mM EGTA) using a dounce homogenizer applied with 30–40 strokes.  
Crude mitochondria were further purified using differential centrifugation. When needed, 
pure mitochondria were isolated by ultracentrifugation through a continuous nycodenz 
gradient.   
 
Fluorescence microscopy 
The sdh8 mutant strain transformed with plasmids expressing Sdh8-GFP and 
MtRFP was grown in SD medium overnight.  Cells were back-diluted in fresh media to 
0.1 OD and allowed to grow for several hours.  Images were captured using a Zeiss 
Axioplan 2 Imaging microscope (Carl Zeiss). 
 
Steady-state protein analysis 
Yeast mitochondria were solubilized in Laemmli buffer.  Samples were resolved 
by SDS-PAGE and assessed by immunoblot.  Drosophila extracts from either 20 µg 







Assessment of submitochondrial localization and solubility 
Submitochondrial fractionation was performed using a protocol adapted from 
Boldogh and Pon (2007).  Mitochondria were incubated in the isotonic SH buffer (20mM 
HEPES-KOH, pH 7.4, 0.6M Sorbitol) of hypotonic H buffer (20mM HEPES-KOH, pH 
7.4) with and without 1% Tritin-X100. Samples were treated with Protease K (New 
England BioLabs) on ice for 30 min.  Addition of PMSF to each sample was used to 
terminate protease digestion.  Samples were resolved by SDS-PAGE and assessed by 
immunoblot. 
Solubility of Sdh8 was assessed by ultracentrifugation.  Mitochondria were 
suspended in SH buffer and subjected to sonication.  Mitochondrial membranes were 
isolated by ultracentrifugation at 100,000 x g for 30 min (MLA-130, Beckman Coulter).  
The membrane (membrane fraction) was resuspended in 2X Laemmli buffer.  The 
supernatant (soluble fraction) was precipitated in 20% TCA and resuspended in 2X 
Laemmli buffer.  Samples were resolved by SDS-PAGE and assessed by immunoblot.   
 
Yeast enzyme activity assays 
SDH and MDH activity assays were performed on mitochondria isolated from 
yeast cells as previously described in Hao et al. (2009).   
 
Yeast metabolomic analysis  
Metabolomic analysis was carried out in the Metabolomics Core Research 
Facility at the University of Utah School of Medicine.  Yeast cultures were grown to an 
OD of 1 in synthetic media containing 2% glycerol and 2% ethanol. 
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Mammalian cell culture  
C2C12 myoblasts (ATCC CLR-1772) were maintained in DMEM with 10% FBS, 
2mM Glutamax (Gibco), and 1% Primocin (Invitrogen).  All knockdowns were 
performed by treating cells with 5 nM total siRNA, using the Lipofectamine RNAiMax 
tranfection reagent (Invitrogen).  The All-Stars nontargeting siRNA (Qiagen) was used as 
a control for siRNAs targeting SDHAF4 (NM_026503), which were designed using 
Dharmacon siDesign Center tool (http://www.dharmacon.com/designcenter/Design 
CenterPage.aspx).  Sequences of the sense strands of targeting siRNAs, which include a 
3’ tt DNA overhang, are as follows: (si1) UGAGUUAUCAGGAAGGAAA and (si3) 
UCUCACAACUGCAGAAUCA. Cells were subjected to knockdown on day 0, again on 
day 3, and harvested for analysis on day 6.  Total RNA was isolated with the RNeasy 
Mini Kit (Qiagen) and reverse transcribed to cDNA using the High Capacity cDNA 
Reverse Transcriptase Kit (Applied Biosystems).  Quantitative PCR was performed on 
cDNA with a Roche 480 LightCycler using LightCycler 480 SYBR Green 1 Master Mix 
(Roche) to confirm knockdown.   
 
Isolation of mammalian mitochondria  
The procedure was adapted from (Bozidis et al., 2007). C2C12 cells were 
trypsinized, washed twice with ice cold PBS, and pelleted.  The cell pellet was 
resuspended in 2 mL ice cold MTE buffer and lysed by sonication (Branson Model 250, 
continuous pulse, power setting 3.5, 3 cycle, 10 s. each).  Cell debris and nuclei were 
pelleted at 1,400 x g for 10 min.  Mitochondria were recovered from the supernatant by 
centrifugation at 10,000 x g for 10 min.  Mitochondria were resuspended in MTE.  
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Protein concentration was determined by Advanced Protein Assay Reagent 
(Cytoskeleton).    
 
Immunoprecipitation of Sdh8-His6HA3 and Sdh2-His6HA3 
Crude mitochondria were isolated and resuspended to a concentration of 5 mg/mL 
in XWA buffer.  Soluble proteins were extracted by sonication and centrifugation at 
20,000 x g for 20 mins.  Membrane proteins were extracted in buffer containing 0.7% 
digitonin for 1 hour and centrifugation at 20,000 x g for 20 minutes. Cleared 
mitochondrial lysates were incubated with anti-HA antibody conjugated agarose (Sigma) 
for 2 hours at 4˚C.  The agarose was washed 3–5 times and eluted in buffer containing 1 
mg/mL HA peptide.  Elution samples were precipitated in 20% TCA, resolved by SDS-
PAGE, and assessed by mass spectroscopy and/or immunoblot.   
 
Blue native polyacrylamide gel electrophoresis (BN-PAGE) 
BN-PAGE was performed as described previously (Wittig et al., 2006).  
Mitochondria were resuspended in lysis buffer (50 mM NaCl, 5 mM 6-aminocaproic acid, 
50 mM imidazole, 1 mM AEBSF, and protease inhibitor cocktail). Yeast and Drosophila 
mitochondria were solubilized with 1% digitonin and mammalian mitochondria with 2% 
digitonin.  Lysates were resolved on a 3%–13% gradient native gel using a PROTEAN®II 
xi Cell gel running system (Bio-Rad).  Western blot performed as described elsewhere 






PRISM software was used to graph all quantitative data and perform statistical 
analyses. P values for pairwise comparisons were determined using a Student’s t test and 
p values for multiple comparisons were calculated using one-way analysis of variance 
(ANOVA) with a Bonferroni correction. Metabolomics data is presented in box-plot 
form, where the box represents the 25th–75th percentile, the line is the median, and the 
whiskers represent the range of the data. All other quantitative data is shown as the mean 
± SEM. P values for Kaplan-Meier survival curves were calculated using a log-rank test. 
 
Results 
Yeast Sdh8 is a conserved mitochondrial matrix protein required 
for maximal SDH activity 
Sdh8 is a small protein of approximately 15 kDa that belongs to a paneukaryotic 
protein family, which we have named the SDHAF4 family (Figure 4.1A). We confirmed 
the published annotation of Sdh8 as a mitochondrial protein by assaying the subcellular 
localization of an Sdh8-GFP fusion protein expressed under the control of the native 
SDH8 promoter and terminator (Reinders et al., 2006). Although fusion proteins with 
GFP at the N- and C-terminus were unable to complement the phenotype of an sdh8Δ 
mutant strain and were therefore deemed to be nonfunctional, efficient rescue was seen 
when GFP was fused into a predicted unstructured region within Sdh8, between residues 
S82 and N83 (Figure 4.1E).  Sdh8-GFP exhibited complete colocalization with a 
mitochondrially localized RFP in an sdh8Δ strain, confirming the mitochondrial 















Figure 4.1.  Yeast Sdh8 is a conserved matrix protein required for 
maximal SDH activity.   
(A) Sequence alignment of the SDHAF4 protein family (Clustal Omega).  (B) Intact 
mitochondria, hypotonic-swollen mitoplasts, and Triton X-100-solubilized mitochondria 
of a sdh8Δ strain expressing Sdh8-His6HA3 were treated either with (+) or without (-) 
proteinase K and analyzed by immunoblot along with the whole-cell lysate (WCL) and 
postmitochondrial supernatant (PMS).  Fzo1, Cyb2, and Mge1 are outer mitochondrial 
membrane, inner-membrane space, and matrix proteins, respectively.  (C) Mitochondria 
isolated from sdh8Δ mutant cells expressing Sdh8-His6HA3 were separated into soluble 
and membrane fractions.  Each fraction was assessed by SDS-PAGE and immunoblot.  
Sdh5 and Porin are used as controls and represent soluble and membrane bound proteins, 
respectively.  (D) The sdh8Δ mutant expressing Sdh8-GFP and MitoRFP were grown to 
early log phase and imaged by fluorescent microscopy.  (E) Ten fold serial dilutions of 
wild-type (WT) yeast transformed with an empty vector (EV), sdh8Δ mutants 
transformed with EV, or sdh8Δ transformed with SDH8-His6HA3, all in a W303 
background, were grown on different carbon sources and incubated at 30˚C.  (F–H)  
GC/MS was used to measure the abundance of metabolites in WT and sdh8Δ yeast 
(W303 background). The data is depicted in box plot format, with the box representing 
the lower and upper quartiles, the horizontal line representing the median, and the bars 
representing the minimum and maximum data points. (N = 6 biological replicates. **p < 









The subcellular and submitochondrial localization of this protein was further 
investigated using biochemical fractionation.  We generated an Sdh8-His6HA3 fusion 
analogous to the internal Sdh8-GFP fusion and confirmed it to be fully functional (Figure 
4.2A).  Upon biochemical fractionation, Sdh8-His6HA3 was readily detected in the whole 
cell lysate but was undetectable in the postmitochondrial supernatant (Figure 4.1B, left 
panel).  Sdh8-His6HA3 was present in purified mitochondria and was protected from 
Proteinase K except in the presence of Triton X-100, consistent with its localization to 
the mitochondrial matrix (Figure 4.1B, right panel). Sdh8-His6HA3 appears to not be 
stably associated with membranes as it was soluble following sonication, like the soluble 
Sdh5 protein and unlike the integral membrane protein porin (Figure 4.1C).  Taken 
together, these results demonstrate that Sdh8 is a soluble protein localized to the 
mitochondrial matrix.   
To begin to assess the role of Sdh8 in mitochondrial function, an sdh8Δ mutant 
was established in two strains (BY4741 and W303), both of which were used for key 
experiments to control for genetic background. While sdh8Δ mutants grew normally in 
glucose medium, growth was impaired on glycerol and acetate, demonstrating a defect in 
mitochondrial respiration (Figures 4.2A and 4.1E). Interestingly, growth was particularly 
impaired on acetate-containing medium, which is a hallmark of mutants that affect SDH 
activity. Consistent with this possibility, metabolomic analysis of sdh8Δ mutants revealed 
an apparent block in the TCA cycle at SDH, with an accumulation of  succinate and 
depletion of the two TCA cycle intermediates downstream of SDH, fumarate and malate, 
in both strain backgrounds (Figures 4.2B and 4.1F–4.1H). We also measured the 

















Figure 4.2.  Yeast Sdh8 is a conserved mitochondrial matrix protein 
required for maximal SDH activity and assembly. 
(A) Ten-fold serial dilutions of wild-type (WT) yeast transformed with an empty vector 
(EV) or sdh8Δ mutants transformed with either EV or a plasmid expressing SDH8-
His6/HA3, all in a BY4741 background, were grown on the indicated carbon sources at 
30˚C for 2 days (glucose) or 4 days (glycerol, acetate).  (B) GC/MS was used to measure 
the abundance of metabolites in WT and sdh8Δ yeast (BY4741 background). The data is 
depicted in box plot format, with the box representing the lower and upper quartiles, the 
horizontal line representing the median, and the bars representing the minimum and 
maximum data points.  N = 6 biological replicates. ****p < 0.0001; **p < 0.005; *p < 
0.05).  (C) SDH and (D) malate dehydrogenase enzyme assays were performed on 
mitochondrial extracts of WT, sdh8Δ, and sdh1Δ strains, normalized to total protein (± 
SEM; N = 3 biological replicates. **, p < 0.005).  (E) Mitochondria from WT and sdh8Δ 
cells were solubilized in digitonin, fractionated by BN-PAGE, and analyzed by 
immunoblotting to detect Atp2 (complex V), Cor1/2 (complex III), Cox3 (complex IV), 
Sdh1 (complex II), or Por1 (Porin). (F) Ten-fold serial dilutions of the indicated strains 
were grown on the indicated carbon sources at 30˚C as in (A).  SDHAF4 and dSdhaf4 are 
the human and Drosophila orthologs of SDH8, respectively, and were each expressed 

















cells. SDH activity in sdh8Δ cells was decreased 60% relative to WT (Figure 4.2C), 
while malate dehydrogenase (MDH) activity was unaffected (Figure 4.2D).  Finally, the 
steady state level of the SDH holocomplex was assessed by blue native polyacrylamide 
gel electrophoresis (BN-PAGE).  Mitochondria purified from either WT or sdh8Δ cells 
were solubilized in digitonin, resolved by BN-PAGE, and probed by immunoblot.  We 
observed a marked decrease in assembled SDH complexes of similar magnitude to the 
decrease in SDH activity (Figure 4.2E). Taken together, these data demonstrate that Sdh8 
is required for the stability and activity of SDH.  
Based on sequence alignments, Sdh8 appears to be a member of a broadly 
evolutionarily conserved protein family (Figure 4.1A). As a first step toward determining 
if its function is conserved across eukaryotic species, the human and Drosophila 
orthologs of SDH8 (SDHAF4 and dSdhaf4, respectively) were expressed in the sdh8Δ 
mutant under the control of the native SDH8 promoter and terminator.  Both orthologs 
complement the sdh8Δ growth defects (Figure 4.2F), suggesting that the role of Sdh8 in 
SDH assembly is an evolutionarily conserved feature of the SDHAF4 family.  
 
 
Mammalian SDHAF4 is required for maximal SDH activity 
To assess a possible role for mammalian SDHAF4 in SDH function, we 
transfected C2C12 mouse myoblasts with a nontargeting control siRNA (control) or 
either of two siRNAs targeting mouse SDHAF4 (si1 and si2).  Knockdown of SDHAF4 
mRNA was confirmed (Figure 4.3A) and mitochondria were harvested from cells 
transfected with control, si1, and si2 siRNAs.  Immunoblot of the isolated mitochondria 









Figure 4.3. Mammalian SDHAF4 is required for maximal SDH activity. 
(A) C2C12 cells were transfected with either a control nontargeting siRNA or either of 
two siRNAs directed against SDHAF4 (si1 and si3), and SDHAF4 mRNA abundance was 
assayed by quantitative RT-PCR and normalized to tubulin mRNA (± SEM. N = 3 
biological replicates. ***, p < 0.0001).  (B) SDH enzyme activity was measured in 
mitochondria harvested from C2C12 cells treated as in (A) (± SEM. N = 3 biological 
replicates. ***p < 0.0005; *p < 0.05).  (C) Mitochondria extracted C2C12 cells treated as 
in (A) were solubilized in digitonin, fractionated by BN-PAGE, and analyzed by 
immunoblotting for ATP5A (complex V monomers (CVI) or dimers (CVII), QCR2 








(mammalian ortholog of yeast Sdh1) or SDHB (mammalian ortholog of yeast Sdh2; 
Figure 4.4A).  We detected, however, a dose-dependent decrease in SDH enzymatic 
activity in SDHAF4 knockdown cells (Figure 4.3B), with no significant change in MDH 
activity (Figure 4.4B).  In addition, cells transfected with si1 or si2 showed a 
reproducible and specific decrease in steady-state SDH complexes as assayed by BN-
PAGE, of a magnitude similar to that seen in SDH activity (Figure 4.3C). We conclude 
that SDHAF4 is required for the proper assembly and activity of SDH in both yeast and 
mammalian cells.  
 
Drosophila Sdhaf4 is required for succinate dehydrogenase activity 
To further define the function of Sdh8 and to examine its role in the context of a 
multicellular organism, we extended our analysis to Drosophila. Three mutations were 
generated in the gene encoding the Drosophila ortholog of SDH8 (CG7224) that we have 
renamed Drosophila Sdhaf4 (dSdhaf4). Two of these alleles were deletion/insertion 
mutations generated using TALEN endonuclease-mediated gene targeting (dSdhaf1 and 
dSdhaf42) that are predicted to cause a frameshift and premature stop codon in the N- 
terminal half of the protein (Figure 4.5A). Genetically matched control strains for these 
alleles were also generated in a w1118 genetic background. The third allele (dSdhaf3) is an 
independently derived deletion that removes most of the dSdhaf4 coding region, 
generated by imprecise excision of a P-element (Figure 4.5A). A stock that carries a 




















Figure 4.4.  Mammalian SDHAF4 is required for maximal SDH 
activity.   
(A) Mitochondria extracted C2C12 cells transfected with AS, si1, or si2 were subjected 
to SDS-PAGE and analyzed by immunoblot of SDHA, SDHB, ATP5A, and VDAC.  (B) 
MDH enzyme activity was measured in mitochondria harvested from C2C12 cells 






















Figure 4.5. Metabolomic analysis of multiple dSdhaf4 mutants reveals 
changes in several metabolic pathways. 
(A) dSdhaf4 alleles generated and used in this study. TALEN induced alleles (dSdhaf41 
and dSdhaf42) are shown in red, while the deletion generated by imprecise excision 
(dSdhaf43) of the pCG7224[KG07581] P element, is shown in blue. The dSdhaf43 allele 
contains a remnant of the pCG7224[KG07581] element that was not excised. Another strain 
in which the pCG7224[KG07581] element was precisely excised (Ex32+) was generated, 
confirmed by PCR, and used as a control for all studies with the dSdhaf43  allele. (B) 
Either LC/MS or GC/MS was used to measure the abundance of metabolites in 
transheterozygous dSdhaf41/3 mutants compared to genetically matched dSdhaf4+/Ex32+ 
controls. (C) Changes in non-TCA cycle metabolites in dSdhaf41/2 or dSdhaf41/3 flies 
compared to their respective controls measured using GC/MS. The data is depicted in box 
plot format, with the box representing the lower and upper quartiles, the horizontal line 
representing the median, and the bars representing the minimum and maximum data 
points. Eight to twelve biological replicates from two independent experiments were 











Similar to our findings in yeast, metabolomic analysis of dSdhaf4 mutants 
revealed a significant accumulation of succinate and depletion of malate and fumarate 
(Figures 4.5B and 4.6A). Acetyl-CoA was also elevated, while citrate and isocitrate were 
reduced in the mutants (Figures 4.5B and 4.6A). These effects may be due to a reduction 
in oxaloacetate (which was undetectable in our experiments) that is required for the 
formation of citrate from acetyl-CoA. Consistent with this, aspartate, which is 
interconvertible with oxaloacetate, is depleted in dSdhaf4 mutants (Figure 4.5C). 
Interestingly, NADH and NADPH are reduced in dSdhaf4 mutants, while ATP levels are 
unaffected (Figures 4.5B and 4.6A). dSdhaf4 mutants also display significant changes in 
the abundance of several other metabolites, including homocysteine, glycine, glutamate, 
the neurotransmitter gamma aminobutyrate (GABA) and methylcitrate (Figure 4.5C). 
Similar changes were observed upon metabolomic analysis of flies carrying a dSdhaf4 
TALEN-induced allele over the independently derived imprecise excision, indicating that 
these results are consistent across genetic backgrounds (Figures 4.5B, 4.5C, and 4.6A). 
Consistent with this metabolomic profile, dSdhaf4 mutant mitochondria display an 85% 
reduction in SDH activity compared to controls (Figure 4.6B). No significant effect, 
however, was seen on citrate synthase (CS) activity, indicating that the reduced SDH 
activity is not associated with general mitochondrial dysfunction (Figure  
4.6C). Based on these data, we conclude that, like yeast sdh8Δ mutants, dSdhaf4 mutants 




















Figure 4.6. Drosophila Sdhaf4 is required for SDH activity. 
(A) Either LC/MS (acetyl-CoA, succinyl-CoA, ATP, AMP, NAD, NADH, NADP, and 
NADPH) or GC/MS (citrate, isocitrate, alpha-ketoglutarate, succinate, fumarate and 
malate) was used to measure the abundance of metabolites in transheterozygous 
dSdhaf41/2 (dSdhaf4–) mutants compared to genetically matched w1118 controls 
(dSdhaf4+). The data are depicted in box plot format, with the box representing the lower 
and upper quartiles, the horizontal line representing the median, and the bars representing 
the minimum and maximum data points.  Eight to twelve biological replicates from two 
independent experiments were combined per genotype. (B) Succinate dehydrogenase or 
(C) citrate synthase enzymatic activity was measured in extracts from mitochondria 
isolated from either control or dSdhaf4 mutant flies (± SEM. N = 4–6 biological 
replicates. **p < 0.01 and ***p < 0.001). Two independent experiments were performed 
















Drosophila Sdhaf4 is required for the stability of SdhA and SdhB 
The decrease in SDH activity in dSdhaf4 mutants is greater than that seen in yeast 
sdh8Δ mutants, suggesting that there might be a more profound effect on the steady-state 
level of SDH. Consistent with this, the SDH holocomplex was undetectable in BN-PAGE 
experiments, whereas the levels of Complex V were unaffected (Figure 4.7A). This lack 
of SDH holocomplex was accompanied by an apparent reduction in the stability of the 
SdhA and SdhB subunits in dSdhaf4 mutants (Figures 4.7B, 4.8A, and 4.8B). We also 
examined whether loss of one copy of dSdhaf4 or dSdhaf4 overexpression could affect 
SDH function. dSdhaf4 heterozygous mutants, however, displayed similar SDH activity 
to controls (Figure 4.8C), and dSdhaf4 overexpression had no effect on SDH activity or 
SDH subunit protein levels (Figures 4.8D and 4.8E).  
The reduced levels of SDH subunits in the dSdhaf4 mutant suggest that we might 
see genetic interactions between dSdhaf4 alleles and mutations in SDH subunit-encoding 
genes. Consistent with this, we found that dSdhaf4 mutant flies heterozygous for a strong 
loss-of-function mutation in SdhA or homozygous for a hypomorphic mutation in SdhB 
displayed reduced viability compared to controls (Figures 4.7C and 4.8F). This genetic 
interaction is specific for SDH subunit-encoding genes, as dSdhaf4 mutants heterozygous 
for a null allele of  Cytrochrome oxidase Va subunit (CoVa) (Mandal et al., 2005) 
displayed normal viability (Figure 4.7C). Taken together, these biochemical and genetic 
studies indicate that dSdhaf4 is required for SDH assembly and activity, likely through 

























Figure 4.7. Drosophila Sdhaf4 is required for SdhA and SdhB stability. 
(A) Mitochondrial extracts from either w1118 controls (dSdhaf4+) or dSdhaf41/2 mutants 
(dSdhaf4–) were fractionated by BN-PAGE and analyzed by immunoblotting to detect 
Atpα (Complex V monomers or dimers) or SdhB (Complex II). (B) Total protein from 
mitochondria isolated from either control or dSdhaf4 mutant flies was resolved using 
SDS-PAGE, followed by immunoblotting to detect SdhA, SdhB, or ATPα. (C) Flies 
carrying either control or dSdhaf4 mutant chromosomes over a balancer chromosome 
were crossed to flies carrying a strong loss-of-function allele for either SdhA or 
Cytochrome c oxidase Va subunit (CoVa) over a balancer. The resulting progeny were 
scored for the absence or presence of the marker linked to the balancer chromosome. The 
proportion of the expected progeny that eclosed, based on Mendelian ratios of the 
indicated genotypes, is shown. (± SEM. N = number of progeny assayed from each cross. 


















Figure 4.8. Drosophila Sdhaf4 is required for the stability of SdhA and 
SdhB, but is not a rate-limiting factor in SDH assembly. 
(A) Mitochondrial extracts from w1118 control (dSdhaf4+) or dSdhaf41/2 (dSdhaf4–) flies 
were resolved by SDS-PAGE; the gel was washed and then either exposed to ultraviolet 
light to visualize flavinated SdhA (top) or stained with Coomassie Blue (bottom) to 
visualize total protein. Two biological replicates are shown. The reduction in flavinated 
SdhA reflects the overall reduction in SdhA protein levels, indicating little if any effect of 
the mutation on flavination. (B) Protein from whole-fly homogenates was resolved by 
SDS-PAGE followed by immunoblotting to detect SdhB or tubulin. The asterisk denotes 
a nonspecific band. Two biological replicates are shown.  (C) Mitochondria were isolated 
from either control w1118 (dSdhaf4+/+) or heterozygous dSdhaf4+/1  (dSdhaf4+/–) flies and 
SDH enzymatic activity was assayed. (D) Mitochondria were isolated from flies carrying 
a ubiquitous Tubulin-GAL4 driver or a UAS-dSdhaf4 element alone or in combination, 
and SDH enzymatic activity was assayed. (E) Mitochondria were isolated from flies 
carrying a ubiquitous Tubulin-GAL4 driver or a UAS-dSdhaf4 element alone or in 
combination, and SdhA, SdhB or ATP∝ subunit levels were assayed by western blot 
analysis. (F) Flies harboring either control (dSdhaf4+) or dSdhaf41/2 (dSdhaf4–) mutant 
chromosomes linked to a hypomorphic SdhB allele or wild type SdhB locus over a 
balancer were crossed to each other in various combinations. The resulting progeny from 
these crosses were then assayed for the absence or presence of the marker linked to the 
balancer chromosome. The proportion of the expected progeny eclosed based on 
Mendelian ratios of the indicated genotype is shown. The n values displayed in 
parentheses in the graph represent the total number of progeny assayed resulting from 








dSdhaf4 mutants display neurodegenerative phenotypes, early-
adult lethality,  and sensitivity to oxidative stress 
Consistent with their metabolic defects, dSdhaf4 mutants died earlier than 
controls, with a median lifespan of 12 days compared to a median lifespan of 69 days for 
control flies (Figure 4.9A). Interestingly, these mutants also displayed two phenotypes 
that are hallmarks of mitochondrial dysfunction, bang sensitivity, and erect wings 
(Figures 4.9B, 4.9C, 4.10A, and 4.10B) (Fergestad et al., 2006; Greene et al., 2003). 
Since bang sensitivity is often associated with neurodegeneration (Celotto et al., 2006a; 
Gnerer et al., 2006; Liu et al., 2007), we examined the photoreceptors of dSdhaf4 mutant 
compound eyes by transmission electron microscopy. This study revealed that dSdhaf4 
mutant retinas displayed a marked disorganization of retinal architecture (Figure 4.9D, 
asterisks) consistent with a neurodegenerative phenotype (Feany and Bender, 2000). The 
photoreceptors were also highly vesicularized (Figure 4.9D, arrows) (Kiselev et al., 
2000), with aberrant mitochondrial morphology (Figure 4.9D, arrowheads). This 
neurodegeneration phenotype is tissue-autonomous as specific expression of wild-type 
dSdhaf4 in neurons was sufficient to rescue the bang sensitivity of dSdhaf4 mutants 
(Figures 4.9E, 4.10C, and 4.10D). Moreover, global expression of human Sdhaf4 in 
dSdhaf4 mutants partially rescued the bang sensitivity of these animals, providing further 
evidence of a conserved function for Sdhaf4 (Figures 4.9E, 4.10C, and 4.10D). Taken  
together, these results demonstrate that dSdhaf4 is required in neurons to maintain tissue 
structure and function. Defects in mitochondrial ATP production and ROS homeostasis 
have been previously shown to cause neurodegenerative phenotypes similar to those 













Figure 4.9. Drosophila Sdhaf4 mutants display neurodegenerative 
phenotypes, early-adult lethality, and sensitivity to oxidative stress. 
(A) The number of surviving w1118 control (dSdhaf4+) or dSdhaf41/2 mutant (dSdhaf4–) 
females maintained on standard laboratory food at normoxia was assayed at 2–4 day 
intervals. Each data point is the percentage of surviving flies ± SEM, with at least 110 
flies assayed per genotype. (B) Control or dSdhaf4 mutant females aged 6–8 hours, 2–4 
days, or 8–12 days were vortexed for 15 seconds and the percentage of paralyzed flies 
was counted as described (Ganetzky and Wu, 1982). (±SΕΜ. N > 32 flies per age per 
genotype. ** p < 0.01 and *** p < 0.001 [ANOVA]). (C) The length of time required for 
the dSdhaf4 mutant flies in (A) to recover from paralysis is presented as a bar graph, with 
the number of paralyzed dSdhaf4 mutants analyzed from each age group depicted above 
the bar. (D) Cross sections of compound eyes from 8–12 day old control or dSdhaf4 
mutant flies visualized by transmission electron microscopy. Arrows point to aberrant 
vesicularization of dSdhaf4 mutant photoreceptors, arrowheads point to mitochondria, and 
asterisks denote vacuoles. (E) Control or dSdhaf4 mutant flies at 8–12 days of age 
carrying either the ubiquitous Daughterless-Gal4 (Da-GAL4) driver, the pan-neuronal 
Elav-Gal4 driver, or no driver, in the presence or absence of either a UAS-dSdhaf4 
transgene or a UAS-human Sdhaf4 (hSdhaf4) transgene, were vortexed as in (A). Note 
that UAS-dSdhaf4 alone has leaky dSdhaf4 activity since it partially rescues in the 
absence of a GAL4 driver. (±SEM. N = 15–40. *** p < 0.001 [ANOVA]). (F) Control or 
dSdhaf4 mutant females at 2–4 days of age were transferred to 100% oxygen and the 
number of surviving animals was counted each day. The median lifespan of controls 
under hypoxia is 9 days and the median lifespan of dSdhaf4 mutants under hypoxia is 1 
day. Data is shown as the percentage of surviving flies ± SEM. At least 40 flies were 
assayed per genotype.  P values for both survival curves (panels A and F) were calculated 





































Figure 4.10. dSdhaf4 mutants are sensitive to bang induced paralysis, 
but not starvation. 
(A) Adult dSdhaf4+/Ex32+ (dSdhaf4+) or dSdhaf41/3  (dSdhaf4–) females aged 6–8 hours, 2–
4 days, or 8–12 days were vortexed for 15 seconds and the percentage of paralyzed flies 
was counted. N > 35 flies at each age per genotype. ***p < 0.001 (ANOVA). (B) The 
percentage of 3–7 day old w1118 control or dSdhaf41/2 females that hold their wings in an 
upright position is shown.  N > 180 flies per genotype. ***p < 0.001 (Student’s t test). 
The mean ± SEM is shown in A and B. (C) Controls or dSdhaf4 mutant flies carrying the 
ubiquitous Daughterless driver (Da-GAL4) or no driver in the presence or absence of 
either a UAS-dSdhaf4 transgene or a UAS-human Sdhaf4 (hSdhaf4) transgene were 
homogenized. Proteins from these homogenates were resolved by SDS-PAGE followed 
by immunoblotting to detect either SdhB or tubulin. Note that UAS-dSdhaf4 is leaky 
since it partially rescues in the absence of a GAL4 driver. (D) The amount of time 8–12 
day old flies paralyzed in Figure 4.9E take to recover from paralysis was quantified. The 
percentage of flies paralyzed <2 minutes, 2–6 minutes, 8–10 minutes or > 10 minutes are 
shown. The number above each bar represents the total number of flies of the indicated 
genotype paralyzed and is the sample size from which each data set is based. (E) Two to 
four day old controls or dSdhaf4 mutant females were starved and the number of 
surviving animals was counted every 12 hours. The median lifespan under starvation 3.5 
days for controls and 3.25 days for dSdhaf4 mutants. Data shown as the percentage of 
surviving flies ± SEM. At least 90 flies were assayed per genotype. P value calculated 
using a log-rank test. 
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(Celotto et al., 2012; Fergestad et al., 2006; Liu et al., 2007). Since loss of dSdhaf4 does 
not appear to affect steady state ATP levels (Figures 4.6A and 4.5B), we hypothesized 
that dSdhaf4 may be required for protection against ROS toxicity. Consistent with this, 
dSdhaf4 mutants were highly sensitive to oxidative stress induced by hyperoxia (Figure 
4.9F), but showed no sensitivity to starvation, which is unassociated with ROS 
production (Figure 4.10E). These data suggest a connection between the role of dSdhaf4 
in SDH assembly and oxidative stress resistance.  
 
Yeast Sdh8 is a chaperone for soluble and covalently flavinated Sdh1 
Data from three distinct eukaryotic systems indicate that the SDHAF4 protein 
family plays an evolutionarily conserved role in SDH assembly and activity.  Turning 
back to yeast, we sought to understand the mechanism by which Sdh8 supports SDH 
biogenesis.  To identify proteins interacting with Sdh8, we performed a large scale HA 
immunoprecipitation from either WT or Sdh8-His6HA3 containing mitochondria. The 
final eluates were resolved by SDS-PAGE, revealing a band of ~70 kDa that was present 
only in the Sdh8-His6HA3 immunoprecipitation.  Using mass spectrometry, we found that 
this band contained Msd1, a nuclear-encoded mitochondrial tRNA synthetase for 
aspartate (Gampel and Tzagoloff, 1989) and Sdh1, the catalytic subunit of SDH (Figure 
4.11A).  Due to the strong connection with SDH assembly and function, we focused on 
this putative interaction between Sdh8 and Sdh1, which was confirmed by 
immunoprecipitation of Sdh8 followed by identification of Sdh1 in the eluate using an 
Sdh1-specific antibody (Figure 4.12A, lanes 1 and 6 vs. 2 and 7).  This experiment also 















Figure 4.11. Yeast Sdh8 is a cochaperone for unbound and covalently 
flavinated Sdh1.   
(A) A large scale HA immunoprecipitation of mitochondria isolated from sdh8Δ cells 
expressing Sdh8-His6HA3 and WT cells as a control.  The final eluates were resolved by 
SDS-PAGE and visualized by silver stain (Thermo Scientific).  The proteins present in 
each band were identified by mass-spectroscopy.  (B) WT, sdh8Δ, and sdh5Δ 
mitochondria were resolved by SDS-PAGE and imaged for covalent FAD (ultraviolet 
light) or immunoblotted for Sdh1.  (C) Sdh8-His6HA3  was immunoprecipitated using 
anti-HA conjugated agarose from digitonin-solublilized mitochondria.  Mitochondria 
were extracted from sdh8Δ cells expressing Sdh8-His6HA3 or sdh1Δsdh8Δ cells 
expressing Sdh8-His6HA3 and Sdh1H90S mutant (BY4741 background).  (D) Sdh8-
His6HA3 was immunoprecipitated from WT and sdh5Δ mitochondria using anti-HA 
conjugated agarose (W303 background).  (E) Mitochondrial lysates isolated from control 
cells (WT), sdh8Δ cells expressing Sdh8-His6HA3, sdh1Δsdh8Δ cells expressing Sdh8-
His6HA3, sdh2Δsdh8Δ cells expressing Sdh8-His6HA3, sdh8Δ cells, sdh2Δsdh8Δ cells, 
and sdh5Δsdh8Δ cells expressing Sdh8-His6HA3 were fractionated by SDS-PAGE.  
Levels of each protein were assessed by immunoblot for Sdh1, Sdh2, and HA (Sdh8-
His6HA3).  Immunoblot of Porin was used as a loading control (W303 background).  (F) 
Sdh2- His6HA3 was immunoprecipitated from digitonin-solubilized mitochondria.  
Mitochondria were extracted from control cells (WT), sdh2Δsdh4Δ cells expressing 





















Figure 4.12. Yeast Sdh8 is a cochaperone for unbound and covalently 
flavinated Sdh1. 
(A) Sdh8-His6HA3 was immunoprecipitated using anti-HA antibody-conjugated agarose 
from digitonin-solubilized mitochondria isolated from the yeast strains described as 
follows.  Lanes 1 and 6, WT cells; Lanes 2 and 7, sdh8Δ cells expressing Sdh8-His6HA3; 
Lanes 3 and 8, sdh2Δ sdh8Δ cells expressing Sdh8-His6HA3; Lanes 4 and 9 sdh1Δ sdh8Δ 
cells expressing Sdh8-His6HA3 and Sdh1H90A; Lanes 5 and 10, sdh1Δ sdh2Δ sdh8Δ cells 
expressing Sdh8-His6HA3 and Sdh1H90A.  (B) Mitochondrial lysates isolated from the 
following strains were fractionated by SDS-PAGE. Lane 1, sdh8Δ cells expressing Sdh8-
His6HA3; Lane 2, sdh1Δ sdh8Δ cells expressing Sdh8-His6HA3; Lane 3, sdh2Δ sdh8Δ 
cells expressing Sdh8-His6HA3; Lane 4, sdh8Δ cells; Lane 5, sdh2Δ sdh8Δ cells 
(BY4741 background). Steady state protein abundance was assessed by immunoblot 
using antibodies against Sdh1, Sdh2, and HA (Sdh8-His6HA3).  (C) Mitochondria 
isolated from the following yeast strains were solubilized in digitonin and fractionated by 
BN-PAGE. Lane 1, sdh8Δ cells expressing Sdh8-His6HA3; Lane 2, sdh2Δ sdh8Δ cells 
expressing Sdh8-His6HA3; Lane 3, sdh1Δ sdh2Δ sdh8Δ cells expressing Sdh8-His6HA3; 
Lane 4, sdh2Δ sdh8Δ; Lane 5, sdh4Δ sdh8Δ cells expressing Sdh8-His6HA3; Lane 6, 
sdh1Δ sdh4Δ sdh8Δ cells expressing Sdh8-His6HA3; Lane 7, sdh4Δ sdh8Δ cells.  
Immunoblotting was used to detect Atp2 (complex V) as a control and complexes 
containing Sdh1, Sdh2, and HA (Sdh8-His6HA3).  SDH complex (~232 kDa), Sdh1/Sdh8 




under WT conditions and that Sdh2 is likely not a member of this complex as it is 
undetectable in the eluate (Figure 4.12A). 
Since Sdh8 binds Sdh1 independent of Sdh2, we hypothesized that Sdh8 may be 
acting as a chaperone for a free soluble pool of Sdh1 in the mitochondrial matrix. If this 
is true, then deletion of SDH2 might shift Sdh1 to a free soluble form, which would 
increase the demand for Sdh8 function.  Consistent with this possibility, sdh2Δ mutant 
mitochondria exhibit an accumulation of Sdh8 (Figure 4.12B, lane 1 vs. lane 3), while 
sdh1Δ mutant mitochondria exhibit a depletion of Sdh8 (Figure 4.12B, lane 1 vs. lane 2). 
Furthermore, this accumulation of Sdh8-His6HA3 results in enhanced Sdh1-Sdh8 
association in the sdh2Δ mutant (Figure 4.12A, lanes 2 and 7 vs 3 and 8) despite an 
approximately two-fold decrease in steady state Sdh1 levels (Figure 4.12B, lane 1 vs. 
lane 3). Although the stability of Sdh8 depends on Sdh1, Sdh1 abundance is unaffected 
by the deletion of SDH8 (Figure 4.12B). However, Sdh2 levels are reduced in an sdh8Δ 
mutant, likely due to decreased Sdh1 competence for interaction with Sdh2 (Figure 
4.12B). This is further supported by the observation that the formation of the Sdh1-Sdh2 
soluble dimer, which is readily apparent in a mutant lacking the Sdh4 membrane anchor, 
is impaired in an sdh8Δ mutant (Figure 4.11F).  Interpretation of this experiment is 
complicated by the decreased Sdh2 steady state level in the sdh1Δ mutant, but the data 
are most consistent with the hypothesis that Sdh8 is required to maintain Sdh1 in a state 
that is fully competent to bind Sdh2 and assemble in the SDH holocomplex. Sdh1 is 
known to be covalently flavinated at H90 in a reaction that requires the activity of Sdh5 
(Hao et al., 2009). Initially, we found that deletion of SDH8 does not impact the 
flavination of Sdh1 (Figure 4.11B). 
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We reasoned, however, that Sdh8 might act specifically on the flavinated form of free 
Sdh1. Accordingly, we immunoprecipitated Sdh8-His6HA3 from mitochondria that 
express wild-type Sdh1, Sdh1H90A, or Sdh1H90S, which are Sdh1 mutants that cannot 
covalently bind FAD.  Indeed, Sdh1H90A and Sdh1H90S both failed to copurify with Sdh8-
His6HA3 (Figures 4.12A, lanes 2 and 7 vs. lanes 4 and 9, and 4.11C) even in the absence 
of Sdh2 (Figure 4.12A, lanes 2 and 7 vs. lanes 5 and 10).  In further support of this 
hypothesis, we found that Sdh1 failed to interact with Sdh8-His6HA3 in sdh5Δ mutant 
cells (Figure 4.11D), which lack covalent Sdh1 flavination (Figure 4.11B) (Hao et al., 
2009). Furthermore, Sdh8-His6HA3 was destabilized in the sdh5Δ mutant as was 
observed for the sdh1Δ mutant (Figure 4.11E, lane 1 vs. 6).  Finally, Sdh8-His6HA3 is not 
present in the SDH holocomplex, as assayed by BN-PAGE (Figure 4.12C, lane 1).  We 
also observed that deletion of SDH2 or SDH4, which ablates the SDH holocomplex, 
causes the emergence of a subcomplex of ~150 kDa, which lacks Sdh2 but clearly 
contains both Sdh1 and Sdh8 (Figure 4.12C, lanes 2 and 5). This is not coincidental 
comigration as loss of either Sdh1 or Sdh8 causes this subcomplex to disappear from 
sdh2Δ and sdh4Δ mutant strains (Figure 4.12C, lanes 3, 4, 6, and 7).  Taken together, 
these data demonstrate that Sdh8 interacts specifically with flavo-Sdh1, independent of 
other components of the SDH complex, and its stability depends upon this interaction.  
 
Sdh8 protects the cell from oxidative stress 
The data presented thus far demonstrate that Sdh8 acts as a chaperone for Sdh1 to 
promote formation of the Sdh1/Sdh2 dimer. We found that overexpression of Sdh1 does 
not rescue the growth defects of sdh8Δ mutants but, rather, is toxic to both WT and 
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sdh8Δ cells on respiratory carbon sources, with the sdh8Δ mutant being particularly 
sensitive (Figures 4.13A and 4.14A). Within the mitochondrial matrix, Sdh1 can form 
soluble complexes with two proteins — Sdh2 and Sdh8.  To further interrogate potential 
toxicity associated with unbound Sdh1 we assayed the growth of sdh2Δsdh8Δ mutant 
cells compared to each single mutant.  In this double mutant all Sdh1 will be in the free 
unbound state.  Indeed, deletion of both SDH2 and SDH8 causes a synthetic growth 
phenotype, while no apparent phenotype was observed for either single deletion strain 
(Figure 4.13B).  These observations raise the possibility that free Sdh1 is toxic and that 
this toxicity may be alleviated by Sdh8.  To test this, we cooverexpressed Sdh8 with 
Sdh1 and observed a significant rescue of the Sdh1 toxicity (Figure 4.13C). We conclude 
that, in addition to promoting assembly of the Sdh1/Sdh2 dimer; Sdh8 also prevents the 
toxicity associated with free Sdh1. 
In considering possible mechanisms for toxicity of free Sdh1, we hypothesized 
that the exacerbated sdh8Δ phenotype on acetate compared to glycerol medium (Figure 
4.2A) may be the result of increased oxidative stress.  This is consistent with previous 
reports using acetate to trigger ROS-dependent cell death in yeast (Carmona-Gutierrez et 
al., 2010), as well as the sensitivity of dSdhaf4 mutants to hyperoxia (Figure 4.9F).  In 
support of this hypothesis, we found that the sdh8Δ mutant is profoundly hypersensitive 
to paraquat in glycerol media relative to WT cells (Figure 4.13D).  If this impaired 
growth is the result of elevated ROS, then overexpression of genes involved in ROS 
detoxification might suppress the growth phenotype.  In fact, overexpression of YAP1, a 
transcription factor that stimulates the expression of many genes important for oxidative 










Figure 4.13.  Sdh8 protects the cell from oxidative stress. 
(A) Ten-fold serial dilutions of WT and sdh8Δ yeast either transformed with an empty 
vector or overexpressing Sdh1 were plated on media containing the indicated carbon 
source and incubated at 30˚C (W303 background) for 2 days (glucose), 3 days (raffinose) 
or 4 days (glycerol, acetate).  (B) WT, sdh2Δ, sdh8Δ, and sdh2Δ sdh8Δ cells were back-
diluted in synthetic complete media with 2% glucose and incubated at 30˚C.  Growth was 
assessed by measuring the optical density (600 nm) of each culture at various time points. 
(±SEM. N = 3. Time point (TP) 1—sdh2Δ vs. sdh2Δsdh8Δ p = .007, sdh8Δ vs. 
sdh2Δsdh8Δ p = .01; TP 2—sdh2Δ vs. sdh2Δsdh8Δ p = .03, sdh8Δ vs. sdh2Δsdh8Δ p = 
.03; TP 3—sdh2Δ vs. sdh2Δsdh8Δ p = .01, sdh8Δ vs. sdh2Δsdh8Δ p = .02; TP 4—sdh2Δ 
vs. sdh2Δsdh8Δ p < .0001, sdh8Δ vs. sdh2Δsdh8Δ p = .0003; TP 5—sdh2Δ vs. 
sdh2Δsdh8Δ p = .001, sdh8Δ vs. sdh2Δsdh8Δ p < .0001; TP 6—sdh2Δ vs. sdh2Δsdh8Δ p 
= .004, sdh8Δ vs. sdh2Δsdh8Δ p = .0025).  (C) Ten-fold serial dilutions of WT yeast 
transformed with an empty vector, WT yeast overexpressing Sdh1, and WT yeast 
overexpressing Sdh1 and Sdh8 were plated on media containing acetate and incubated at 
30˚C (W303 background) as in (A). (D) Ten-fold serial dilutions of WT yeast 
transformed with an empty vector, sdh8Δ cells transformed with an empty vector, and 
sdh8Δ cells expressing Sdh8-His6HA3 were plated on media containing glycerol with and 
without 1mM paraquat and incubated at 30˚C (W303 background) as in (A). (E) Ten-fold 
serial dilutions of WT yeast transformed with an empty vector, sdh8Δ cells transformed 
with an empty vector, and sdh8Δ cells overexpressing YAP1 were plated on media 
containing the indicated carbon source and incubated at 30˚C (BY4741 background) as in 
(A).  (F) Shown here is an updated model of the assembly of SDH.  Upon entry into the 
mitochondrial matrix, apo-Sdh1 is rapidly flavinated in a reaction that requires Sdh5 
(Hao et al., 2009).  Acting as a cochaperone, Sdh8 binds and occupies Sdh1 forming an 
important intermediate subcomplex that prevents Sdh1 autoxidation (2).  Sdh8 occupies 
Sdh1 until it is ready to further proceed through the assembly pathway and presumably 
facilitates the formation of Sdh1/Sdh2 soluble dimers upon the import of a freshly 
translated Sdh2 (3).  In the end, the Sdh1/Sdh2 dimer is free to dock on the IMM via 



























Figure 4.14.  Sdh8 protects the cell from oxidative stress. 
(A) Ten-fold serial dilutions of WT yeast transformed with an empty vector, WT yeast 
overexpressing SDH1, sdh8Δ cells transformed with an empty vector, and sdh8Δ cells 
overexpressing SDH1 were plated on media containing the indicated carbon source and 
incubated at 30˚C (BY4741 background).  (B) Ten fold serial dilutions of WT yeast 
transformed with an empty vector, sdh8Δ cells transformed with an empty vector, and 
sdh8Δ cells overexpressing SOD2 were plated on media containing the indicated carbon 







superoxide dismutase SOD2, completely or partially rescued the growth phenotype of 
sdh8Δ cells (Figures 4.13E and 4.14B).  
 
Discussion 
The critical role of SDH in primary cellular metabolism is reflected by the variety 
of diseases associated with its dysfunction. Unlike other ETC complexes, which require 
multiple factors for their assembly, only two factors have been identified that are required 
for the assembly of the SDH holocomplex within the inner mitochondrial membrane. 
Herein we use three distinct eukaryotic model systems, yeast, Drosophila, and 
mammalian cells, to demonstrate that the SDHAF4 protein family consists of 
evolutionarily conserved SDH assembly factors.  We show that SDHAF4 binds directly 
to flavinated Sdh1, blocking the generation of excess ROS and facilitating its interaction 
with Sdh2 and the subsequent assembly of the SDH holocomplex. These functions for 
SDHAF4 appear to be conserved in metazoans and suggest a role for this factor in 
disease, as Drosophila Sdhaf4 mutants display muscular and neuronal dysfunction as well 
as neurodegeneration. Yeast and Drosophila Sdhaf4 mutants exhibit the classic  
metabolomic phenotype of SDH deficiency, with an apparent block in the TCA cycle that 
results in an accumulation of succinate and a depletion of fumarate and malate, the two 
TCA cycle intermediates downstream of SDH (Figures 4.2B and 4.6A). Consistent with 
these effects, the yeast and fly mutants display a reduction in the steady-state levels of the 
SDH holocomplex and reduced SDH enzyme activity, indicating an important role for 
SDHAF4 in SDH stability and activity (Figures 4.2C, 4.2E, 4.6B, and 4.7A). siRNA-
mediated knockdown of SDHAF4 in mammalian cells leads to similar defects (Figures 
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4.3B and 4.3C). Moreover, expression of either fly or human SDHAF4 is sufficient to 
rescue the growth defects of an sdh8Δ mutant yeast strain (Figure 4.2F). Taken together, 
these results demonstrate that the central requirement for SDHAF4 in SDH assembly has 
been conserved through evolution, from yeast to mammals. 
Our biochemical studies in yeast provide a mechanistic context for understanding 
the role of SDHAF4 in SDH assembly. An unbiased proteomic analysis of SDHAF4-
associated proteins revealed a physical interaction between Sdh8 and Sdh1, the catalytic 
subunit of SDH (Figure 4.11A). We confirmed the specificity of this interaction by co-
immunoprecipitation and demonstrated that an Sdh1/Sdh8 subcomplex of ~150 kDa can 
be detected in unstressed WT cells, albeit at very low levels (Figure 4.12A). Increased 
levels of this subcomplex, however, become readily detectable upon genetic disruption of 
the SDH complex through deletion of either Sdh2 or Sdh4 (Figure 4.12C). Taken 
together, these results support the model that Sdh8 interacts with a soluble pool of Sdh1 
prior to the formation of the Sdh1/Sdh2 soluble dimer and assembly of the holocomplex. 
Moreover, Sdh8 interacts specifically with the flavinated form of Sdh1, indicating that 
this association follows Sdh1 flavination by Sdh5/SDHAF2 (Figures 4.12A, 4.11C, and 
4.11D) (Hao et al., 2009). This model is consistent with the localization of Sdh8 to the 
mitochondrial matrix where it can readily access free flavo-Sdh1, which is subsequently 
tethered to the IMM through its association with Sdh2 and the membrane-bound 
Sdh3/Sdh4 dimer (Figure 4.13F). 
We observed that Sdh8 stability directly relates to its association with Sdh1, 
further supporting the centrality of its role as an Sdh1 chaperone (Figure 4.12B). Thus, 
deletion of Sdh1 leads to a dramatic reduction in Sdh8 levels while deletion of Sdh2, 
  
178 
which causes greatly increased availability of free Sdh1, leads to an increase in Sdh8 
(Figure 4.12B). Although Sdh1 protein levels are unperturbed in sdh8Δ cells, we 
observed considerable destabilization of Sdh2, which is consistent with impaired 
formation of Sdh1/Sdh2 dimers (Figure 4.12B).  Therefore, we hypothesize that the 
occupation of free Sdh1 by Sdh8 facilitates the formation of Sdh1/Sdh2 dimers.  This 
dimer fails to form efficiently in the absence of Sdh8, and Sdh2 is destabilized as it is in 
mutants lacking Sdh1 altogether.  
Interestingly, the loss of dSdhaf4 appears to have more severe consequences in 
Drosophila than in yeast or mammalian cells. dSdhaf4 mutants display a profound 
reduction in SDH enzyme activity, destabilization of both SdhA and SdhB, and a 
significant loss of SDH holocomplexes (Figures 4.6B, 4.7A, and 4.7B). In contrast, yeast 
sdh8Δ mutants and C2C12 mouse myoblasts treated with SDHAF4 siRNA maintain ~40–
50% of wild-type SDH activity and preserve a similar fraction of assembled SDH 
holocomplexes (Figures 4.2C, 4.2E, 4.3B, and 4.3C). This difference may be caused by a 
greater dependence of SdhA on its SDHAF4 chaperone in Drosophila. While yeast 
sdh8Δ mutants have relatively normal levels of Sdh1, dSdhaf4 mutants have greatly 
reduced levels of SdhA, which probably underlies the nearly complete loss of SDH 
holocomplexes. It is possible that yeast and mammalian cells express an additional 
SDHA chaperone that can function in the absence of SDHAF4, maintaining the levels of 
SDHA to support holocomplex assembly. Identification of the mechanism that underlies 
this discrepancy, however, will require further study of SDH assembly in both yeast and 
flies. Regardless, it is important to note that dSdhaf4 mutants retain some SDH activity 
(~15%) and that this is sufficient to support limited viability, albeit with both muscular 
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(erect wings) and behavioral (neurodegeneration) dysfunction.  In contrast, SdhA null 
mutants are lethal, demonstrating that a further reduction in SDH activity cannot be 
tolerated (Mast et al., 2008). Thus, while the SDHAF4 protein family is clearly involved 
in SDH stability and activity, it does not appear to be an absolute requirement as some 
level of SDH activity remains in the absence of the respective SDHAF4 ortholog in all 
three model systems.  
Our demonstration that Sdh8 acts through Sdh1 to facilitate formation of the 
Sdh1/Sdh2 dimer and subsequently the SDH holocomplex further emphasizes the 
importance of dedicated chaperones for ETC complex assembly.  We propose that this 
unique demand might relate to the need to protect the redox-active cofactors present in 
many ETC complex subunits (Messner and Imlay, 2002). Prior to assembly, these 
cofactors are exposed to solvent and, therefore, susceptible to damaging chemical 
reactions.  Interestingly, a cosubmitted report characterized two additional SDH assembly 
factors, Sdh6/SDHAF1 and Sdh7/SDHAF3, which appear to serve a similar role for Sdh2 
as Sdh8 serves for Sdh1 (Na et al., Submitted manuscript; Chapter 5).  These factors 
chaperone monomeric Sdh2, and potentially the Sdh1-Sdh2 dimer, protecting the Sdh2 
Fe-S clusters during assembly.  Taken together with the previous discovery of Sdh5, 
which is required for Sdh1 flavination (Hao et al., 2009), these studies suggest that a 
series of dedicated chaperones play important roles in the assembly of SDH as they do 
for other ETC complex members (Figure 4.13F).   
The susceptibility of free cofactors to damaging chemical reactions is exemplified 
by our data suggesting that free flavinated Sdh1 is toxic and that this toxicity is alleviated 
by Sdh8.  The modest phenotype of both sdh2Δ and sdh8Δ single mutant cells grown in 
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glucose is greatly enhanced when these two deletions are combined (Figure 4.13B). 
Furthermore, overexpression of Sdh1 causes growth defects in WT cells, but this 
phenotype is exacerbated in sdh8Δ mutants and ameliorated by co-overexpression of 
Sdh8 (Figures 4.13A and 4.13C). Thus, we conclude that the chaperone activity of Sdh8 
protects the cell from potentially damaging effects of unbound Sdh1, which are likely due 
to the generation of reactive oxygen species enabled by solvent-accessible FAD. Sdh1, 
which contains a covalently bound, redox active FAD cofactor is capable of oxidizing 
succinate to fumarate independent of the SDH complex. This oxidation of succinate leads 
to the reduction of FAD, which is then auto-oxidized by molecular oxygen to yield 
superoxide (Guzy et al., 2008; Messner and Imlay, 2002). The observation that Sdh8 
interacts specifically with covalently flavinated Sdh1, but not with apo-Sdh1, is 
consistent with Sdh8 acting to prevent this mechanism of oxidative stress.  Further, 
sdh8Δ mutant cells were unable to grow on respiratory medium in the presence of the 
superoxide producer paraquat (Figure 4.13D).  Similarly, dSdhaf4 mutant flies are highly 
sensitive to oxidative stress induced by hyperoxia (Figure 4.9F). More importantly, 
overexpression of two genes involved in the detoxification of reactive oxygen species—
YAP1 and SOD2—rescued the sdh8Δ growth defects in yeast (Figures 4.13E and 4.14B).  
We conclude that, in addition to promoting Sdh2 binding and holocomplex assembly, 
Sdh1 protects the redox-active FAD cofactor from potentially deleterious solvent 
interactions. 
These biochemical aberrations resulted in profound physiological defects in 
Drosophila lacking dSdhaf4, all of which are hallmarks of mitochondrial dysfunction and 
which suggest possible links to human disease. Most notably, dSdhaf4 mutants display 
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bang sensitivity, a phenotype characterized by a susceptibility to mechanically induced 
paralytic seizures, which is commonly elicited by defects in mitochondrial function 
(Fergestad et al., 2006; Liu et al., 2007). dSdhaf4 mutants also display neurodegeneration 
and reduced lifespan, which often accompanies bang sensitivity (Fergestad et al., 2008). 
In addition, we observed abnormal wing posture in dSdhaf4 mutants, which is 
characteristic of muscular dysfunction (Greene et al., 2003). Similar phenotypes have 
been reported in flies harboring mutations in several known disease-causing genes that 
impact mitochondrial function. For example, Pink and Parkin mutants display abnormal 
wing posture, and mtATP6 mutants are bang sensitive (Celotto et al., 2006b; Fernandes 
and Rao, 2011). Human mutations in Pink/Parkin and mtATP6 are known to cause 
familial Parkinson’s disease and mitochondrial encephalopathy, respectively (Schapira, 
2012). Moreover, as described in more detail below, some neurodegenerative diseases 
such as Leigh’s syndrome are known to be associated with a loss of SDH activity. Our 
studies of dSdhaf4 thus provide a genetic model for better understanding the 
pathophysiology of neurodegenerative disorders that are caused by SDH deficiency 
(Hoekstra and Bayley, 2013; Rutter et al., 2010). 
Similar to dSdhaf4 mutants, SdhB hypomorphic mutants that retain ~40% of 
normal SDH activity are sensitive to oxidative stress and display a reduced lifespan 
(Walker et al., 2006). The SdhB hypomorphs, however, were not reported to undergo 
mechanically induced paralytic seizures or display neurodegenerative phenotypes 
(Walker et al., 2006). This lack of neuronal phenotypes in SdhB mutants could be due to 
the higher overall SDH activity seen in these partial loss-of-function mutants relative to a 
complete loss of dSdhaf4 activity. It is also possible, however, that the neurodegeneration 
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phenotype is driven by increased ROS production rather than a defect in mitochondrial 
ATP production.  In support of this model, clones generated using a lethal null allele of 
SdhA in the eye display retinal degeneration similar to that seen in dSdhaf4 mutants, 
which was shown to be specifically caused by increased ROS production (Mast et al., 
2008). This is also consistent with our finding that dSdhaf4 mutants are not depleted of 
ATP (Figures 4.5B and 4.6A), possibly enabled by metabolic compensation (Celotto et 
al., 2011) and/or decreased movement (data not shown). Thus, our study of dSdhaf4, and 
other work characterizing SdhA, SdhB, and dSdhaf3 mutants in Drosophila, suggests that 
tissue dysfunction induced by a loss of SDH appears to be largely driven by increased 
ROS production (Mast et al., 2008; Na et al., Submitted manuscript; Walker et al., 2006). 
This is consistent with our hypothesis that SDH assembly factors may have evolved as a 
mechanism to protect cells and organisms from ROS production during SDH assembly.  
Mutations in all genes encoding previously published SDH subunits and assembly 
factors have been shown to cause human disease. These include neurodegenerative 
diseases (Leigh’s Syndrome, Leukodystrophy, and Leukoencephalopathy), which have 
been linked to mutations in SDHA, SDHB, and SDHAF1 (Alston et al., 2012; Ghezzi et 
al., 2009; Horvath et al., 2006; Ohlenbusch et al., 2012). Mutations in SDHA, SDHB, 
SDHC, SDHD, and SDHAF2 have also been shown to cause paragangliomas and 
pheochromocytomas—two classes of neuroendocrine tumors (Astuti et al., 2001; 
Fishbein and Nathanson, 2012; Hao et al., 2009). Recently, several cases of wild-type 
gastrointestinal stromal tumors (WT GIST) have been linked to germline loss-of-function 
mutations in SDHA and SDHB (Celestino et al., 2012; Italiano et al., 2012; Janeway et al., 
2011; Oudijk et al., 2013). This wealth of evidence linking SDH dysfunction to disease 
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raises the possibility that damaging mutations in SDHAF4 may cause human disease. In 
fact, several cases of SDH-deficient diseases, including Leigh’s Syndrome and WT GIST, 
lack mutations in the genes encoding all known SDH subunits (Horvath et al., 2006; Jain-
Ghai et al., 2013; Janeway et al., 2011). Our phenotypic studies raise the important 
possibility that SDHAF4 is a candidate gene for these and other diseases characterized by 
SDH deficiency. Our future efforts will focus on determining the incidence of these 
possible causative SDHAF4 mutations. 
On the basis of the data presented in this report, we conclude that the SDHAF4 
gene family encodes a novel SDH assembly factor.  Insights gained in our studies of this 
protein have allowed us to propose a more complete model of SDH assembly (Figure 
4.13F).  Upon import into the matrix by TOM and TIM apo-Sdh1 is flavinated in a 
reaction that requires Sdh5 (Hao et al., 2009).  Free flavo-Sdh1 is then bound by Sdh8 to 
form a ~150 kDa subcomplex.  This subcomplex occupies Sdh1, preventing auto-
oxidation and supporting its ability to dimerize with Sdh2.  The Sdh1/Sdh2 soluble dimer 
is then recruited to the IMM via interactions with Sdh3 and Sdh4 to form the SDH 
holocomplex (Figure 4.13F).  This model highlights the importance of subunit-specific 
chaperones in the process of assembly.  Indeed, failure of SDHAF4 to occupy free SdhA 
prevents normal SDH assembly in three eukaryotic systems and has profound 
physiological consequences. The identification and characterization of the SDHAF4 
protein family thus provide important new insights into the process of SDH assembly, the 
mechanisms by which SDH subunits are protected for generating ROS, and a new 
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Disorders arising from impaired assembly of succinate dehydrogenase (SDH) 
result in a myriad of pathologies, consistent with its unique role in linking the citric acid 
cycle and electron transport chain. In spite of this critical function, however, only a few 
factors are known to be required for SDH assembly and function. We show here that two 
factors, Sdh6 (SDHAF1) and Sdh7 (SDHAF3), mediate maturation of the FeS cluster 
SDH subunit (Sdh2/SDHB). Yeast, Drosophila and mammalian cells lacking SDHAF3 
are impaired in SDH activity with reduced levels of Sdh2. Drosophila lacking the Sdh7 
ortholog SDHAF3 are hypersensitive to oxidative stress and exhibit muscular and 
neuronal dysfunction. Yeast studies revealed that Sdh6 and Sdh7 act together to promote 
Sdh2 maturation by binding to a Sdh1:Sdh2 intermediate, protecting it from the 
deleterious effects of oxidants. These studies in yeast, Drosophila, and mammalian cells 
raise the possibility that SDHAF3 mutations may be associated with idiopathic SDH-
associated diseases. 
Introduction 
Succinate dehydrogenase (SDH) is an integral component of the mitochondrial 
respiratory chain and a component of the tricarboxylic acid (TCA) cycle. It catalyzes the 
two-electron oxidation of succinate to fumarate with the reduction of ubiquinone to 
ubiquinol (succinate:ubiquinone oxidoreductase). SDH is embedded within the inner 
membrane (IMM) of mitochondria and consists of four nuclear-encoded subunits, 
designated Sdh1 through Sdh4 in yeast and SDHA through SDHD in mammalian cells. 
SDH deficiency in humans results in infant encephalomyopathy and optic atrophy, 
myopathy or tumorigenesis in the adult (Finsterer, 2008; Rustin and Rotig, 2002). Germ 
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line loss-of-function mutations in human genes for SDHA, SDHB, SDHC, and SDHD are 
strongly linked with susceptibility to familial paraganglioma, pheochromocytoma, 
gastrointestinal stromal tumors, renal cell carcinoma, and neuroblastoma (Bardella et al., 
2011; Baysal et al., 2000; Feichtinger et al., 2010; Janeway et al., 2011). Tumorigenesis 
arising from SDH-deficiency is purportedly related to the deleterious effects of 
supraphysiological levels of succinate, which is a known inhibitor of a myriad of 
a-ketoglutarate (aKG)-dependent enzymes including prolyl hydroxylases, histone 
demethylases, and DNA demethylases (Selak et al., 2005; Xiao et al., 2012).  
 The tetrameric enzyme contains five redox cofactors including a covalently bound 
FAD and three iron-sulfur clusters in a hydrophilic segment consisting of two subunits 
Sdh1 and Sdh2 and a membrane anchor domain consisting of Sdh3 and Sdh4 subunits 
with a heme moiety bound at the subunit interface (Robinson and Lemire, 1996). The 
Fe/S clusters form an electron wire to facilitate electron transfer to the ubiquinone-
binding site formed between Sdh2 and the membrane anchor subunits (Sun et al., 2005). 
 Assembly factors are frequently used to facilitate cofactor insertion in 
mitochondrial respiratory complexes and mitigate unwanted reactions during biogenesis. 
Recently, two SDH assembly factors associated with human pathogenesis were 
identified. SDHAF1 was found in a study of infantile mitochondrial diseases in which 
two families presented with multiple afflicted children with leukoencephalopathy (Ghezzi 
et al., 2009). Biochemical analyses revealed a SDH deficiency in muscle samples and 
fibroblasts from these patients along with missense mutations in SDHAF1. Deletion of 
the yeast ortholog of SDHAF1 (SDH6) resulted in a respiratory deficiency and a specific 
reduction in SDH activity (Ghezzi et al., 2009). SDH deficiency has subsequently been 
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reported in other patients that carry SDHAF1 mutations (Ohlenbusch et al., 2012). 
SDHAF2 was shown to be required for the covalent attachment of FAD to the catalytic 
Sdh1 subunit (Hao et al., 2009). Yeast lacking Sdh5 were respiratory deficient due to the 
lack of SDH activity. Germline loss-of-function mutations in SDHAF2 were identified in 
SDH-deficient, neuroendocrine paraganglioma tumors (Hao et al., 2009). A number of 
SDH-deficient pathologies, including Leigh syndrome, gastrointestinal stromal tumors, 
and neuroblastomas, have also been reported that lack mutations in known SDH 
assembly factors or SDH structural subunits (Feichtinger et al., 2010; Janeway et al., 
2011). Thus, additional SDH assembly factors may remain to be discovered, potentially 
providing insights into the causes of idiopathic SDH-associated diseases.  
 Sdh6 is a member of the LYR protein family that consists of 10 proteins in the 
human proteome and four in the yeast proteome (Figure 5.1A). Within yeast, the 
founding member is the mitochondrial Isd11 protein that functions in the matrix FeS 
biogenesis pathway as an effector of the Nfs1 cysteine desulfurase (Adam et al., 2006; 
Wiedemann et al., 2006). We demonstrated that a second LYR protein Mzm1 is a 
chaperone for the Rieske FeS subunit of OXPHOS Complex III (Atkinson et al., 2011; 
Cui et al., 2012). The remaining yeast LYR proteins are Sdh6 and Acn9 (human ortholog 
Q9NRP4). Although Sdh6 is required for proper SDH activity, its molecular mechanisms 
remain unknown. Moreover, Acn9 (designated Sdh7 in yeast and SDHAF3 in humans) 
has no known function.  Here we show that these two factors are required for SDH 
biogenesis in eukaryotes. Both Sdh6 and Sdh7 function in the maturation of the Fe/S 
cluster subunit Sdh2 in yeast and shields Sdh2 maturation from the deleterious effects of 














Figure 5.1. Succinate dehydrogenase deficiency in cells lacking two 
LYR motif family proteins, Sdh6 and Sdh7.  
(A) L-X-L/A-Y-R-X-X-L/I-R/K motif conserved in four LYR motif family proteins in 
yeast. Isd11, a chaperone required for cysteine desulfurase activity of Nfs1 in Fe/S 
biogenesis pathway (Adam et al., 2006); Mzm1, a protein facilitating the Rieske FeS 
protein insertion into bc1 (Cui et al., 2012); Sdh6, an ortholog of human SDHAF1; Sdh7, 
a protein originally identified for normal acetate utilization in yeast (B) Ten-fold serial 
dilutions of cells starting from OD600 = 0.5 were spotted on synthetic complete (SC) 
media containing different carbon sources as indicated, and incubated at 30˚C. (C) Ten-
fold serial dilutions of cells starting from OD600 = 0.5 were spotted on uracil (-) SC media 
and incubated at 30˚C. EV, empty vector (D) Metabolites extracted from cells cultured in 
synthetic minimal media containing 2% raffinose / 0.2% glucose were analyzed using 
GC/MS. Cells were harvested at OD600 = 2. Relative levels of metabolites to WT are 
represented as mean ± SEM (N ≥ 4 biological replicates; *p < 0.05; **p < 0.005). (E) 
Relative SDH activity in isolated mitochondria compared to WT. Mitochondria were 
isolated from cells grown in SC media plus 2% raffinose / 0.2% glucose for 24 h 
(midlog) and 48 h (stationary). Succinate-dependent/quinone-mediated reduction of 
DCPIP was measured at 600 nm for SDH activity. Oxaloacetate-dependent oxidation of 
NADH was measured at 340 nm for MDH activity. Data are shown as mean ± SD is 
shown (N = 3; ** p < 0.05). (F) Blue-Native (BN) PAGE analysis to visualize protein 
complexes. Mitochondria isolated from the strains harvested at late-log phase were 
solubilized with 1% digitonin. After clarification, soluble fractions were separated on 
BN-PAGE and then transferred to membranes for detection of protein complexes using 
appropriate antibodies. Sdh1, a FAD-containing subunit of SDH; F1β, a subunit of ATP 









or mammalian cells leads to a marked SDH-deficiency analogous to that in yeast, with 
defects in muscular and neuronal function in mutant flies. This study identifies two new 
SDH assembly factors, providing a more complete understanding of its critical role in 
cellular energy production and a potential molecular framework for defining currently 




Yeast strains and plasmids 
S. cerevisiae strains used in this study are listed in Table 5.1. Yeast cells were 
grown in synthetic complete or minimal media containing 2% raffinose and 0.2% glucose 
unless indicated otherwise. Deletion strains were generated by homologous 
recombination and confirmed by PCR analysis of locus as described earlier (Longtine et 
al., 1998). Plasmids used in this study are listed in Table 5.2 and were constructed using 
general subcloning techniques. 
 
Mammalian cell culture and siRNA 
HEK293 cells fibroblasts were maintained in DMEM supplemented with 10% 
FBS, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM Glutamax at 37˚C in a 
humidified incubator with 5% CO2. Transfection of siRNA was performed by treating 
cells with 10 nM total siRNA with Lipofectamine RNAiMax transfection reagent, 
according to the manufacturer’s instructions (Invitrogen). ON-TARGETplus SDHAF1 
siRNA SMARTpool and ON-TARGETplus Non-Targeting Pool were purchased from 
Dharmacon. Total RNA was isolated using the standard Trizol method. Total cDNA was  
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obtained using a High Capacity cDNA Reverse Transcription Kit with random oligomers 
(Applied Biosystems). TaqMan Probe-Based Gene Expression Analysis was performed 
to evaluate knockdown efficiency with probes purchased from Applied Biosystems using 
ABI PRISM 7000. 
 
Metabolomic analysis 
Metabolite profiling analysis was performed as described previously (Bricker et 
al., 2012). For yeast, overnight starter cultures in YPD medium were washed with sterile 
water, and then re-inoculated in synthetic minimal media containing 2% raffinose/0.2% 
glucose with appropriate auxotrophy if strains contained exogenous plasmids. The initial 
inoculation was at OD600 = 0.01. The cultures were grown to OD600 = 1 or 2 and 
metabolites were extracted as described (Canelas et al., 2009) for GC/MS analysis. For 
Drosophila, control wild-type Canton S flies and dSdhaf3 mutants were collected at 5 
days after eclosion and snap frozen in liquid nitrogen, using 20 male animals per sample 
and collecting six samples for each experiment, and the results presented are combined 
from two independent experiments. 
 
Proteinase K assay 
Mitochondrial aliquots (30 µg protein) were treated with 20 mM HEPES (pH 7.4) 
hypotonic buffer for swelling or lysised with hypotonic buffer containing 1% Triton X-
100 for 30 min on ice in the presence or absence of proteinase K, respectively. Intact 
mitochondria were kept in 20 mM HEPES plus 0.6 M sorbitol in the presence or absence 
of proteinase K for 30 min on ice. Proteins were recovered by TCA precipitation and then 
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analysed by general procedures for immunoblotting. 
 
High-copy suppressor screening 
Genomic DNA isolated from sdh6∆ strains was partially digested with Sau3AI. 1 
to 12 Kb fragments were recovered by gel extraction, which was subjected to ligation 
with high-copy pRS424 digested with BamH1. Approximately 60,000 colonies were 
recovered with ampicillin selection after E. coli transformation, and 40% of plasmids 
appeared to contain genomic DNA inserts based on blue-white screening and plasmid 
mapping. High copy plasmids were isolated as a pRS424 library using a Qiagen Maxi 
prep kit. The library was transformed to sdh6∆ strains. Approximately 30,000 colonies 
were obtained on synthetic complete (SC) glucose media lacking tryptophan. Colonies 
showing enhanced growths on SC acetate media lacking tryptophan after replica plating 
were selected and kept as a master collection. In order to verify that enhanced growth on 
acetate media was dependent on plasmids, drop-test was performed after plasmid 
shedding with 5-fluoroanthranilic acid (Toyn et al., 2000). Plasmids were recovered and 
sequenced only from colonies showing that their enhanced growths were dependent on 
plasmids. 
 
Mitochondrial enzymatic activity assay 
Succinate dehydrogenase (SDH) and aconitase activity assays were performed as 
described previously (Atkinson et al., 2011). To measure SDH activity, isolated 
mitochondria were incubated in 40 mM potassium phosphate (pH 7.4) buffer with 0.5% 
Tween 80, 20 mM succinate, and 20 µM antimycin A for 5 min at RT. The reaction was 
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initiated by adding 90 µM decylubiquinone and 120 µM dichlorophenolindophenol 
(DCPIP), and then the rate of reduction of DCPIP was measured spectrophotometrically 
at 600 nm for 5 min. Aconitase activity measured in soluble fractions of mitochondria 
disrupted by repetitive freeze-thaw with 100 µM cis-aconitate in 50 mM Tris (pH 7.4) at 
240 nm. For malate dehydrogenase (MDH) activity assay, soluble mitochondrial fractions 
were obtained using sonication followed by centrifugation. Oxidation of 0.2 mM NADH 
was monitored in the presence of 2 mM oxaloacetate in 100 mM Tris (pH 7.4) at 340 nm 
(Hayes et al., 1991).  
 
Mitochondrial protein import assay 
Mitochondrial protein import assay was performed as described previously 
(Wagener et al., 2011). Briefly, SDH2 and RIP1 open reading frames were subcloned in 
pGEM-4Z for in vitro transcription/translation, respectively. Radiolabeled precursor 
proteins were obtained using reticulocyte lysate (Promega) in the presence of 35S-Met. 
Precursors were imported into 75 µg of isolated mitochondria in 50 mM HEPES-KOH 
(pH 7.2) buffer containing 0.6 M sorbitol, 0.5 mg/ml BSA, 2 mM potassium phosphate, 
75 mM KCl, 10 mM magnesium acetate, 2 mM EDTA, 2.5 mM MnCl2, 2 mM ATP, 
2 mM NADH, 10 mM creatine phosphate, 0.1 mg/ml creatine kinase, 2.5 mM malate, 
and 2.5 mM succinate for 30 min at 25˚C for pulse. Import was stopped by adding 5 µM 
valinomycin and then chased for the periods of time indicated. Nonimported precursors 
were removed by degradation using proteinase K after dilution with 20 mM HEPES-
KOH (pH 7.2) plus 0.6 M sorbitol on ice. Samples were separated on SDS-PAGE and 




Mitochondria were solubilized in 10 mM sodium phosphate (pH 7.4), 500 mM 
NaCl, 1 mM EDTA, 1% digitonin and 1X protease inhibitor cocktail (Roche) for 30 min 
on ice. Crosslink was performed simultaneously with solubilization by adding 1 mM of 
Dithiobis[succinimidylpropionate] (Pierce) for 30 min at RT. Supernatants after 
centrifugation at 14,000 x g were incubated with magnetic anti-Myc beads (Cell 
Signaling Tech.) for 4 h at 4˚C. Beads were washed with 10 mM sodium phosphate (pH 
7.4), 500 mM NaCl, 1 mM EDTA, 0.1 % digitonin, and 1 mM PMSF. After washing 
three times, bound substances were recovered by boiling with 2X SDS-PAGE sample 
buffer, which was subjected to immunoblotting. 
 
Hydrogen peroxide sensitivity assay 
Hydrogen peroxide sensitivity assay was performed as described previously 
(Khalimonchuk et al., 2007). Briefly, strains were precultured in YPD media up to late-
log phase. Precultures were diluted by 2-fold in YPD and incubated for 2 h in the 
presence or absence of 6 mM H2O2. After washing with sterile water, 10-fold serial 




Yeast mitochondria isolation was performed using the method of Glick and Pon 
(Glick and Pon, 1995), and mammalian mitochondria isolation was performed as 
described previously (Chen et al., 2012). Standard procedures were performed for SDS
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PAGE and immunoblotting. BN-PAGE was performed as described previously with 
mitochondrial lysates in 1% digitonin solution (Wittig et al., 2006). Samples were 
separated on 4%–16% NativePAGE Bis-Tris Gel (Life technology) and transferred to 
PVDF membrane for immunodetection. Anti-Sdh1, Sdh2, and Sdh3 were from the 
previous study (Kim et al., 2012). Antibodies to Por1 were from Molecular Probes, and 
SDHA, SDHB, SDHC, and ATP5a were from Abcam.  Protein concentration was 
determined by the Bradford assay. 
 
Drosophila strains 
Flies were maintained on standard Bloomington Stock Center medium with malt 
at 25˚C. The following stocks were obtained from the Bloomington Stock Center: 
SdhAHP21216/CyO (Bloomington # 22087), SdhB12081/CyO (Walker et al., 2006) da-Gal4 
(Wodarz et al., 1995), Act5C-Gal4/CyO (Bloomington # 25374).  
  
Generation of dSdhaf3 mutant  
dSdhaf3 mutants were generated using “ends-out” homologous recombination 
essentially as previously described (Maggert et al., 2008). The targeting vector was 
designed with 3 kb homology arms corresponding to the genomic sequence upstream of 
the dSdhaf3 start codon and downstream of dSdhaf3 exon 2, such that homologous 
recombination would cause the replacement of dSdhaf3 exons 1–2 with the miniwhite 
marker. First, homology arms were amplified by PCR using Phusion Taq Polymerase 
(NEB) with the following primers: 5'’ HA—CGGGCGCGCCAATACGAGCGAA 
TAACAACTGTT and CGCCTAGGGGAGCACTCCGTTCGTACT; 3’ HA—
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CGGCGGCCGCTTGTGCGATTCTTCAGCAAC and CGGGATCCAAAAGGCGC 
CATACTAAGCA. PCR products were then subcloned into Topo TA (Invitrogen) 
cloning vectors, after which, the presence of the correct flanking homology arms was 
verified by restriction digestion and DNA sequencing. Next, the 3’ homology arm was 
excised from the Topo TA vector using BamHI and NotI, and ligated into a pW25.2 
vector cut with the same enzymes. Following this step, the 5’ homology arm was excised 
from the Topo TA vector using AvrII and AscI and ligated into the pW25.2 vector 
containing the 3’ homology arm cut with the same enzymes. The presence of both 
homology arms was then verified by restriction digestion and used to generate transgenic 
flies using P-element mediated transformation.  
 Two strains containing the dSdhaf3 targeting construct on the second 
chromosome over CyO (donor strain 1 and donor strain 2) were isolated and crossed to 
yw; Flp, SceI, Noc/CyO flies. Third instar progeny resulting from this cross were heat-
shocked at 38˚C for 1 hr to induce Flp and SceI expression to drive target construct 
linearization and subsequent homologous recombination at the dSdhaf3 locus. Once the 
heat-shocked larvae completed metamorphosis, w+ mosaic females were crossed to Flp; 
TM3/TM6, Ubx flies. Individual w+ progeny from these crosses were crossed to a ApXa 
/SM5; TM3 stock to determine if the miniwhite marker had translocated to the 3rd 
chromosome. Two lines from donor strain 1, and five lines from donor strain 2 with 
miniwhite on chromosome 3 were isolated. The replacement of exons 1 and 2 in the 
dSdhaf3 gene was then verified in one line derived from donor strain 2 strain by DNA 
sequencing and by Southern blot analysis. The 32P-labeled probe for the Southern blot 
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experiment was generated by PCR amplification the using 5'-AACAAGTGATCCCA 
CCAAGC-3' and 5'-GGTGCAGAGCGTGTGTGTAT-3' oligonucleotide primers. 
 
Generation of the UAS-dSdhaf3 transgenic flies 
The dSdhaf3 cDNA was amplified from a commercially available plasmid (BDGP 
DGC gold RE23580) using the primers CGGAATTCTGAGTTTTTAGCCGGCTG and 
CGCTCGAGTACACTGATTTATTTGCCTTGC. The dSdhaf3 cDNA amplicon was 
then cut with EcoRI and XhoI, and subsequently ligated into the pUAST plasmid cut with 
the same enzymes. The presence of the dSdhaf3 cDNA in the pUAST plasmid was 
verified by restriction digestion and DNA sequencing, and was then used to generate 
transgenic lines by P-element mediated transformation.  
 
Isolation of mitochondria from Drosophila 
Mitochondria for western blot studies or SDH assays were purified from flies as 
described with modifications (Schwarze et al., 1998). Briefly, 200–300 flies per sample 
were homogenized gently 20 times with an A type dounce pestle in cold mitochondrial 
isolation media (250 mM sucrose, 10 mM Tris pH 7.4, 1 mM EDTA). These 
homogenates were centrifuged at 1000 g for 1 min through a 40 µM cell strainer 
(#352340, BD Falcon Franklin Lakes, NJ) in a 50 ml tube to remove cuticle debris, 
followed by a second centrifugation at 1000 g at 4˚C for 5 min to remove cell debris. 
Mitochondrial pellets were obtained by centrifugation at 13,000 g at 4˚C for 5 min and 
then resuspended in 1 ml mitochondrial isolation medium. The protein concentration was 
determined using Bio-Rad Protein Assay Dye Reagent (Cat#: 500-0006). Mitochondrial 
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pellets were stored frozen for western blot analysis or resuspended in incubation medium 
(220 mM sucrose, 5 mM KH2PO4, 20 mM KCl, 10 mM HEPES, pH 7.2) for enzyme 
activity assays and stored at -80˚C. 
 
Drosophila SDH activity assay 
Succinate dehydrogenase activity in mitochondrial extracts was measured using a 
colorimetric-continuous method, essentially as described (Munujos et al., 1993). This 
method uses iodonitrotetrazolium chloride as an electron acceptor and measures its 
reduction at 500 nm in the presence or absence of succinate. Enzyme activity is presented 
as the percentage of control w1118  flies from three independent experiments, using six 
replicates for each sample. 
 
Western blot analysis of Drosophila mitochondrial proteins 
Purified mitochondrial pellets were resuspended in RIPA buffer (50 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate) and dissolved in sample buffer (50 mM Tris–HCl, pH 6.8, 
2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02 % bromophenol 
blue) for SDS-PAGE. Western blot and chemiluminescence were performed as described 
(Yu et al., 2012).  Rabbit anti-Human SdhA polyclonal antibody (1:1500) and mouse 
anti-Bovine ATP5 monoclonal antibody (1:10,000) were purchased from Abcam. Rabbit 





Drosophila motility assays 
The climbing assay was performed essentially as described (Gargano et al., 2005). 
Briefly, 20 animals per vial were raised on standard medium and transferred to empty 
vials, with a line drawn four centimeters from the bottom of the vial. Flies were then 
tapped down gently to the bottom of the vial and allowed to climb for 10 seconds. Videos 
of the climbing flies were replayed for quantification, scoring the number of flies that 
climbed above the line after 5 seconds. Flies in four vials were assayed under each 
condition, and all experiments were repeated three times. Recovery from paralysis was 
assayed essentially as described previously (Ganetzky and Wu, 1982). Briefly, 20 
animals per vial were raised on standard medium and transferred to empty vials. The 
vials were vortexed for 30 seconds after which the flies were allowed to recover. Videos 
were replayed for quantification, scoring the number of flies that moved away from the 
bottom of the vials after 10 sec.  Flies in four vials were assayed under each condition, 
and all experiments were repeated three times.   
 
Drosophila lifespan analyses 
Vials containing 20 five-day old male or female control w1118 flies or dSdhaf3 
mutants were transferred to vials with 1% agar in PBS for starvation, 5% ethanol, 1% 
agar in PBS for alcohol treatment, or 30 mM paraquat in semidefined medium (Backhaus 
et al., 1984) for paraquat treatment (Rzezniczak et al., 2011). Surviving animals were 
scored every 24 h except animals subjected to starvation, which were assayed at 12 h 
intervals. The hyperoxia experiments were performed by transferring flies to vials with 
fresh medium and then sealing the vials in a polyethylene bag (Scienceware 12” x 16”) 
  
208 
filled with 100% oxygen. Surviving animals were scored every 24 h and the bags were 
filled with fresh oxygen. In all experiments, flies were scored from 15–20 vials of flies 
per experiment, from 3–5 independent experiments. 
 
Statistics 
Yeast data were analyzed using Microsoft Excel 2011. Data are presented as 
mean ± SD or mean ± SEM as indicated. Statistical significance was evaluated using 
Student’s test. p < 0.05 was considered significant. Statistical analysis and graphical 
presentation for Drosophila studies were performed using PRISM software. Student’s t 
test was used for pairwise comparisons, and one-way analysis of variance (ANOVA) was 
used for multiple comparisons. Fly metabolomic data are graphically represented as box 
plots, with the box representing the lower and upper quartiles, the horizontal line 
representing the median, and the bars representing the minimum and maximum data 
points. All other data are shown as the mean ± SEM. 
 
Results 
Cells lacking Sdh6 and Sdh7 exhibit SDH deficiency 
As a first step toward characterizing Sdh6 and Sdh7 function, we examined the 
growth phenotypes of sdh6∆ or sdh7∆ mutants on nonfermentable carbon sources using 
S. cerevisiae. Cells lacking Sdh6 or Sdh7 exhibit a partial growth defect on 
glycerol/lactate media and a severe growth defect on acetate medium compared to wild-
type cells (Figure 5.1B), which is consistent with previous studies (Ghezzi et al., 2009; 
McCammon, 1996). We confirmed that the respiratory growth defects of sdh6∆ and  
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sdh7∆ mutants were attributed to deletions of SDH6 and SDH7, as respiratory growth of 
sdh6∆ and sdh7∆ cells was restored with epitope-tagged Sdh6 and Sdh7, respectively 
(Figure 5.2). Since both Sdh6 and Sdh7 belong to the LYR motif protein family, we 
looked for genetic interactions between their encoded proteins (Figure 5.1A). The sdh6∆ 
sdh7∆ double deletion strain exhibited a marked synthetic growth defect on 
glycerol/lactate medium (Figure 5.1B). In addition, the overexpression of SDH6 partially 
suppressed the respiratory growth defect of sdh7∆ cells (Figure 5.1C); however, 
overexpression of SDH7 failed to restore respiratory function of sdh6∆ cells (data not 
shown).  
Metabolomic profiling was used to identify the biological process impaired in 
sdh6∆ and sdh7∆ mutants, assaying the levels of approximately 100 polar metabolites. 
We cultured cells in synthetic minimal medium with 2% raffinose and 0.2% glucose up 
to stationary phase. Metabolites extracted from cells were analyzed using gas 
chromatography-mass spectrometry (GC/MS) (Figure 5.1D). Cells lacking either Sdh6 or 
Sdh7 exhibited elevated succinate levels and attenuated fumarate and malate levels 
consistent with impaired conversion of succinate to fumarate by SDH in the citric acid 
cycle. These observations in sdh6∆ cells are consistent with the previous study in 
fibroblasts harboring mutations in SDHAF1 gene, which is the human SDH6 ortholog 
(Ghezzi et al., 2009). Moreover, the sdh6∆ sdh7∆ double mutant showed an enhanced 
accumulation in succinate, consistent with the synergistic respiratory growth defects in 
these cells. 
To confirm that the increased succinate/fumarate ratio in sdh7∆ mutants was due 






























Figure 5.2. Complementation of sdh6∆ and sdh7∆ mutants with 
exogenously expressed epitope-tagged Sdh6 and Sdh7, respectively.  
Low-copy plasmids with either MET25 promoter for His6-2Myc or own endogenous 
promoters for His6-3HA were transformed. Ten-fold dilutions starting from OD600 = 0.5 
were spotted on synthetic complete media containing carbon sources indicnated, and then 






wild-type (WT) and mutant cells lacking Sdh6 or Sdh7. Mitochondria isolated from 
sdh6∆ and sdh7∆ cells harvested at midlog phase exhibited modest diminutions of SDH 
activity, but the deficit was magnified in stationary phase cells (Figure 5.1E). In addition, 
sdh6∆ sdh7∆ double mutants showed markedly decreased SDH activity (34% of WT, 
data not shown) relative to the single mutants in accordance with the synergistic 
respiratory growth defect and TCA cycle intermediates in sdh6∆ sdh7∆ double mutants. 
Enzymatic activities of pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, 
aconitase, malate dehydrogenase, and bc1 Complex III were unaffected in cells lacking 
Sdh6 or Sdh7 (data not shown).  
A moderate diminution of the assembled tetrameric SDH complex was seen in 
mitochondria isolated from late-log cultures of sdh6∆ or sdh7∆ mutants as visualized by 
BN-PAGE (Figure 5.1F). The abundance of the SDH complex was further attenuated in 
sdh6∆ sdh7∆ double mutant cells. Thus, Sdh6 and Sdh7 are required to maintain normal 
SDH levels and activity in yeast. In addition to reduced levels of tetrameric SDH in the 
mutant cells, a Sdh1 subcomplex is evident, and the same subcomplex is seen in cells 
lacking Sdh2 or Sdh4 (Figures 5.1F and 5.2). Therefore, Sdh6 and Sdh7 may function in 
SDH assembly rather than the regulation of SDH activity.  
 
Maturation of Sdh2, an SDH subunit containing Fe/S clusters, is 
impaired in the absence of Sdh6 or Sdh7 
To further characterize the roles of Sdh6 and Sdh7, the steady-state levels of SDH 
subunits were quantified in mitochondria isolated from mutant cells. The levels of Sdh2 
were attenuated in both sdh6∆ and sdh7∆ mutants and further diminished in the sdh6∆ 
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sdh7∆ double mutant (Figure 5.3A). Sdh1 levels were unchanged in the mutant cells and 
covalent flavinylation of Sdh1 was not significantly altered (Figures 5.3A and 5.4). We 
demonstrated previously that cells lacking Sdh5 were compromised in Sdh1 flavinylation 
leading to a reduced stability of Sdh1 (Hao et al., 2009; Kim et al., 2012).  
A mitochondrial in vitro protein import assay was used to address a role of Sdh6 
and Sdh7 in Sdh2 maturation. The import assay consisted of the in vitro import of 35S-
methionine labeled Sdh2 into purified mitochondria isolated from sdh2∆ cells. Sdh2-
deficient mitochondria were used to ensure that unassociated Sdh1 pool would be 
available for a stabilizing interaction with imported Sdh2. Furthermore, any changes in 
the mitochondrial membrane potential, which drives protein import, due to already 
decreased SDH activities in sdh6∆ mutants and sdh7∆ mutants are negated by using 
sdh2∆ cells. The stability of 35S-Sdh2 as monitored during the chase phase of the reaction 
was compromised in cells lacking Sdh6 or Sdh7 especially in mitochondria isolated from 
stationary phase cultures (Figure 5.3B). This result is consistent with the exacerbated 
defect in SDH activity seen in mutant cells at late stages of growth. Unlike Sdh2, 
radioisotope-labeled Rip1, a target of the LYR protein Mzm1, remained unaffected by 
loss of either Sdh6 or Sdh7. 
A subcomplex of Sdh1 and Sdh2 is known to accumulate in cells lacking the 
membrane anchor subunits Sdh3 and/or Sdh4 (Kim et al., 2012) (Figure 5.3D, compare 
lanes 1 and 3). We observed that cells depleted of the membrane anchor contain 
increased steady-state levels of both Sdh6 and Sdh7 (Figure 5.3C). The increased levels 














Figure 5.3. Sdh6 or Sdh7 functions are linked to the Fe/S Sdh2  
subunit.  
(A) Steady-state levels of mitochondrial proteins. FAD-containing Sdh1 was visualized 
by UV excitation. Other proteins visualized by immunoblotting include Mdh1, malate 
dehydrogenase and Por1 (a protein constituting voltage-dependent anion channel). (B) 
35S-methionine labeled proteins were incubated with isolated mitochondria for 30 min 
(pulse), followed by blocking protein import with valinomycin for 30 and 60 min (chase), 
respectively. Radiolabeled proteins were resolved on SDS-PAGE and detected by 
autoradiography. (C) Functional Sdh6-His6-3HA or Sdh7-His6-3HA under their own 
endogenous promoters was expressed from plasmids in cells lacking either Sdh2 or Sdh4 
along with endogenous Sdh6 or Sdh7 depleted, respectively. Steady-state levels are 
shown by immunoblotting. (D) Co-immunoprecipitation of Sdh6-His6-2Myc after 
crosslinking. Mitochondria were solubilized with 1% digitonin in the presence of 1 mM 
dithiobis[succinimidylpropionate]. The crosslinking reaction was stopped with Tris 
buffer (pH 7.4), and the supernatants were absorbed to anti-Myc antibody-conjugated 
magnetic beads. Bound substances to Myc beads were resolved on SDS-PAGE and 
detected by immunoblotting. Input, 4% of total lysates; Aco1, 4Fe-4S aconitase. (E) 
Standard co-immunoprecipitation of Sdh7-His6-2Myc was performed with isolated 
mitochondria without crosslinking. Input, 2% of total lysates. (F) Steady-state levels of 
Sdh2 in sdh1∆ mutants with overexpression of proteins indicated. Yap1, transcription 
factor up-regulating oxidative stress response genes. (G) SDH activity in sdh6∆ mutants 
with SDH2 overexpression was detected spectroscopically as described in Figure 5.1E. 
Data are represented as mean ± SD (N = 3). (H) Succinate levels in sdh7∆ mutants with 










Figure 5.4. BN-PAGE analysis of respiratory complexes.  
Mitochondria from the strains were solubilized with 1% digitonin. Soluble fractions were 
separated on BN-PAGE and transferred to membranes for detection of protein complexes 




that Sdh6 and Sdh7 may interact with the Sdh1/Sdh2 subcomplex. We performed co-
immunoprecipitation on epitope-tagged Sdh6 and Sdh7 in mitochondria from WT cells 
and cells stalled in SDH assembly. A fraction of Sdh1 and Sdh2 were copurified with 
either Sdh6 or Sdh7 from cells lacking the membrane anchor domain but not in cells 
devoid of Sdh2 (Figures 5.3D, 5.3E, and 5.5A). These interactions are seen in the 
presence and absence of crosslinking prior to resin adsorption. These results suggest that 
Sdh6 and Sdh7 interact with Sdh2 within a Sdh1/Sdh2 subcomplex. Moreover, these 
interactions appear to occur in the mitochondrial matrix, consistent with the known 
matrix location of Sdh1, Sdh2, and Sdh6 (Ghezzi et al., 2009). Sdh7 is also a matrix 
protein as revealed by proteinase K treatment of purified mitochondria, which degrades 
Sdh7 only in the presence of detergents and not upon hypotonic disruption of only the 
outer membrane (Figure 5.5B). 
The physical interactions of Sdh6 and Sdh7 with Sdh2 prompted the hypothesis 
that Sdh6 and Sdh7 may be chaperones for Sdh2. To test this, we first examined the 
ability of overexpressed Sdh6 or Sdh7 to stabilize the highly labile Sdh2 present in sdh1∆ 
cells (Kim et al., 2012). Elevated levels of Sdh6, but not Sdh7, led to increased steady-
state Sdh2 levels under these conditions (Figure 5.3F). This result raised a possibility that 
Sdh6 may function as a chaperone for Sdh2 prior to its interaction with Sdh1. We tested 
whether SDH2 overexpression in sdh6∆ mutants or sdh7∆ mutants would restore SDH 
activity and suppress the respiratory growth defects. However, SDH2 overexpression 
neither restored SDH activity nor reversed succinate accumulation or rescued respiratory 





Figure 5.5. Co-immunoprecipitation of Sdh6-His6-2Myc in various strains and 
localization study of Sdh7.  
(A) Mitochondrial lysates were obtained after solubilization with 1% digitonin, which 
were subjected to anti-Myc antibody-conjugated magnetic beads. Bound substances to 
Myc antibody beads were resolved on SDS-PAGE and detected by immunoblotting. 
Load, 4% of total lysates. (B) Proteinase K assay to assess the localization of Sdh7. Sdh7-
Myc was expressed in sdh7∆ mutants and mitochondria were isolated. Intact mitochodria, 
hyoptonic buffer treated mitochondria, and 1% Triton X-100 treated mitochondria were 
incubated with proteinase K for 30 min on ice. Sample were resolved on SDS-PAGE. 








Figure 5.6. Growth tests of sdh6∆ mutants and sdh7∆ mutants with 
SDH2 overexpression and iron supplementation  
(A,B). Cell harboring either high-copy SDH2 plasmid or empty vector (EV) were spotted 
on synthetic complete media by 10-fold serial dilutions, and incubated at 30˚C. (C) 
Steady-state levels of Sdh2 overexpressed. (D) Enhanced respiratory growths of sdh6∆ 
mutants and sdh7∆ mutants with iron supplementation 10-fold serial dilutions of cells 
starting from OD600 = 0.5 were spotted on synthetic complete media ± FeCl2 or ZnCl2 as 





These results suggest that Sdh6 and Sdh7 may have a more active role in Sdh2 
maturation.  
 
Antioxidants ameliorate defects in sdh6∆ mutants and sdh7∆ mutants 
Further clues to the function of Sdh6 emerged from a genetic suppressor study in 
which extragenic suppressors of the acetate growth defect of sdh6∆ mutants were 
recovered. We generated a high-copy plasmid library with partially digested genomic 
DNA from sdh6∆ mutants. This library was transformed to sdh6∆ mutants and the 
transformants that exhibited enhanced growth on acetate medium were collected. 
Interestingly, multiple independent suppressors were recovered that encoded Yap1, 
which is a transcriptional activator that induces the expression of a battery of antioxidant 
genes, including thioredoxin, thioredoxin reductase and glutathione reductase, in 
response to oxidative stress (Fernandes et al., 1997). The overexpression of YAP1 in 
subcloned vectors robustly suppressed the acetate growth defect of cells lacking Sdh6 
(Figure 5.7A). Consistent with the antioxidant role of Yap1 expression, supplemental 
glutathione or N-acetyl-cysteine also restored limited respiratory growth in sdh6∆ 
mutants (Figure 5.7B).  
Since we observed a genetic interaction between SDH6 and SDH7, we tested 
whether overexpression of YAP1 could also restore respiratory growth in sdh7∆ mutants. 
Indeed, YAP1 overexpression suppressed the respiratory growth defect of sdh7∆ mutants, 
although the suppression was less pronounced compared to sdh6∆ mutants (Figure 5.7A). 








Figure 5.7. Exogenous antioxidants rescue the growth defect of 
sdh6∆ and sdh7∆ mutants.  
(A) Cells harboring either empty vector (EV) or high-copy YAP1 plasmid were spotted 
on SC media lacking leucine by 10-fold serial dilutions and incubated at 30˚C. (B) 10-
fold serial dilutions of cells were spotted on SC media ± 5 mM N-acetyl cysteine or 2 
mM glutathione and incubated at 30˚C. (C) Succinate levels in cells overexpressing YAP1 
were measured as described in Figure 5.1D. Cells were harvested at OD600 = 1. Mean ± 






sdh7∆ mutants (Figure 5.7B). To confirm that YAP1 overexpression restored SDH 
activity in sdh6∆ and sdh7∆ single mutant cells, we assessed SDH activity by measuring 
succinate levels using metabolomics. Indeed, YAP1 overexpression decreased succinate 
levels in both sdh6∆ and sdh7∆ mutants significantly, while YAP1 overexpression did not 
affect succinate levels in sdh2∆ mutants as a negative control (Figure 5.7C). Therefore, 
we conclude that YAP1 overexpression contributes to the restoration of SDH activity in 
sdh6∆ and sdh7∆ mutants. Elevated levels of Yap1, however, have no effect on the 
respiratory growth defects in sdh6∆ sdh7∆ double mutants (Figure 5.7A).  
 
Stabilization of Sdh2 by Sdh6 and Sdh7 is manifested under 
oxidative stress conditions 
We hypothesized that Sdh6 and Sdh7 may be important for Sdh2 maturation 
under oxidative stress conditions. Initially, we tested whether cells lacking Sdh6 or Sdh7 
were hypersensitive to the superoxide anion generator paraquat. The respiratory growth 
defect of sdh6∆ and sdh7∆ single mutants was dramatically exacerbated in the presence 
of paraquat (Figure 5.8A). Likewise, steady-state levels of Sdh2 were markedly 
attenuated in paraquat-treated sdh6∆ and sdh7∆ mutants compared to WT cells (Figure 
5.8B). In contrast, steady-state levels of other mitochondrial Fe/S containing proteins 
were not significantly altered by paraquat in the mutant cells (Figure 5.8B). 
The paraquat sensitivity of sdh6∆ and sdh7∆ mutants may arise from either 
enhanced ROS damage or the accumulation of a pro-oxidant in the mutants.  We 





Figure 5.8. sdh6∆  and sdh7∆ mutants are sensitive to oxidative stress. 
(A) Ten-fold serial dilutions of cells were spotted on SC media ± 2 mM paraquat with 
indicated carbon sources and incubated at 30˚C. (B) Steady-state levels of proteins in 
mitochondria isolated from strains cultured in SC media with 2% raffinose / 0.2% 
glucose supplemented with 2 mM paraquat. Yah1, ferredoxin of the mitochondrial 
matrix. (C) Aconitase activity specific to cis-aconitate conversion in isolated 
mitochondria. Data are shown as mean ± SD (N = 3). (D) Precultures grown up to late-
log phase in YPD media were diluted 2-fold, followed by addition of 6 mM H2O2 and 
incubated for 2 h at 30˚C. Cells were washed with sterile water and 10-fold serial 




two different assays. First, we quantified aconitase (Aco1) activity. The 4Fe-4S cluster in 
aconitase is susceptible to ROS damage (Gardner, 2002); thus aconitase activity is an 
indicator of ROS stress in vivo.  We did not observe a diminution of aconitase activity in 
sdh6∆ and sdh7∆ mutants compared to WT (Figure 5.8C). Second, we tested the mutant 
cells for hydrogen peroxide sensitivity on rich glucose medium. As cells accumulate 
ROS, they become sensitized to exogenous ROS and subsequently lose viability 
(Khalimonchuk et al., 2007). After a 2-hour treatment of cells with 6 mM H2O2, the 
viability of sdh2∆, sdh3∆, and sdh4∆ mutant strains was significantly compromised 
(Figure 5.8D). However, sdh6∆ and sdh7∆ mutant cells exhibited no growth defects. The 
lack of impairment in aconitase activity and hydrogen peroxidase sensitivity suggest that 
ROS levels are not elevated in sdh6∆ and sdh7∆ mutants as compared to WT cells. It is 
noteworthy that sdh1∆ and sdh5∆ single mutants and the sdh4∆ sdh5∆ double mutant did 
not show hydrogen peroxide sensitivity compared to sdh2∆, sdh3∆, and sdh4∆ strains, 
which suggests that an assembly intermediate containing FAD-Sdh1 may be the source 
for electron leakage for the generation of ROS in sdh2∆, sdh3∆, and sdh4∆ single 
mutants. 
 
Drosophila Sdhaf3 mutants are sensitive to oxidative stress  
The Drosophila genome encodes a close ortholog of Sdh7 (Figure 5.9A), but has 
only a weak candidate homolog of Sdh6. Accordingly, we examined the functions of 
Sdh7 in Drosophila to determine if its roles in SDH assembly and activity have been 
conserved through evolution and to define its possible physiological functions. Gene 










Figure 5.9. Generation and characterization of dSdhaf3 null mutants  
(A) Amino acid sequence alignment of Sdh7 orthologs in eukaryotes using Clustal 
Omega. (B) Gene targeting was used to disrupt the dSdhaf3 locus. A miniwhite selectable 
marker was flanked by two 3 kb regions of homology to the dSdhaf3 locus (5’HA and 
3’HA), resulting in the deletion of 339 bp of dSdhaf3 coding region upon homologous 
recombination. (C) The structure of the mutated dSdhaf3 locus was confirmed by 
Southern blot hybridization.  Genomic DNA was isolated from three genetic 
backgrounds: (1) w1118 control flies, (2) two independent transformant lines that carry the 
dSdhaf3 targeting construct integrated randomly in the genome (donor strains 1 and 2), 
and (3) the dSdhaf3 deletion mutant generated using donor strain #2 (see Supplemental 
Experimental Procedures). The DNA was cut using HindII and EcoRV restriction 
endonucleases and analyzed by Southern blot hybridization using probes to detect the 5’ 
and 3’ regions of the dSdhaf3 locus. These probes will detect a 2.8 kb fragment from the 
wild-type locus, and 0.73 and 3.4 kb fragments from the disrupted gene containing the 
miniwhite marker. The Southern blot shows that only the 2.8 kb fragment is present in 
the w1118 control, as expected (lane 1). The two donor strains carry both the wild-type 
locus and the 3.4 kb and 0.73 kb fragments from the targeting construct (lanes 2 and 3). 
The homozygous dSdhaf3 mutant has only the 3.4 kb and 0.73 kb fragments, as expected 
(lane 4).  Note that the ~7 kb fragment in donor strain #1 is of unknown origin. Donor 
strain #2 was used to generate the dSdhaf3 mutant used in this study. (D) GC/MS was 
used to compare the relative levels of small metabolites in wild-type controls (grey 
boxes) and dSdhaf3 mutants (white boxes). N = 12 samples from two independent 
experiments with 20 flies/sample (5-day old).  ***p < 0.001. (E) Proteins from purified 
mitochondria were extracted from w1118 controls (+) and dSdhaf3 mutants (–), 
fractionated by non-denaturing PAGE, and analyzed for total protein by Commassie Blue 
staining or for flavinylated SdhA. A SdhA marker is included as a control (M). (F) 
Control w1118 flies and dSdhaf3 mutants were tested for paralysis as described in 
Supplemental Experimental Procedures, scoring for the number of flies that moved off 
the bottom of the vial after vortexing. Results are from three independent experiments 












(CG14898), which we refer to here as dSdhaf3 (Figures 5.9B–5.9D). These mutants were 
outcrossed for six generations to w1118, which was used as a control for most studies. 
dSdhaf3 mutants progress normally through development and have a normal lifespan 
when maintained on standard growth media. These animals are, however, sensitive to  
ethanol (Figure 5.10A) and oxidative stress, resulting from either paraquat treatment 
(Figure 5.10B) or hyperoxia (Figure 5.10C). The response to hyperoxia is most 
pronounced, with a 50% reduction in lifespan relative to controls, although SdhB12081 
hypomorphic mutants display a more severe effect (Walker et al., 2006). Interestingly, 
most Sdhaf3 mutants exposed to 100% oxygen for 4 days held their wings erect, a 
hallmark of mitochondrial dysfunction and muscle degeneration (DeSimone et al., 1996; 
Greene et al., 2003). A similar abnormal wing posture was observed in SdhB12081 mutants 
maintained under normal conditions (10–15%) or exposed to hyperoxia (80–100%).  
 
dSdhaf3 mutants display reduced SdhB protein levels and SDH activity 
If the function of dSdhaf3 has been conserved through evolution, then dSdhaf3 
mutants should display a specific defect in SDH function. Consistent with this possibility, 
metabolomic profiling of dSdhaf3 mutants revealed relatively few significant changes in 
metabolite levels, with elevated succinate and reduced levels of citrate, fumarate, and 
malate (Figure 5.10D). Biochemical analysis of mitochondrial extracts from dSdhaf3 
mutants demonstrated that dSdhaf3 mutants have normal levels of SdhA, but significantly 
reduced levels of SdhB (Figure 5.10E), resulting in an approximate 50% reduction in 
SDH enzymatic activity (Figures 5.10F and 5.10G), similar to the phenotypes of sdh7∆ 













Figure 5.10.  dSdhaf3 mutants are sensitive to oxidative stress and 
display reduced levels of SdhB, reduced SDH activity, and motility 
defects.  
Five-day old w1118 control (solid line) and dSdhaf3 mutant (dotted line) males were 
transferred to vials with (A) 5% ethanol, 1% agar in PBS, (B) 30 mM paraquat in semi-
defined medium, or (C) 100% O2 with standard medium, and living animals were scored 
daily. Homozygous SdhB12081 mutants (dashed line) were included in the hyperoxia 
experiment.  Each graph was compiled from 3–5 experiments, using a total of 15–21 vials 
with 20 animals per vial. Error bars represent ±SEM.  *p < 0.05,  **p < 0.01,   ***p < 
0.001. (D) GC/MS was used to compare the relative levels of small metabolites in wild-
type controls (grey boxes) and dSdhaf3 mutants (white boxes). N = 12 samples from two 
independent experiments with 20 flies/sample (5-day old).  ***p < 0.001. (E) Proteins 
were extracted from mitochondria isolated from w1118 controls, dSdhaf3 mutants, or UAS-
dSdhaf3/+ transformants, and analyzed by immunoblotting to detect SdhA, SdhB, and 
ATPα, (a subunit of complex V). (F) A continuous colorimetric assay was used to 
measure SDH enzyme activity in extracts of purified mitochondria from w1118 controls, 
dSdhaf3 mutants, and UAS-dSdhaf3/+ transformants. ***p < 0.001. (G) Proteins from 
purified mitochondria were extracted from w1118 controls and dSdhaf3 mutants, 
fractionated by nondenaturing PAGE, and analyzed for SDH and Complex IV activity. 
(H) Control w1118 flies and dSdhaf3 mutants were tested for motility in three independent 
experiments using a total of 18 vials with 20 adults/vial at 1, 2, 3, or 4-weeks of age. *p < 









Combining the hypomorphic SdhB12081 allele with the dSdhaf3 mutation resulted in a 
dramatic decrease in viability, demonstrating a strong genetic interaction, consistent with 
the reduced levels of SdhB in dSdhaf3 mutants and confirming the functional interaction 
between dSdhaf3 and SDH (Figure 5.11A). 
Interestingly, although dSdhaf3 mutants are fully viable and fertile, they display a 
clear age-dependent reduction in movement (Figure 5.10H). While mutants at 1 week of 
adult life show no difference in motility relative to controls, mutants display an 
approximate 50% reduction in movement by 2 weeks of age and a more severe motility 
defect at later stages (Figure 5.10H). Mutants are also significantly more sensitive to 
paralysis by 2 weeks of age, relative to controls (Figure 5.9F).  Thus, like its counterpart 
in yeast, dSdhaf3 is required to maintain normal SDH levels and activity and is required 
for proper wing muscle function and motility in Drosophila. 
  
Antioxidant and genetic rescue of dSdhaf3 mutants 
Consistent with the ability of antioxidants to suppress the growth defects in sdh7∆ 
yeast mutants, either a dietary (N-acetyl cysteine) or genetic (Sod2 expression) reduction 
in oxidative stress rescued the hyperoxia sensitivity of dSdhaf3 mutants (Figures 5.12A 
and 5.2B). Unlike the yeast studies, however, overexpression of the putative Sdh6 
homolog (encoded by CG34229), using Act5C-GAL4 to drive a UAS-CG34229 transgene 
in dSdhaf3 mutants, had no effect on their sensitivity to hyperoxia (Figure 5.11B). This 
result, however, is difficult to interpret because there is only limited sequence homology 
between CG34229 and Sdh6. We conclude that this functional interaction between Sdh6 

















Figure 5.11. dSdhaf3 interacts with SdhB and overexpression of 
CG34229 fails to rescue the hyperoxia sensitivity of dSdhaf3 mutants. 
(A) Flies carrying either control or dSdhaf3 mutant chromosomes over a balancer 
chromosome were crossed to flies carrying a hypomorphic allele for SdhB over a 
balancer. The resulting progeny were scored for the absence or presence of the marker 
linked to the balancer chromosome. The proportion of the expected progeny that eclosed, 
based on Mendelian ratios of the indicated genotypes, is shown. “+” represents a TM3 
balancer for dSdhaf3 and a CyO balancer for SdhB12081. (N) = number of progeny assayed 
from each cross in a total of four independent experiments. The mean ± SEM is shown 
and ***p < 0.001 (B) A BLAST search for a Drosophila Sdh6 homolog identified 
CG34229, which shares limited sequence similarity with both the yeast protein and 
human LYR proteins. Widespread overexpression of CG34229 using Act5C-GAL4 to 
drive a UAS-CG34229 transgene in dSdhaf3 mutants (orange line), however, had no 
effect on their sensitivity to hyperoxia. We conclude that the functional interaction 
between Sdh6 and Sdh7 may not be conserved through evolution or that the true 

































Figure 5.12. dSdhaf3 function is required in the muscles and nervous 
system.  
Five-day old w1118 control (solid line) and dSdhaf3 mutant (dotted line) males were 
transferred to vials with 100% O2 with standard medium, and living animals were scored 
daily. (A) 0.1% N-acetyl cysteine was added to the culture medium for a quarter of the 
vials. (B) Expression of Sod2 using the ubiquitous Act5C-GAL4 driver (Act > Sod2; 
purple line) partially rescues the hyperoxia sensitivity of dSdhaf3 mutants. (C) 
Expression of wild-type dSdhaf3 using the ubiquitous Act5C-GAL4 driver (Act > 
dSdhaf3; purple line) rescues the hyperoxia sensitivity of dSdhaf3 mutants. (D) The 
muscle-specific C57-GAL4 driver provides minor, but significant, rescue of the hyperoxia 
sensitivity of dSdhaf3 mutants (purple line) relative to the control that carries the UAS-
dSdhaf3 transgene alone (green line), while the CNS-specific elav-GAL4 driver provides 
more efficient rescue (orange line). Expression of wild-type dSdhaf3 by using either the 
ubiquitous Act5C-GAL4 driver (E, purple), the muscle-specific C57-GAL4 driver (F, 
purple), or the CNS-specific elav-GAL4 driver (F, orange) rescues the climbing defect in 
dSdhaf3 mutants. The Act > dSdhaf3 rescue in C and E was performed in females; other 
rescue studies were performed in males (A, B, D, F). The apparent partial rescue of 
dSdhaf3 mutants by a single copy of the UAS-dSdhaf3 transgene (C, D, green line) 
appears to be due to genetic background since UAS-dSdhaf3 transformants have normal 
levels of SdhB and SDH activity (E, F). Each graph was compiled from two experiments 












functional homolog of Sdh6. The wing posture and motility defects in dSdhaf3 mutants 
suggested that these animals suffer from muscular and neuronal dysfunction. Consistent 
with this model, widespread expression of WT dSdhaf3 (Act > dSdhaf3) in dSdhaf3 
mutants fully rescues their sensitivity to hyperoxia (Figure 5.12C), while muscle-specific 
(C57 > dSdhaf3) or neuronal-specific (elav > dSdhaf3) expression provides partial rescue 
(Figure 5.12D). Similar effects are seen on the climbing defects in dSdhaf3 mutants 
(Figures 5.12E and 5.12F). Genetic rescue in the fat body (Cg-GAL4) or intestine (Mex-
GAL4), however, provided no significant rescue (data not shown). Widespread 
overexpression of dSdhaf3 in wild-type flies has no significant effect on their resistance 
to hyperoxia (data not shown). Taken together, we conclude that dSdhaf3 function is 
conserved through evolution and that proper SDH levels and activity are required for 
resistance to oxidative stress as well as muscular and neuronal function, consistent with 
their dependence on mitochondrial oxidative phosphorylation.  
 
SDHB, but not SDHA, is specifically impaired in human cells 
deficient in wild-type SDHAF1 
Although the original study of the human Sdh6 ortholog, SDHAF1, demonstrated 
that it is required for SDH activity and abundance in fibroblasts (Ghezzi et al., 2009), its 
mechanism of action remained undefined. We therefore addressed whether SDHAF1 
protects SDHB (the human Sdh2 ortholog) from ROS damage similar to yeast Sdh6. 
First, we determined steady-state levels of SDH structural subunits in SDHAF1-depleted 
HEK293 cells by siRNA knockdown. SDHB and SDHC levels were significantly 



















Figure 5.13. SDHB is destabilized in human cells with reduced levels 
of SDHAF1.  
(A) Relative SDHAF1 mRNA levels in HEK293 cells 72 h after SDHAF1 knockdown 
using siRNA (left panel) and steady-state levels of proteins from total cell lysates (right 
panel). (B) HEK293 cells were treated with either control siRNA or SDHAF1 siRNA. 
Paraquat was added to cultures 24 h after siRNA transfection. Total cell lysates were 
obtained 48 h after paraquat supplementation. (C) Steady-state levels of proteins in 
mitochondria isolated from control fibroblasts and patient fibroblasts harboring mutations 
on SDHAF1 (Ohlenbusch et al., 2012). (D) Model of the role of Sdh6(SDHAF1) and 
Sdh7(SDHAF3) in maturation of the FeS centers in Sdh2(SDHB). Sdh6 and Sdh7 
associate with Sdh2 within a Sdh2/Sdh1 intermediate. Sdh1 maturation requires covalent 
flavinylation by Sdh5 followed by formation of the Sdh1/Sdh2 subcomplex that is 












unaffected. Next, we tested the effects of paraquat on SDHAF1-depleted HEK293 cells. 
In accordance with the yeast and fly data, SDHB levels were further attenuated in  
SDHAF1-deficient cells exposed to paraquat (Figure 5.13B), which suggests that 
SDHAF1 resembles Sdh6 in protecting the FeS SDH subunit from ROS damage.   
We also examined the steady-state SDHB levels in patient fibroblasts with a 
known SDHAF1 mutation. Both SDHB and SDHC levels were diminished in 
mitochondria isolated from the patient fibroblasts, whereas SDHA levels remained 
unaffected compared to controls (Figure 5.13C). It is noteworthy that the degree of 
diminution in SDHB levels was comparable to SDH activity as patient #1 fibroblasts and 
patient #2 retained 52% and 40% SDH activity of control fibroblasts, respectively. 
 
Discussion 
The present work demonstrates that maturation of the FeS subunit of Sdh2 
(SDHB) requires the participation of two assembly factors, Sdh6 (SDHAF1) and Sdh7 
(SDHAF3). These factors are shown to guide Sdh2 maturation within the mitochondrial 
matrix in the midst of endogenous oxidants. Yeast, flies and mammalian cells lacking one 
of these factors are impaired in SDH activity and assembly with Sdh2 exhibiting a 
heightened susceptibility to oxidants. Endogenous oxidants arising from the respiratory 
chain are deleterious to FeS cluster stability. Oxidative metabolism in the mitochondria 
leads to the formation of superoxide anions from the one electron reduction of O2. 
Superoxide anions can readily dissociate FeS clusters, so the assembly of FeS cluster 
centers in mitochondrial enzymes is susceptible to oxidative damage. The present studies 
in yeast, flies, and mammalian cells suggest that Sdh6 and Sdh7 exert a conserved 
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function in the assembly of the three FeS cluster centers in Sdh2 and shield the centers 
from oxidants.  
 Yeast studies reveal that Sdh6 and Sdh7 act in concert in the maturation of Sdh2  
with a limited redundancy in function. Yeast lacking either factor show a marked SDH 
deficiency in late-log cultures that rely on oxidative metabolism. Under these conditions, 
the mutant cells contain a reduced level of the assembled tetrameric enzyme. These cells 
exhibit a hypersensitivity to the superoxide generator paraquat. The respiratory defect of 
these mutants is readily suppressed by overexpression of the Yap1 transcriptional 
activator of oxidative stress genes or exogenous reductants. These studies highlight the 
role of Sdh6 and Sdh7 in shielding Sdh2 maturation from deleterious effects of oxidants.  
 Flies lacking the Sdh7 ortholog SDHAF3, likewise, are hypersensitive to paraquat 
and hyperoxia. The mutant flies show diminished levels of active SDH and as a result 
accumulate succinate. The dSdhaf3 mutants are viable and fertile, yet display impaired 
movement that intensifies with age. The erect wing phenotype exhibited under hyperoxic 
conditions and the motility defects evident in aged mutant flies are consistent with 
muscular and neuronal dysfunction. Moreover, neuronal or muscle-specific expression of 
wild-type dSdhaf3 is sufficient to partially rescue the hyperoxia sensitivity of the 
mutants, demonstrating the importance of SDH function in these tissues that rely heavily 
on OXPHOS. The hyperoxia sensitivity of dSdhaf3 mutants is also partially suppressed 
by dietary N-acetyl cysteine or overexpression of the matrix mangano-superoxide 
dismutase encoded by Sod2. These effects of antioxidants mimic the rescue of yeast 
sdh7Δ mutant oxidative growth and demonstrate the apparent close conservation of 
Sdh7/SDHAF3 function through evolution.  
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 Conservation in SDH6/SDHAF1 function between yeast and humans also exists. 
Attenuation of SDHAF1 in HEK293 culture cells leads to a hypersensitivity in the 
stability of the FeS SDHB subunit to paraquat. SDHB instability is also seen in two 
SDHAF1 patient fibroblast lines. One implication of the observed antioxidant rescue of 
the defect of sdh6Δ yeast cells and dSdhaf3 mutant flies is the potential use of antioxidant 
therapeutics for patients afflicted with SDHAF1 (and perhaps SDHAF3) mutations. 
Patients with SDHAF1 mutations have presented with SDH-deficient 
leukoencephalopathy (Ghezzi et al., 2009; Ohlenbusch et al., 2012) and have a survival 
window that may be amenable to antioxidant therapy. Two case studies were reported 
that attempted to alleviate clinical symptoms in SDH-deficient patients harboring 
SDHAF1 mutations by supplementing riboflavin and CoQ10. The clinical outcomes, 
however, were not significantly improved (Jain-Ghai et al., 2013). More recently, a 
candidate therapeutic, EPI-743, is being tested for treatment of Leigh syndrome patients 
(Martinelli et al., 2012). EPI-743 is a vitamin E quinone, which is orally bioavailable and 
crosses the blood-brain barrier (Shrader et al., 2011). Future studies will focus on the 
efficacy of antioxidants with SDHAF1 patient fibroblasts. In addition, it is important to 
note that every gene encoding an SDH subunit or known assembly factor is causally 
associated with human disease.  We thus anticipate that SDHAF3 mutations will be 
associated with one or more previously idiopathic SDH-associated diseases and propose 
that SDHAF1 and SDHAF3 are candidate susceptibility factors for undefined SDH-
deficient tumors.  
 The present work provides insights into the physiological function of Sdh6 and 
Sdh7 in Sdh2 maturation. Sdh6 and Sdh7 are shown to bind to the Sdh1:Sdh2 assembly 
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intermediate that accumulates in mutants lacking the SDH membrane anchor. In addition, 
both Sdh6 and Sdh7 accumulate in the membrane anchor mutant cells. Sdh6 was found to 
impart stabilization to Sdh2 in cells lacking the FAD subunit Sdh1, suggesting that at 
least Sdh6 has a specific interface for Sdh2. These assembly factors do not appear to be 
mere Sdh2 chaperones since elevated levels of Sdh2 do not suppress the respiratory 
defects of sdh6Δ or sdh7Δ mutants. Rather, a role in Sdh2 maturation is implicated by the 
observed accumulation of an Sdh1 assembly intermediate in sdh6Δ or sdh7Δ mutants. 
Sdh2 maturation requires the insertion of three distinct FeS clusters. A 2Fe-2S cluster 
exists in the N-terminal domain of Sdh2, which forms an interface with Sdh1 (Sun et al., 
2005). The C-terminal domain of Sdh2 contains both 4Fe-4S and 3Fe-4S clusters. FeS 
cluster synthesis in the mitochondrial matrix occurs on the ISU/ISA scaffold complexes 
and the preformed clusters are transferred to client proteins. The transfer of labile 
preformed FeS clusters may be sensitive to the deleterious effects of endogenous 
oxidants, so Sdh6 and Sdh7 may serve a role in chaperoning this transfer step. The two 
proteins are likely to have separate roles in this transfer step since the proteins are not 
completely redundant. A candidate role in the FeS cluster insertion step is supported by 
the observed partial suppression of respiratory growth defect of sdh6Δ or sdh7Δ mutants 
by supplemental iron (Figure 5.6D). Superoxide inactivation of the 4Fe-4S center in 
aconitase leads to a dissociation of one iron ion forming an inactive 3Fe-4S center that 
can be reactivated by supplemental iron salts (Gardner and Fridovich, 1992). Future 
studies will focus on the detailed mechanism by which Sdh6 and Sdh7 participate in FeS 
cluster maturation of Sdh2. Moreover, the observation that the two LYR proteins Sdh6 
and Sdh7 function with the FeS cluster Sdh2 subunit has significant implications for the 
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uncharacterized LYR proteins present in the human proteome. Our studies raise the 
possibility that future functional studies of LYRM1, LYRM2, LYRM5, and LYRM9 will 
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Mitochondria are dynamic and complex organelles that play a central role in 
many aspects of cellular biology, including energy production, intermediary metabolism, 
and apoptosis (Wallace, 2005). Consistent with these broad cellular functions, 
mitochondrial dysfunction is associated with a wide range of diseases, including cancer, 
type 2 diabetes, and neurodegenerative disorders such as Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (Baysal et al., 
2000; Chatterjee et al., 2006; Hanahan and Weinberg, 2011; Lin and Beal, 2006; Mootha 
et al., 2003; Patti et al., 2003; Petersen et al., 2004; Yan et al., 2009). The critical role of 
mitochondria in normal cellular function and human disease have led to large efforts to 
define the mitochondrial proteome (Calvo and Mootha, 2010). The most comprehensive 
proteomic analysis to date identified over 1,000 proteins that localize to mitochondria in 
mammals (Pagliarini et al., 2008). Remarkably, however, roughly 20% of these proteins 
have no known function (Pagliarini et al., 2008; Schmidt et al., 2010). These include 
many proteins that are highly conserved throughout eukarya, which indicates that they 
perform a fundamentally important function. We have been working to functionally 
characterize these conserved mitochondrial proteins using yeast and Drosophila model 
systems. Through this approach, we have discovered novel factors critical for 
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mitochondrial energy metabolism. In Chapter 2, we identify components of the 
previously unidentified mitochondrial pyruvate carrier (MPC), which links glycolysis to 
the TCA cycle through the import of pyruvate through the inner mitochondrial membrane 
(IMM). In a follow up study presented in Chapter 3, we demonstrate that Drosophila 
mutants lacking the MPC display characteristics of diabetes, including hyperglycemia, 
impaired glucose tolerance, and defects in the insulin signaling pathway (Inzucchi, 2012; 
Kirk et al., 2008). In Chapters 4 and 5, we identify two novel succinate dehydrogenase 
complex assembly factors (SDHAFs), thus providing a more comprehensive 
understanding of the process of SDH assembly and revealing new candidate-causative 
genes for diseases characterized by SDH deficiency.  
 
The MPC proteins are required for mitochondrial pyruvate 
uptake in yeast, Drosophila, and humans 
Over the past ~40 years, a series of biochemical experiments performed on 
isolated mitochondria have shown that a specific pyruvate carrier was present at the IMM 
(Schell and Rutter, 2013). Despite this extensive biochemical characterization, the 
molecular identity of the MPC was never elucidated (Hildyard and Halestrap, 2003; 
Todisco et al., 2006). In Chapter 2, we show that the MPC is comprised of members of 
the evolutionarily conserved and related MPC1 and MPC2 protein families (Figure 2.5). 
MPC1 and MPC2 are part of an ~150 kDa transmembrane protein complex localized to 
the IMM (Figures 2.1B, 2.1C, 2.6D, and 2.6E). Drosophila MPC1 (dMPC1) mutants 
display defects in carbohydrate metabolism, including an inability to survive on a sugar-
only diet, elevated carbohydrate levels, and reduced ATP (Figures 2.2A and 2.2C–2.2E). 
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Moreover, Drosophila and yeast MPC1 mutants accumulate pyruvate, whereas TCA 
cycle intermediates are depleted in dMPC1 mutants fed the sugar-only diet, indicating the 
presence of a specific disruption in pyruvate metabolism (Figures 2.2F and 2.3A). Since 
PDH activity is not significantly affected in mitochondria isolated from yeast MPC1 
mutant cells (Figure 2.3C) we hypothesized that the MPC1 proteins may be involved in 
mitochondrial pyruvate import. Consistent with this hypothesis, mitochondria isolated 
from yeast MPC1 mutants display reduced uptake of radiolabeled pyruvate (Figure 2.3E). 
Furthermore, through the identification of a point mutant in yeast MPC1 that promotes 
resistance to a known inhibitor of the MPC, we demonstrate that MPC1 is either a target 
of the drug or closely associated with its target (Figures 2.3F and 2.3G) (Halestrap, 
1976). This result demonstrates that the MPC1/MPC2 complex exhibits a key defining 
feature of the MPC described almost 40 years ago (Halestrap, 1976; Halestrap and 
Denton, 1974). Finally, we show that RNA interference (RNAi)-mediated silencing of 
MPC1 or MPC2 reduces pyruvate oxidation in cultured mammalian cells, demonstrating 
that the role of the MPC proteins is conserved from yeast to humans (Figures 2.4A and 
2.4B). Building on this observation, we showed that patients described in a previous 
publication with a hereditary disease associated with a defect in mitochondrial pyruvate 
uptake carry causative mutations in the MPC1 locus (Figures 2.4C–2.4H) (Brivet et al., 
2003). Overall, we conclude that the MPC proteins are required for mitochondrial 
pyruvate import across Eukarya and thus provide a molecular framework for further 
studies of this critical link between cellular glycolysis and mitochondrial OxPHOS 
(Halestrap and Denton, 1974; Schell and Rutter, 2013). 
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This discovery raises several interesting questions that should be addressed in 
future work. First, it is unclear whether there are any other unidentified components of 
the MPC involved in mitochondrial pyruvate import. In a paper copublished with ours, it 
was shown that expression of MPC1 and MPC2 together, but not individually, is 
sufficient to promote pyruvate uptake in bacterial cells (Herzig et al., 2012). This result 
suggests that the MPC is comprised of MPC1 and MPC2 exclusively (Herzig et al., 
2012). Members of the Rutter lab, however, have been unable to reproduce this result 
(Jared Rutter, personal communication). This could be due to the technical difficulty 
associated with this kind of experiment, or perhaps, it could indicate that components 
other than MPC1/MPC2 are required to truly reconstitute pyruvate transport in a 
heterologous system. In future studies, it will be interesting to differentiate between these 
possibilities. A recent perspective article from Halestrap called into question whether the 
MPC proteins are truly involved in pyruvate transport, suggesting that the apparent 
pyruvate uptake defect observed in our study and the paper by Herzig et al. results from a 
pyruvate metabolic defect in MPC1 mutants (Halestrap, 2012a). The subsequent 
demonstration that methyl-pyruvate can bypass pyruvate metabolic defects in cells in 
which MPC1 is silenced, however, supports our conclusion (Divakaruni et al., 2013). 
Since methyl-pyruvate can diffuse freely across the inner mitochondrial membrane before 
it is cleaved by esterases in the matrix to generate intramitochondrial pyruvate, this result 
provides further evidence that the MPC complex is required for pyruvate uptake 
specifically, and not downstream pyruvate metabolic steps (Divakaruni et al., 2013).  
Our current model for the structure of the MPC is a hetero-oligomeric complex of 
MPC1 and MPC2, each of which is relatively small and only contains two to three 
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transmembrane domains (Figure 2.5) (Divakaruni and Murphy, 2012; Herzig et al., 
2012). This is an unusual configuration for a membrane metabolite transporter, which is 
typically represented by a single protein containing 6 to 12 transmembrane domains 
(Halestrap, 2012b; Palmieri and Pierri, 2010). Interestingly, this raises the possibility that 
the relative stoichiometry of the subunits may be a regulatory mechanism to control MPC 
activity in vivo. There is precedent for this type of regulatory mechanism exemplified by 
the mitochondrial calcium uniporter (MCU), which is a heterotetramer of two small and 
related proteins—MCU and MCUb (Patron et al., 2013). In this complex, MCUb 
functions as a negative regulator, inhibiting uniporter activity (Raffaello et al., 2013). 
Thus, the stoichiometry of MCU and MCUb in a given complex may be used to regulate 
mitochondrial calcium efflux differently under a variety of conditions (Raffaello et al., 
2013). There is some evidence that the MPC might represent a rate-limiting step in 
pyruvate metabolism suggesting that the regulation of MPC activity may be a mechanism 
to modulate pyruvate utilization, although this topic is controversial (Halestrap and 
Armston, 1984; Pande and Parvin, 1978; Shearman and Halestrap, 1984; Titheradge and 
Coore, 1976). A potential regulatory function of the MPC is particularly interesting in 
light of the recent discoveries that a PPAR gamma-sparing thiazolidinedione (TZD) 
derivative and a phosphodiesterase inhibitor Zaprinast both promote metabolic changes in 
cultured cells and inhibit the MPC (Colca et al., 2013; Divakaruni et al., 2013; Du et al., 
2013). These results suggest that the MPC could be responsible for some of the 
physiological responses elicited by these drugs. In future studies, we will attempt to 
determine if the MPC can be regulated through the stoichiometry of its subunits similar to 
the MCU. Building on these analyses, it will also be interesting to determine if MPC 
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function is affected in disorders like type 2 diabetes (discussed in Chapter 3) and cancer, 
where alterations in pyruvate metabolism are known to correlate with disease progression 
(McFate et al., 2008; Schummer et al., 2008).  
 
Drosophila MPC1 mutants display defects in carbohydrate  
homeostasis and hallmarks of diabetes 
 In Chapter 3, we describe further studies of the defects in carbohydrate 
homeostasis seen in Drosophila MPC1 mutants. We discovered that dMPC1 mutants 
display several defining hallmarks of diabetes including sensitivity to dietary sugar, 
hyperglycemia during fasted and fed states, impaired glucose tolerance, and a reduction 
in insulin signaling activity in peripheral tissues (Figures 3.1A–3.1D, 3.2A, 3.2B, 3.4A–
3.4C, 3.5B, and 3.5C) (Inzucchi, 2012). Since mitochondrial pyruvate metabolism by 
PDH was previously shown to be critical for glucose-stimulated insulin secretion (GSIS) 
in mice, we hypothesized that the MPC might be required for DILP secretion in 
Drosophila (Srinivasan et al., 2010). Consistent with this hypothesis, we observed a 
defect in the secretion of a Drosophila insulin-like peptide (DILP) from the insulin 
producing cells (IPCs) of dMPC1 mutants (Figures 3.6A and 3.6B). Based on these 
results, we conclude that the MPC in Drosophila facilitates a metabolic state that 
promotes euglycemia and normal insulin signaling. The exact mechanism underlying this 
function, however, is unclear and is the subject of the future directions described in 
Chapter 3. Interestingly, the role of the MPC in the regulation of glucose homeostasis and 
insulin signaling may be conserved in mammals, as a PPARγ sparing TZD derivative was 
identified that ameliorates diabetic phenotypes and directly inhibits the MPC in 
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Drosophila and mammalian cells (Colca et al., 2013; Divakaruni et al., 2013; Rohatgi et 
al., 2013). It is unclear, however, if MPC inhibition underlies the beneficial effects of 
these drugs. Therefore, continuing to characterize the diabetic phenotypes of dMPC1 
mutants is likely to provide insight into the role of the MPC in euglycemia and insulin 
signaling that may translate to humans.  
Independent of the diabetic phenotypes, our characterization of dMPC1 mutants 
provides insight into the physiological role of the MPC in Drosophila. For example, our 
analysis suggests that dMPC1 mutants display a developmental delay, but not lethality, 
which indicates that the MPC is not absolutely required for viability. Conversely, flies 
carrying transgenes that induce global silencing of PDH by RNAi die during 
development (Dona Wisidagama, personal communication). Since pyruvate must enter 
the mitochondrion to be converted to Acetyl-CoA by PDH, we would expect that a 
complete block in mitochondrial pyruvate should also cause lethality (Gray et al., 2013). 
Therefore, these results suggest that the MPC is not completely required for 
mitochondrial pyruvate import in Drosophila in vivo. Consistent with this hypothesis, we 
observe that the flux of glucose-derived carbons to TCA cycle intermediates is reduced, 
but not absent, in dMPC1 mutants (data not shown). Thus, it appears that loss of dMPC1 
results in an incomplete block in mitochondrial pyruvate import. This residual transport 
could potentially be explained by the presence of a plasma membrane monocarboxylate 
transporter as one has been purported to also localize to mitochondria in mammalian cells 
(Brooks et al., 1999). It will be interesting to determine if MPC1 and MPC2 are essential 
genes in other species and whether the magnitude of their contribution to mitochondrial 
pyruvate import varies across evolution. 
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The identification of novel succinate dehydrogenase complex 
assembly factors provides a more comprehensive 
understanding of SDH assembly 
 The SDH complex occupies a pivotal step in cellular energy metabolism since it 
directly links the TCA cycle with the ETC (Berg et al., 2002). Despite this fundamental 
metabolic role, little is known about how the SDH complex is assembled (Rutter et al., 
2010). Two proteins, called Sdhaf1 and Sdhaf2 (Sdh6 and Sdh5 in yeast), were shown to 
be required for SDH assembly (Ghezzi et al., 2009; Hao et al., 2009). Sdhaf2 is required 
for the covalent flavination of the SdhA subunit, whereas the molecular function of 
Sdhaf1 was not determined (Ghezzi et al., 2009; Hao et al., 2009). In Chapters 4 and 5, 
we identify and characterize two novel SDH assembly factors called Sdhaf3 and Sdhaf4 
(Sdh7 and Sdh8 in yeast) and also describe the molecular function of Sdhaf1. For clarity, 
the nomenclature of SDH assembly factors and SDH complex subunits in animals will be 
used hereafter. Sdhaf1, Sdhaf3, and Sdhaf4 are all mitochondrial matrix proteins that play 
an evolutionarily conserved role in facilitating SDH function (Ghezzi, et al., 2009) 
(Figures 4.1B, 4.1D, and 5.5B). Loss of any one of these factors results in an 
accumulation of succinate and a depletion of fumarate and malate in yeast and flies 
(Figures 4.1F, 4.2, 4.5B, 4.6A, 5.1D, and 5.10D), as well as reduced steady-state levels of 
SDH holocomplex (Figures 4.2E, 4.3C, 4.4A, 5.1F, 5.10E, 5.13A, and 5.13C) and SDH 
activity (Figures 4.2C, 4.3B, 4.6B, 5.1E, 5.10F, and 5.10G). Each of these proteins 
directly interacts with an SDH subunit to promote SDH assembly. SDHAF4 physically 
interacts with soluble flavo-SdhA in the matrix prior to its association with SdhB and the 
rest of the SDH complex at the IMM (Figures 4.11A, 4.11C, 4.11D, 4.12A, and 4.12C), 
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potentially to prevent reactive oxygen species (ROS) production from FAD auto-
oxidation. Consistent with this model, yeast Sdhaf4 mutant cells produce excess 
endogenous ROS (Figures 4.13E and 4.14B) and both yeast and Drosophila Sdhaf4 
mutants are sensitive to exogenous oxidative stressors (Figures 4.9F and 4.13D). 
Moreover, toxicity associated with SdhA overexpression in yeast is worsened by loss of 
Sdhaf4 and ameliorated by Sdhaf4 overexpression (Figures 4.13A, 4.13B, and 4.14A). On 
the contrary, Sdhaf1 and Sdhaf3 physically interact with the iron sulfur (FeS) cluster-
containing SdhB subunit in the mitochondrial matrix (Figures 5.3D, 5.13E, and 5.5A). 
Like Sdhaf4, Sdhaf1 and Sdhaf3 are critical for ROS homeostasis, as yeast and fly Sdhaf3 
mutants and yeast Sdhaf1 mutants, are sensitive to oxidative stress (Figures 5.7A–5.7C, 
5.8A, 5.8B, 5.8D, 5.10B, 5.10C, 5.12A, and 5.12B). Unlike Sdhaf4 mutants, however, the 
toxicity associated with ROS in Sdhaf1 and Sdhaf3 mutants is caused specifically by 
ROS-mediated destabilization of SdhB, and not by the increased activity of a pro-oxidant 
molecule (Figures 5.7A–5.7C and 5.8A–5.8D). Moreover, Sdhaf1 and Sdhaf3 may 
facilitate the maturation of FeS clusters in SdhB, as supplementation of exogenous iron 
can partially rescue yeast Sdhaf1 or Sdhaf3 mutant phenotypes (Figure 5.6D). The exact 
mechanism by which Sdhaf1 and Sdhaf3 promote FeS cluster maturation, however, is 
unclear and will be the subject of future studies. Taken together, these results provide us 
with a more complete model for SDH complex assembly (Figure 6.1). First SdhA is 
flavinated in an Sdhaf2-dependent manner (Figure 6.1A). Flavo-SdhA then binds to 
Sdhaf4 to prevent SdhA auto-oxidation, thus facilitating the stability of SdhA and/or 










Figure 6.1. Model of SDH assembly. 
The proposed steps of SDH complex assembly are depicted in chronological order. (A) 
SdhA is flavinated in an Sdhaf2-dependant manner. (B) Flavinated SdhA binds to Sdhaf4 
to protect against SdhA auto-oxidation. (C) Sdhaf1 and Sdhaf3 promote the maturation of 
the iron sulfur (FeS) clusters in SdhB by shielding them from the damaging effects of 
reactive oxygen species (ROS). The actions of Sdhaf3 and Sdhaf1 facilitate the formation 
of the SdhA/SdhB dimer. (D) The SdhA/SdhB dimer is anchored to the inner 
mitochondrial membrane (IMM) by SdhC/SdhD. The intermembrane space (IMS) is also 






SdhB subunit, potentially by protecting the FeS clusters from the damaging effects of 
ROS, such that SdhB can bind to SdhA (Figure 6.1C). The combined actions of these 
assembly factors are required for the proper assembly of functional SDH complexes 
(Figures 6.1A–6.1D). In addition, the identification of Sdhaf3 and Sdhaf4 yields novel 
candidate causative genes that may be involved in a group of pathologies characterized 
by SDH deficiency, which include forms of cancer and neurodegenerative diseases that 
lack mutations in core SDH subunits (Feichtinger et al., 2010; Horvath et al., 2006; Jain-
Ghai et al., 2013; Janeway et al., 2011). In future studies, it will be interesting to 
sequence DNA isolated from patients with these diseases to determine if mutations are 
present in the SDHAF3 or SDHAF4 loci.  
 
Sdhaf3 and Sdhaf4 are critical for neuronal and muscular 
function in Drosophila 
 Consistent with the important role of mitochondria in nervous and muscular 
tissues, Drosophila Sdhaf3 and Sdhaf4 mutants display phenotypes associated with 
neuronal and muscular dysfunction. These include an age-progressive sensitivity to 
mechanically induced seizures (bang sensitivity) and reduced movement in dSdhaf4 
mutants, which are characteristics commonly associated with neurodegeneration in 
Drosophila (Figures 4.9B, 4.9C, 4.10A, and data not shown) (Feany and Bender, 2000; 
Fergestad et al., 2006; Liu et al., 2007). Consistent with these behavioral phenotypes, 
dSdhaf4 mutants display retinal degeneration (Figure 4.9D). Bang sensitivity in dSdhaf4 
mutants can be rescued by specific expression of dSdhaf4 in the nervous system, 
suggesting that dSdhaf4 promotes neuronal maintenance and/or function cell-
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autonomously (Figures 4.9E and 4.10D). In addition, ~30% of dMPC1 mutants hold their 
wings in an abnormal position. This defect is associated with muscular degeneration 
caused by mitochondrial dysfunction (Figure 4.10B) (Clark et al., 2006; Greene et al., 
2003; Park et al., 2006; Yang et al., 2006). Interestingly, neuronal and muscular 
dysfunction are also characteristics of Leigh’s syndrome in humans, one form of which 
was shown be caused by mutations in SdhA in humans (Horvath et al., 2006). Overall, 
loss of dSdhaf3 leads to phenotypes that are similar to those seen in dSdhaf4 mutants, but 
they tend to be less severe. For example, dSdhaf3 mutants are not sensitive to bang-
induced seizures, but they do display an age-progressive reduction in locomotor activity 
(Figures 5.9F and 5.12H). This phenotype can be rescued by expression of dSdhaf3 in the 
muscles or neurons, indicating that it is caused by combined muscular and neuronal 
dysfunction (Figure 5.12F). Moreover, dSdhaf3 and dSdhaf4 mutants are both sensitive to 
oxidative stress induced by hypoxia, but hypoxia is more toxic to dSdhaf4 mutants 
(Figures 4.9F and 5.10C). The weaker phenotypes observed in dSdhaf3 mutants relative 
to dSdhaf4 mutants are consistent with the strength of the SDH defect, as dSdhaf3 
mutants display an  ~50% reduction in SDH activity, whereas dSdhaf4 mutants display an 
~85% reduction in SDH activity (Figures 4.6B and 5.10F). These results also indicate 
that dSdhaf3 and dSdhaf4 are not absolutely required for SDH function. Consistent with 
this idea, reduction of SdhA or SdhB gene dose in dSdhaf3 or dSdhaf4 mutants causes 
lethality, demonstrating that these subunits are present at functionally significant levels 
(Figures 4.7C, 4.8F, and 5.11A). At this point, the mechanism underlying the neuronal 
and muscular defects in dSdhaf3 and dSdhaf4 mutants is unclear. dSdhaf4 mutants do not 
display a reduction in overall ATP levels, suggesting that ROS may drive the pathology 
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in these tissues (Figures 4.5B and 4.6A). Future research will be aimed at addressing this 
question and better characterizing the physiological defects that result from a loss of 
dSdhaf3 or dSdhaf4 function.  
 
References 
Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, 
A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N., et al. (2000).  
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. 
Science 287, 848–851. 
 
Berg, J.M., Tymoczko, J.L., and Stryer, L. (2002). Biochemistry. Volume 5. (New York: 
W. H. Freeman). Accessed online at http://www.ncbi.nlm.nih.gov/books/NBK21154. 
 
Brivet, M., Garcia-Cazorla, A., Lyonnet, S., Dumez, Y., Nassogne, M.C., Slama, A., 
Boutron, A., Touati, G., Legrand, A., and Saudubray, J.M. (2003). Impaired 
mitochondrial pyruvate importation in a patient and a fetus at risk. Mol. Genet. Metab. 
78, 186–192. 
 
Brooks, G.A., Brown, M.A., Butz, C.E., Sicurello, J.P., and Dubouchaud, H. (1999). 
Cardiac and skeletal muscle mitochondria have a monocarboxylate transporter MCT1. J. 
Appl. Physiol. 87, 1713–1718. 
 
Calvo, S.E., and Mootha, V.K. (2010). The mitochondrial proteome and human disease. 
Ann. Rev. Genomics Hum. Genet. 11, 25–44. 
 
Chatterjee, A., Mambo, E., and Sidransky, D. (2006). Mitochondrial DNA mutations in 
human cancer. Oncogene 25, 4663–4674. 
 
Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, 
B.A., and Guo, M. (2006). Drosophila pink1 is required for mitochondrial function and 
interacts genetically with parkin. Nature 441, 1162–1166. 
 
Colca, J.R., McDonald, W.G., Cavey, G.S., Cole, S.L., Holewa, D.D., Brightwell-
Conrad, A.S., Wolfe, C.L., Wheeler, J.S., Coulter, K.R., Kilkuskie, P.M., et al. (2013). 
Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)—
relationship to newly identified mitochondrial pyruvate carrier proteins. PloS One 8, 
e61551. 
 
Divakaruni, A.S., and Murphy, A.N. (2012). Cell biology. A mitochondrial mystery, 




Divakaruni, A.S., Wiley, S.E., Rogers, G.W., Andreyev, A.Y., Petrosyan, S., Loviscach, 
M., Wall, E.A., Yadava, N., Heuck, A.P., Ferrick, D.A., et al. (2013). Thiazolidinediones 
are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. 
USA 110, 5422–5427. 
 
Du, J., Cleghorn, W.M., Contreras, L., Lindsay, K., Rountree, A.M., Chertov, A.O., 
Turner, S.J., Sahaboglu, A., Linton, J., Sadilek, M., et al. (2013). Inhibition of 
mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate 
at the expense of glutamate in the retina. J. Biol. Chem. 288, 36129–36140. 
 
Feany, M.B., and Bender, W.W. (2000). A Drosophila model of Parkinson's disease. 
Nature 404, 394–398. 
 
Feichtinger, R.G., Zimmermann, F., Mayr, J.A., Neureiter, D., Hauser-Kronberger, C., 
Schilling, F.H., Jones, N., Sperl, W., and Kofler, B. (2010). Low aerobic mitochondrial 
energy metabolism in poorly- or undifferentiated neuroblastoma. BMC Cancer 10, 149. 
 
Fergestad, T., Ganetzky, B., and Palladino, M.J. (2006). Neuropathology in Drosophila 
membrane excitability mutants. Genetics 172, 1031–1042. 
 
Ghezzi, D., Goffrini, P., Uziel, G., Horvath, R., Klopstock, T., Lochmuller, H., D'Adamo, 
P., Gasparini, P., Strom, T.M., Prokisch, H., et al. (2009). SDHAF1, encoding a LYR 
complex-II specific assembly factor, is mutated in SDH-defective infantile 
leukoencephalopathy. Nat. Genet. 41, 654–656. 
 
Gray, L.R., Tompkins, S.C., and Taylor, E.B. (2013). Regulation of pyruvate metabolism 
and human disease. Cell. Mol. Life Sci. Advanced online publication. PMID: 24363178. 
 
Greene, J.C., Whitworth, A.J., Kuo, I., Andrews, L.A., Feany, M.B., and Pallanck, L.J. 
(2003). Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin 
mutants. Proc. Natl. Acad. Sci. USA 100, 4078–4083. 
 
Halestrap, A.P. (1976). The mechanism of the inhibition of the mitochondrial pyruvate 
transportater by alpha-cyanocinnamate derivatives. Biochem. J. 156, 181–183. 
 
Halestrap, A.P. (2012a). The mitochondrial pyruvate carrier: has it been unearthed at 
last? Cell Metab. 16, 141–143. 
 
Halestrap, A.P. (2012b). The monocarboxylate transporter family—structure and 
functional characterization. IUBMB Life 64, 1–9. 
 
Halestrap, A.P., and Armston, A.E. (1984). A re-evaluation of the role of mitochondrial 
pyruvate transport in the hormonal control of rat liver mitochondrial pyruvate 




Halestrap, A.P., and Denton, R.M. (1974). Specific inhibition of pyruvate transport in rat 
liver mitochondria and human erythrocytes by alpha-cyano-4-hydroxycinnamate. 
Biochem. J. 138, 313–316. 
 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 
144, 646–674. 
 
Hao, H.X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.P., Kunst, H., 
Devilee, P., Cremers, C.W., Schiffman, J.D., Bentz, B.G., et al. (2009). SDH5, a gene 
required for flavination of succinate dehydrogenase, is mutated in paraganglioma. 
Science 325, 1139–1142. 
 
Herzig, S., Raemy, E., Montessuit, S., Veuthey, J.L., Zamboni, N., Westermann, B., 
Kunji, E.R., and Martinou, J.C. (2012). Identification and functional expression of the 
mitochondrial pyruvate carrier. Science 337, 93–96. 
 
Hildyard, J.C., and Halestrap, A.P. (2003). Identification of the mitochondrial pyruvate 
carrier in Saccharomyces cerevisiae. Biochem. J. 374, 607–611. 
 
Horvath, R., Abicht, A., Holinski-Feder, E., Laner, A., Gempel, K., Prokisch, H., 
Lochmuller, H., Klopstock, T., and Jaksch, M. (2006). Leigh syndrome caused by 
mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J. 
Neurol. Neurosurg. Psychiatry 77, 74–76. 
 
Inzucchi, S.E. (2012). Clinical practice. Diagnosis of diabetes. N. Engl. J. Med. 367, 
542–550. 
 
Jain-Ghai, S., Cameron, J.M., Al Maawali, A., Blaser, S., MacKay, N., Robinson, B., and 
Raiman, J. (2013). Complex II deficiency—a case report and review of the literature. 
Am. J. Med. Genet. Part A 161A, 285–294. 
 
Janeway, K.A., Kim, S.Y., Lodish, M., Nose, V., Rustin, P., Gaal, J., Dahia, P.L., Liegl, 
B., Ball, E.R., Raygada, M., et al. (2011). Defects in succinate dehydrogenase in 
gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl. Acad. 
Sci. USA 108, 314–318. 
 
Kirk, J.K., Graves, D.E., Craven, T.E., Lipkin, E.W., Austin, M., and Margolis, K.L. 
(2008). Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. J. 
Am. Diet. Assoc. 108, 91–100. 
 
Lin, M.T., and Beal, M.F. (2006). Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443, 787–795. 
 
Liu, W., Gnanasambandam, R., Benjamin, J., Kaur, G., Getman, P.B., Siegel, A.J., 
Shortridge, R.D., and Singh, S. (2007). Mutations in cytochrome c oxidase subunit VIa 
cause neurodegeneration and motor dysfunction in Drosophila. Genetics 176, 937–946. 
  
261 
McFate, T., Mohyeldin, A., Lu, H., Thakar, J., Henriques, J., Halim, N.D., Wu, H., 
Schell, M.J., Tsang, T.M., Teahan, O., et al. (2008). Pyruvate dehydrogenase complex 
activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 283, 
22700–22708. 
 
Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., 
Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., et al. (2003). PGC-1alpha-
responsive genes involved in oxidative phosphorylation are coordinately downregulated 
in human diabetes. Nat. Genet. 34, 267–273. 
 
Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, 
G.A., Sugiana, C., Boneh, A., Chen, W.K., et al. (2008). A mitochondrial protein 
compendium elucidates complex I disease biology. Cell 134, 112–123. 
 
Palmieri, F., and Pierri, C.L. (2010). Structure and function of mitochondrial carriers – 
role of the transmembrane helix P and G residues in the gating and transport mechanism. 
FEBS Lett. 584, 1931–1939. 
 
Pande, S.V., and Parvin, R. (1978). Pyruvate and acetoacetate transport in mitochondria. 
A reappraisal. J. Biol. Chem. 253, 1565–1573. 
 
Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, 
J.M., et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is 
complemented by parkin. Nature 441, 1157–1161. 
 
Patron, M., Raffaello, A., Granatiero, V., Tosatto, A., Merli, G., De Stefani, D., Wright, 
L., Pallafacchina, G., Terrin, A., Mammucari, C., et al. (2013). The mitochondrial 
calcium uniporter (MCU): molecular identity and physiological roles. J. Biol. Chem. 288, 
10750–10758. 
 
Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., 
Kohane, I., Costello, M., Saccone, R., et al. (2003). Coordinated reduction of genes of 
oxidative metabolism in humans with insulin resistance and diabetes: potential role of 
PGC1 and NRF1. Proc. Natl. Acad. Sci. USA 100, 8466–8471. 
 
Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., and Shulman, G.I. (2004). Impaired 
mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. 
N. Engl. J. Med 350, 664–671. 
 
Raffaello, A., De Stefani, D., Sabbadin, D., Teardo, E., Merli, G., Picard, A., Checchetto, 
V., Moro, S., Szabo, I., and Rizzuto, R. (2013). The mitochondrial calcium uniporter is a 





Rohatgi, N., Aly, H., Marshall, C.A., McDonald, W.G., Kletzien, R.F., Colca, J.R., and 
McDaniel, M.L. (2013). Novel insulin sensitizer modulates nutrient sensing pathways 
and maintains beta-cell phenotype in human islets. PloS One 8, e62012. 
 
Rutter, J., Winge, D.R., and Schiffman, J.D. (2010). Succinate dehydrogenase – 
Assembly, regulation and role in human disease. Mitochondrion 10, 393–401. 
 
Schell, J.C., and Rutter, J. (2013). The long and winding road to the mitochondrial 
pyruvate carrier. Cancer Metab. 1, 6. 
 
Schmidt, O., Pfanner, N., and Meisinger, C. (2010). Mitochondrial protein import: from 
proteomics to functional mechanisms. Nat. Rev. Mol. Cell Biol. 11, 655–667. 
 
Schummer, C.M., Werner, U., Tennagels, N., Schmoll, D., Haschke, G., Juretschke, H.P., 
Patel, M.S., Gerl, M., Kramer, W., and Herling, A.W. (2008). Dysregulated pyruvate 
dehydrogenase complex in Zucker diabetic fatty rats. Am. J. Physiol. Endocrinol. Metab. 
294, E88–96. 
 
Shearman, M.S., and Halestrap, A.P. (1984). The concentration of the mitochondrial 
pyruvate carrier in rat liver and heart mitochondria determined with alpha-cyano-beta-(1-
phenylindol-3-yl)acrylate. Biochem. J. 223, 673–676. 
 
Srinivasan, M., Choi, C.S., Ghoshal, P., Pliss, L., Pandya, J.D., Hill, D., Cline, G., and 
Patel, M.S. (2010). Beta-cell-specific pyruvate dehydrogenase deficiency impairs 
glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 299, E910–917. 
 
Titheradge, M.A., and Coore, H.G. (1976). Hormonal regulation of liver mitochondrial 
pyruvate carrier in relation to gluconeogenesis and lipogenesis. FEBS lett. 72, 73–78. 
 
Todisco, S., Agrimi, G., Castegna, A., and Palmieri, F. (2006). Identification of the 
mitochondrial NAD+ transporter in Saccharomyces cerevisiae. J. Biol. Chem. 281, 1524–
1531. 
 
Wallace, D.C. (2005). A mitochondrial paradigm of metabolic and degenerative diseases, 
aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359–407. 
 
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., 
Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 mutations in 
gliomas. N. Engl. J. Med. 360, 765–773. 
 
Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., Yang, L., Beal, 
M.F., Vogel, H., and Lu, B. (2006). Mitochondrial pathology and muscle and 
dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued 
by Parkin. Proc. Natl. Acad. Sci. USA 103, 10793–10798. 
 
 
